Combination therapy of arms and natural killer cells
ARMs enhance NK cell therapy by facilitating targeted recognition and interaction with diseased cells, improving therapeutic efficacy while reducing side effects and off-target toxicity.
Patent Information
- Application Number
- JP2024123280
- Authority / Receiving Office
- JP · JP
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2018-12-20
- Filing Date
- 2024-07-30
- Publication Date
- 2024-11-26
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Existing NK cell therapies face challenges in effectively targeting diseased cells while minimizing off-target effects and side effects due to the activation of NK cells, leading to unintended cell death and toxicity.
The use of antibody recruitment molecules (ARMs) that facilitate the recognition and targeting of NK cells to diseased cells by binding to antibodies, thereby enhancing NK cell interactions and reducing off-target effects through directed targeting.
ARMs improve the therapeutic efficacy of NK cell therapy by increasing target-specific killing of diseased cells while minimizing side effects and toxicity, enhancing NK cell activation, and reducing off-target interactions.
Smart Images

Figure 2024164029000343 
Figure 2024164029000344 
Figure 2024164029000345
Abstract
Description
[Technical field]
[0001] CROSS-REFERENCE TO RELATED APPLICATIONS This application claims priority to U.S. Application No. 62 / 783,036, filed December 20, 2018, the entirety of which is incorporated herein by reference. [Background technology]
[0002] Immune system activity can be harnessed to prevent or treat a variety of conditions, disorders and diseases, including cancer. Summary of the Invention
[0003] Natural killer cells (NK) cells can induce cell death of a variety of targets, e.g., diseased cells such as cancer cells. In particular, NK cells (e.g., in vitro expanded and / or preactivated NK cells) have been developed for use in cancer therapy. In some embodiments, the present invention encompasses the recognition that NK cell therapy can be significantly improved by agents that can facilitate and / or promote target recognition by NK cells. In some embodiments, the present invention provides technologies (e.g., methods, compositions, etc.) that include NK cells and such agents, and in particular, in some embodiments, the present invention provides technologies that include NK cells and an antibody mobilizing molecule (ARM) that includes (i) an antibody binding moiety that can bind to one or more antibodies or fragments thereof, (ii) a target binding moiety that can bind to the cells, and optionally (iii) a linker moiety that links the antibody binding moiety and the target binding moiety.
[0004] In some embodiments, the ARM can significantly improve the efficacy of NK cell therapy, for example, by facilitating the recognition of target cells by NK cells. In some embodiments, the ARM can enhance the interaction between NK cells and their target cells and / or promote the killing of target cells induced by NK cells. In some embodiments, the ARM promotes the activation of NK cells, for example, by recruiting antibodies to target cells that can then recruit and activate NK cells.
[0005] Additionally or alternatively, in some embodiments, the ARM reduces and / or delays the onset of one or more side effects of NK cell therapy, for example, by directing NK cells to target cells and reducing off-target effects. In some embodiments, NK cells are typically activated, enriched and / or increased before administration. Such pre-activated NK cells are more potent and may be necessary for effective killing of target cells. However, due to their activation, these cells may cause numerous side effects, such as unintended cell killing. In particular, the present invention provides a technology in which the ARM can direct NK cells to target cells and reduce side effects and toxicity associated with NK cell therapy. Furthermore, in terms of reducing off-target effects, in some embodiments, more activated NK cells can be utilized to further improve therapeutic efficacy.
[0006] In particular, the antibody binding moiety (also referred to in some embodiments as antibody binding terminus (ABT)) can bind to an antibody (or fragment thereof). In some embodiments, the antibody binding moiety binds to a variable region. In some embodiments, the antibody binding moiety binds to a Fab region. In some embodiments, the antibody binding moiety recruits diverse antigen-specific antibodies (or fragments thereof), for example, by binding to an Fc region ("universal ABT" or "uABT"), among others. In some embodiments, the use of uABT can avoid undesirable effects that may result from the dependency of a particular antibody population and the individual variability of a particular antibody population. In some embodiments, uABT preferentially allows the recruitment of IgG1, IgG2 and / or IgG4. In some embodiments, the recruitment of antibodies, e.g., IgG subclasses, is not limited by the amount of ARM administered and / or by the level of antibodies with a particular Fab region in an individual. In some embodiments, the ABT binds to and recruits endogenous antibodies. In some embodiments, the uABT binds to IgG molecules, preferably via human IgA or IgM. Typically, after being bound by the antibody binding moiety, the antibodies become capable of carrying out one or more of their immune activities, e.g., interaction with NK cells which may result in the killing of target cells by NK cells.
[0007] Typically, the target binding moiety (also referred to in some embodiments as the target binding terminus (TBT)) can confer specificity of the ARM to its target, e.g., a diseased cell of interest, by, for example, binding to an entity (e.g., a cell surface receptor) that distinguishes the target from a non-target cell (e.g., a diseased cell derived from another cell type).
[0008] In particular, the ARM may enable target-specific recruitment of antibodies, e.g., endogenous antibodies, administered antibodies, etc., by ABT, and / or induce, generate, promote, and / or enhance NK cell-associated immune activity, e.g., killing of target cells by NK cells. A variety of techniques, e.g., assays, reagents, methods, etc., are available for evaluating antibody binding moieties, target binding moieties, and ARMs and may be utilized in accordance with the present invention.
[0009] In some embodiments, the ARM comprises: antibody binding portion, a target binding moiety, and Optionally, a linker portion wherein the antibody binding moiety is capable of binding to a Fab region of an antibody.
[0010] In some embodiments, the ARM comprises: antibody binding portion, a target binding moiety, and optionally a linker moiety, wherein the antibody binding moiety is capable of binding to the Fc region of an antibody.
[0011] In some embodiments, the ARM comprises: antibody binding portion, a target binding moiety, and Optionally, a linker portion wherein the antibody binding moiety is capable of binding to two or more antibodies having different Fab regions.
[0012] In some embodiments, the antibody binding moiety, e.g., the universal antibody binding moiety, binds to the Fc region of an antibody. In some embodiments, the antibody binding moiety, e.g., the universal antibody binding moiety, binds to the conserved Fc region of an antibody. In some embodiments, the antibody binding moiety binds to the Fc region of an IgG antibody.
[0013] In some embodiments, the agent of the invention, such as an ARM, has Formula I: [ka] wherein each variable is as defined and described herein. or a pharma- ceutically acceptable salt thereof. In some embodiments, the agent is a compound of formula I, or a salt thereof.
[0014] In some embodiments, the agent has Formula Ia: [ka] wherein each variable is as defined and described herein. or a salt thereof. In some embodiments, the agent, such as an ARM, is of formula Ia or a pharma- ceutically acceptable salt thereof. In some embodiments, the compound of formula I is a compound of formula Ia.
[0015] In some embodiments, the agent has Formula Ib: [ka] wherein each variable is as defined and described herein. or a salt thereof. In some embodiments, the agent, such as the ARM, is of formula Ib or a pharma- ceutically acceptable salt thereof. In some embodiments, the compound of formula I provided is of formula Ib.
[0016] In some embodiments, the agent, e.g., an ARM, has Formula II: [ka] wherein each variable is as defined and described herein. or a pharma- ceutically acceptable salt thereof. In some embodiments, the agent is a compound of formula II or a salt thereof. In some embodiments, the compound of formula I is a compound of formula II or a salt thereof. In some embodiments, the compound of formula Ia is a compound of formula II.
[0017] In some embodiments, the agent, e.g., the ARM, has Formula III: [ka] wherein each variable is as defined and described herein. or a pharma- ceutically acceptable salt thereof, in some embodiments, the agent is a compound of formula III or a salt thereof. In some embodiments, the compound of formula I is a compound of formula III or a salt thereof. In some embodiments, the compound of formula Ib is a compound of formula III.
[0018] The combination of NK cells and an agent of the invention, such as an ARM, may be particularly effective in treating a variety of conditions, disorders or diseases. an increased, enriched, and / or preactivated population of natural killer cells; and Antibody mobilizing molecules (ARMs) comprising an antibody binding moiety capable of binding to one or more antibodies or fragments thereof, a target binding moiety capable of binding to a target, and optionally a linker moiety linking the antibody binding moiety and the target binding moiety. The present invention provides a combination comprising:
[0019] In some embodiments, the present invention provides Multiple natural killer cells; and Antibody mobilizing molecules (ARMs) comprising an antibody binding moiety capable of binding to one or more antibodies or fragments thereof, a target binding moiety capable of binding to a target, and optionally a linker moiety linking the antibody binding moiety and the target binding moiety. and exposing the system to both, thereby reducing the number of cells in the system compared to when both the natural killer cell and antibody recruiting molecule are absent.
[0020] Those skilled in the art will appreciate that the techniques provided are suitable for a variety of systems described herein. For example, in some embodiments, the system is an organism. In some embodiments, the system is a subject. In some embodiments, the system is a human. In some embodiments, the system is a patient. In some embodiments, the system is a non-human animal. In some embodiments, the system is a non-human animal useful as a disease model. In some embodiments, the system is an organ. In some embodiments, the system is a tissue. In some embodiments, the system is an in vivo system. In some embodiments, the system is an ex vivo system. In some embodiments, the system is an in vitro system. In some embodiments, the system is or comprises a cell culture.
[0021] In some embodiments, the present invention provides a method for treating a subject with cancer. Multiple natural killer cells; and Antibody mobilizing molecules (ARMs) comprising an antibody binding moiety capable of binding to one or more antibodies or fragments thereof, a target binding moiety capable of binding to cancer cells, and optionally a linker moiety linking the antibody binding moiety and the target binding moiety. and exposing the subject to both.
[0022] In some embodiments, the subject is a human. In some embodiments, the subject is a human patient. In some embodiments, the subject is a non-human animal. In some embodiments, the subject is a non-human animal useful as a disease model.
[0023] In some embodiments, the number of cancer cells in a subject is reduced compared to when both natural killer cells and antibody recruiting molecules are absent.In some embodiments, the proliferation of cancer cells in a subject is reduced compared to when both natural killer cells and antibody recruiting molecules are absent.In some embodiments, the proliferation of cancer cells in a subject is reduced compared to when both natural killer cells and antibody recruiting molecules are absent.In some embodiments, the volume of cancer cells in a subject is reduced compared to when both natural killer cells and antibody recruiting molecules are absent.
[0024] In some embodiments, the present invention provides a method for treating a patient with cancer. Multiple natural killer cells; and An antibody-recruiting molecule comprising an antibody-binding moiety capable of binding to one or more antibodies or fragments thereof, a target-binding moiety capable of binding to cancer cells, and optionally a linker moiety connecting the antibody-binding moiety and the target-binding moiety. The present invention provides a method for treating cancer, comprising administering
[0025] In some embodiments, the present invention provides a method for treating a subject Multiple natural killer cells; and An antibody recruitment molecule comprising an antibody binding moiety capable of binding to one or more antibodies or fragments thereof, a target binding moiety capable of binding to a target of treatment, and optionally a linker moiety connecting the antibody binding moiety and the target binding moiety. The present invention provides a method for reducing the toxicity or side effects of treatment with natural killer cells, comprising administering
[0026] In some embodiments, the present invention provides an improvement in a method of treating a subject by administering a plurality of natural killer cells, which also includes administering an antibody mobilizing molecule (ARM) comprising an antibody binding moiety capable of binding to one or more antibodies or fragments thereof, a target binding moiety capable of binding to a target, and optionally a linker moiety linking the antibody binding moiety and the target binding moiety.
[0027] The agent, eg, an ARM of the present invention, can be administered prior to, simultaneously with, and / or subsequent to the NK cells, eg, expanded, enriched, and / or preactivated NK cells. [Brief description of the drawings]
[0028] [Figure 1] The provided technology has low toxicity. A. NK cell killing frequency. B. The occurrence of dead NK cells normalized to DMSO-treated control.
[0029] [Diagram 2] The provided technology can efficiently kill cancer cells. A. SUDHL-4 cell killing frequency in NK-SUDHL-4 co-cultures. B. SUDHL-4 cell killing frequency in NK-SUDHL-4 co-cultures normalized to DMSO-treated controls.
[0030] [Diagram 3] The techniques provided may reduce plasma cell counts.
[0031] [Figure 4] The techniques provided do not result in or only at low levels of unwanted NK cell fratricide. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
[0032] Detailed Description of Specific Embodiments 1. Specific embodiments of the present invention: As mentioned above, in some embodiments, the present invention provides techniques for inducing cell death, inhibiting cell proliferation, and / or reducing cell number in a system.Alternatively or in addition, in some embodiments, the present invention provides techniques for treating cancer and / or reducing the toxicity and / or side effects of cellular immunotherapy (e.g., NK cell therapy).
[0033] In some embodiments, the present invention utilizes an ARM agent in conjunction with a cellular immunotherapy such as NK cell therapy (e.g., including in vitro expansion of NK cells). In some embodiments, one or more of the ARM agents described herein are administered to a subject who has undergone, is undergoing, or will undergo NK cell therapy, or who otherwise has or will have a population of NK cells targeted to a site of interest (e.g., a tumor). Conversely, in some embodiments, a cellular immunotherapy (e.g., NK cell therapy) is administered to a subject who has undergone, is undergoing, or will undergo treatment with an ARM agent described herein.
[0034] In some embodiments, the present invention utilizes an ARM agent comprising an antibody binding moiety capable of binding to an antibody (or fragment thereof) having a variety of Fab structures ("uABT"). In particular, in some embodiments, the relevant ARM agent comprises an antibody binding moiety that binds to the Fc region of an antibody; in certain embodiments, such binding to the Fc region of an antibody does not interfere with one or more of the antibody's immune activities, such as interaction with an Fc receptor (e.g., CD16a), recruitment of effector cells such as NK cells for ADCC, etc. As will be appreciated by those skilled in the art, the provided technology of the present invention (agents, compounds, compositions, methods, etc.) including uABT can provide a variety of advantages, for example, the provided technology can utilize antibodies with a variety of Fab regions in the immune system to avoid or minimize the effects of undesirable antibody variation in a patient population, and induce and / or enhance immune activity against a target, e.g., a target disease cell such as a cancer cell.
[0035] In some embodiments, the technology of the present invention is useful for recruiting antibodies and NK cells to various targets, e.g., cancer cells. In some embodiments, the technology provided is useful for modulating immune activity against targets (such as disease cells, foreign objects or substances), e.g., ADCC involving NK cells. In some embodiments, the technology provided is useful for modulating NK cells against target cells, e.g., disease cells, such as cancer cells. In some embodiments, the target binding moiety is an inhibitory moiety. In some embodiments, the target binding moiety is an enzyme inhibitory moiety. In some embodiments, the target binding moiety binds to cell surface substances, e.g., proteins, carbohydrates, lipids, etc.
[0036] In some embodiments, the agent, e.g., an ARM, antibody binding moiety, A target binding moiety and Optionally, a linker portion where The antibody binding moiety may bind to a Fab region.
[0037] In some embodiments, the agent, e.g., an ARM, antibody binding moiety, A target binding moiety and optionally a linker moiety, where The antibody binding moiety may bind to the Fc region.
[0038] In some embodiments, the agent, e.g., an ARM, antibody binding moiety, A target binding moiety and optionally a linker moiety, where The antibody binding moiety may bind to two or more antibodies having different Fab regions.
[0039] In some embodiments, agents useful in practicing the techniques of the present invention comprise two or more antibody binding moieties. In some embodiments, agents useful comprise two or more target binding moieties.
[0040] The antibody binding moiety may interact with any part of an antibody. In some embodiments, the antibody binding moiety binds to the Fc region of an antibody. In some embodiments, the antibody binding moiety binds to the conserved Fc region of an antibody. In some embodiments, the antibody binding moiety binds to the Fc region of an IgG antibody. As will be appreciated by those skilled in the art, a variety of antibody binding moieties, linkers and target binding moieties can be utilized by the present invention. In particular, as shown in the examples, in some embodiments, the present invention provides antibody binding moieties, linkers and target binding moieties and combinations thereof that are particularly useful and effective for constructing ARM molecules for recruiting antibodies to target cells and / or for inducing, generating, promoting and / or enhancing immune system activity against target cells, e.g., diseased cells such as cancer cells.
[0041] In some embodiments, the antibody binding moiety can bind to an Fc region bound to an Fc receptor, e.g., FcγRIIIa, CD16a, etc. In some embodiments, the moieties and / or agents provided (e.g., compounds / ARMs of various formulas described herein) comprise an antibody binding moiety that binds to a complex comprising an Fc region and an Fc receptor. In some embodiments, the complex is antibody binding moiety, a target binding moiety, and Optionally, a linker portion Drugs containing Fc region and Fc receptors wherein the antibody binding portion of the agent is capable of binding to two or more antibodies having different Fab regions.
[0042] In some embodiments, the Fc region is the Fc region of the endogenous antibody of the subject. In some embodiments, the Fc region is the Fc region of an exogenous antibody. In some embodiments, the Fc region is the Fc region of an administered drug. In some embodiments, the Fc receptor is a disease cell in the subject. In some embodiments, the Fc receptor is a cancer cell in the subject.
[0043] In certain embodiments, the agent, e.g., an ARM, has Formula I: [ka] [During the ceremony, ABT is the antibody binding moiety; L is a divalent linker moiety connecting ABT and TBT; TBT is the target binding moiety. or a pharma- ceutically acceptable salt thereof.
[0044] In some embodiments, the ABT is a universal antibody binding moiety.
[0045] In some embodiments, the antibody binding moiety comprises one or more amino acid residues. In some embodiments, the antibody binding moiety is or comprises a peptide moiety. In some embodiments, the antibody binding moiety is or comprises a cyclic peptide moiety. In some embodiments, such antibody binding moiety comprises one or more naturally occurring amino acid residues. In some embodiments, such antibody binding moiety comprises one or more non-naturally occurring amino acid residues.
[0046] In some embodiments, the amino acid has the formula AI: [ka] [During the ceremony, R a1 , R a2 , R a3 Each of the groups independently represents -L a - R'; La1 and L a2 Each of the groups independently represents L a and; Each L a are independently a covalent bond or C 1 -C 20 Aliphatic or C with 1-5 heteroatoms 1 -C 20 heteroaliphatic, wherein one or more methylene units of said group are optionally independently selected from -C(R') 2 -, -Cy-, -O-, -S-, -SS-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O) 2 -, -S(O) 2 optionally substituted with -N(R')-, -C(O)S- or -C(O)O-; Each -Cy- is independently 3-20 Cycloaliphatic ring, C 6-20 an optionally substituted divalent group selected from an aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; Each R' is independently -R, -C(O)R, -CO 2 R or -SO 2 R; Each R is independently -H or C 1-30 C having 1 to 10 heteroatoms independently selected from aliphatic, oxygen, nitrogen, sulfur, phosphorus and silicon 1-30 Heteroaliphatic, C 6-30 Aryl, C 6-30 C having 1 to 10 heteroatoms independently selected from arylaliphatic, oxygen, nitrogen, sulfur, phosphorus, and silicon 6-30an optionally substituted group selected from arylheteroaliphatic, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; or The two R groups may optionally independently form a covalent bond or: two or more R groups on the same atom may optionally independently combine with that atom to form an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having in addition to that atom 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; or Two or more R groups on two or more atoms may optionally independently combine with the atoms between them to form an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atoms between them, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. or a salt thereof.
[0047] In some embodiments, the antibody binding moiety is a cyclic peptide moiety. In some embodiments, the compound, e.g., the agent, ARM, has Formula Ia: [ka] [During the ceremony, each Xaa is independently an amino acid residue; t is 0 to 50; z is 1 to 50; L is a linker moiety; TBT is the target binding moiety; Each R c are independent, -L a - R'; Each of a and b is independently 1 to 200; Each L a are independently a covalent bond or C 1 -C20 Aliphatic or C with 1-5 heteroatoms 1 -C 20 heteroaliphatic, wherein one or more methylene units of said group are optionally independently selected from -C(R') 2 -, -Cy-, -O-, -S-, -SS-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O) 2 -, -S(O) 2 optionally substituted with -N(R')-, -C(O)S- or -C(O)O-; Each -Cy- is independently 3-20 Cycloaliphatic ring, C 6-20 an optionally substituted divalent group selected from an aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; Each R' is independently -R, -C(O)R, -CO 2 R or -SO 2 R; Each R is independently -H or C 1-30 C having 1 to 10 heteroatoms independently selected from aliphatic, oxygen, nitrogen, sulfur, phosphorus and silicon 1-30 Heteroaliphatic, C 6-30 Aryl, C 6-30 C having 1 to 10 heteroatoms independently selected from arylaliphatic, oxygen, nitrogen, sulfur, phosphorus, and silicon 6-30 an optionally substituted group selected from arylheteroaliphatic, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; or The two R groups may optionally independently form a covalent bond or: two or more R groups on the same atom may optionally independently combine with that atom to form an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having in addition to that atom 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; or Two or more R groups on two or more atoms may optionally independently combine with the atoms between them to form an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atoms between them, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. or a salt thereof.
[0048] In some embodiments, a is 1. In some embodiments, b is 1. In some embodiments, a is 1, b is 1, and the compound of formula Ia is [ka] It has the structure:
[0049] In some embodiments, each amino acid residue, e.g., each Xaa in formula Ia, is a residue of an amino acid having the structure of formula AI. In some embodiments, each Xaa is independently -N(R a1 )-L a1 -C(R a2 )(R a3 )-L a2 In some embodiments, the amino acid residue has the structure -CO-. In some embodiments, the amino acid residue has two or more side chains in a compound of formula Ia (e.g., R a2 or R a3 and another amino acid residue R a2 or R a3) may optionally form a bridge together (e.g., compounds I-10, I-12, I-14, I-18, I-19, I-22, I-23, I-25, etc.). For example, in some embodiments, two cysteine residues form a -SS- bridge, as typically found in natural proteins. In some embodiments, the bridge formed is L b where L b is L as described herein. a In some embodiments, L b each end is independently connected to a backbone atom of the cyclic peptide (e.g., -(Xaa) in formula Ia) z In some embodiments, L b contains an R group (e.g., L b The methylene unit is -C(R) 2 - or -N(R)-), where R is an R group attached to a skeletal atom (e.g., if R, then R a1 , R a2 , R a3 etc.) and the atoms therebetween together form a ring. b is linked to the ring, e.g., -(Xaa) in formula Ia, by the side chain of the amino acid residue (e.g., Xaa in formula Ia). z - is attached to the ring formed by - In some embodiments, such side chains include amino or carboxylic acid groups.
[0050] In some embodiments, [ka] is the antibody binding moiety ( [ka] binds to the antibody. In some embodiments, [ka] is a universal antibody binding moiety. In some embodiments, [ka] is a universal antibody binding moiety that can bind to antibodies with different Fab regions. [ka] is a universal antibody binding moiety capable of binding to the Fc region. In some embodiments, the antibody binding moiety, e.g., [ka] A universal antibody binding moiety having the structure: [ka] The antibody binding moiety has the structure [ka] In some embodiments, [ka] teeth [ka] It has the structure:
[0051] In certain embodiments, the compound, e.g., an agent, such as an ARM, has Formula II: [ka] [During the ceremony, R 1 , R 3 and R 5 Each of is independently hydrogen or C 1-6an optionally substituted group selected from an aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen or sulfur, or R 1 and R 1’ may optionally be joined together with the carbon atoms therebetween to form an optionally substituted saturated or partially unsaturated 3- to 8-membered spirocyclic carbocyclic ring or a saturated or partially unsaturated 3- to 8-membered spirocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen or sulfur; R 3 and R 3’ may optionally be joined together with the carbon atoms therebetween to form an optionally substituted saturated or partially unsaturated 3-8 membered spirocyclic carbocyclic ring or a saturated or partially unsaturated 3-8 membered spirocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen or sulfur; R attached to the same carbon atom 5 Groups and R 5’ groups may optionally together with the carbon atoms between them form an optionally substituted saturated or partially unsaturated 3- to 8-membered spirocyclic carbocyclic ring or a saturated or partially unsaturated 3- to 8-membered spirocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen or sulfur; or The Two R's 5 The groups, together with the atoms between them, are optionally substituted divalent C 1-10It may form a linear or branched saturated or unsaturated hydrocarbon chain, where one to three methylene units of the chain may independently be selected from the group consisting of -S-, -SS-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -S(O)-, -S(O) 2 -or- Cy 1 -, where each -Cy 1 - is independently a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R 1’ , R 3’ and R 5’ Each of the groups is independently hydrogen or an optionally substituted C 1-3 It is aliphatic; R 2 , R 4 and R 6 Each of the groups is independently hydrogen or an optionally substituted C 1-4 Aliphatic or: R 2 and R 1 may optionally form an optionally substituted saturated or partially unsaturated 4-8 membered monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur; R 4 and R 3 may optionally combine with the atoms therebetween to form an optionally substituted saturated or partially unsaturated 4-8 membered monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur; or R 6 group and adjacent R 5 groups may optionally together with the atoms between them form an optionally substituted saturated or partially unsaturated 4-8 membered monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur; L 1 teeth [ka] is a trivalent linker moiety linking L 2 is a covalent bond or an optionally substituted divalent linear or branched C 1-30 A saturated or unsaturated hydrocarbon chain, wherein 1 to 10 methylene units of the chain are independently selected from the group consisting of -S-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -S(O)-, -S(O) 2 -, [ka] Or -Cy 1 -, where each -Cy 1 - is independently a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; TBT is the target binding moiety; Each of m and n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. or a pharma- ceutically acceptable salt thereof.
[0052] In some embodiments, the antibody binding moiety is or comprises a peptide moiety. In some embodiments, the compound, such as an agent, an ARM, has the formula Ib: [ka] [During the ceremony, each Xaa is independently an amino acid residue; each z is independently 1 to 50; each L is independently a linker moiety; TBT is the target binding moiety, Each R c are independent, -L a - R'; each of a1 and a2 is independently 0 or 1, where at least one of a1 and a2 is not 0; Each of a and b is independently 1 to 200; Each L a are independently a covalent bond or C 1 -C 20 Aliphatic or C with 1-5 heteroatoms 1 -C 20 heteroaliphatic, wherein one or more methylene units of said group are optionally independently selected from -C(R') 2 -, -Cy-, -O-, -S-, -SS-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O) 2 -, -S(O) 2 optionally substituted with -N(R')-, -C(O)S- or -C(O)O-; Each -Cy- is independently 3-20 Cycloaliphatic ring, C 6-20 an optionally substituted divalent group selected from an aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; Each R' is independently -R, -C(O)R, -CO 2 R or -SO 2 R; Each R is independently -H or C 1-30 C having 1 to 10 heteroatoms independently selected from aliphatic, oxygen, nitrogen, sulfur, phosphorus and silicon 1-30 Heteroaliphatic, C 6-30 Aryl, C 6-30 C having 1 to 10 heteroatoms independently selected from arylaliphatic, oxygen, nitrogen, sulfur, phosphorus, and silicon 6-30arylheteroaliphatic, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, optionally substituted; The two R groups may optionally independently be joined together to form a covalent bond, or: two or more R groups on the same atom may optionally independently combine with that atom to form an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having in addition to that atom 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; or Two or more R groups on two or more atoms may optionally independently form an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atoms between them, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. or a salt thereof.
[0053] In some embodiments, a1 is 1. In some embodiments, a2 is 1. In some embodiments, b is 1. In some embodiments, the compound of formula Ib is [ka] In some embodiments, the compound of formula Ib has the structure: [ka] In some embodiments, the compound of formula Ib has the structure: [ka] In some embodiments, the compound of formula Ib has the structure: [ka] It has the structure:
[0054] In some embodiments, each amino acid residue, e.g., each Xaa in formula Ib, is a residue of an amino acid having the structure of formula AI. In some embodiments, each Xaa is independently -N(R a1 )-L a1 -C(R a2 )(R a3 )-L a2 In some embodiments, the amino acid residue has the structure -CO-. In some embodiments, the amino acid residue has two or more side chains in a compound of formula Ia (e.g., R a2 or R a3 and another amino acid residue R a2 or R a3 ) optionally form a bridge together (e.g., compounds I-10, I-12, I-14, I-18, I-19, I-22, I-23, I-25, etc.). For example, in some embodiments, two cysteine residues form a -SS- bridge, as typically found in natural proteins. In some embodiments, the bridge formed is L b where L b is L as described herein. a In some embodiments, L b each end is independently connected to a backbone atom of the cyclic peptide (e.g., -(Xaa) in formula Ia) z In some embodiments, L b contains an R group (e.g., L b The methylene unit is -C(R) 2 - or -N(R)-), where R is an R group attached to a skeletal atom (e.g., if R, then R a1 , R a2 , R a3 etc.) together with the atoms therebetween to form a ring. b is linked to the ring, e.g., -(Xaa) in formula Ia, by the side chain of the amino acid residue (e.g., Xaa in formula Ia). z- is attached to the ring formed by - In some embodiments, such side chains include amino or carboxylic acid groups.
[0055] In some embodiments, R c -(Xaa)z- is an antibody binding moiety (R c -(Xaa)zH binds to an antibody. c -(Xaa)z- is a universal antibody binding moiety. In some embodiments, R c -(Xaa)z- is a universal antibody binding moiety that can bind to antibodies with different Fab regions. c -(Xaa)z- is a universal antibody binding moiety capable of binding to an Fc region. In some embodiments, the antibody binding moiety, e.g., R c A universal antibody binding moiety having the structure -(Xaa)z- can bind to an Fc region bound to an Fc receptor. In some embodiments, R c -(Xaa)z- is [ka] In some embodiments, R c -(Xaa)zL- is [ka] It has the structure:
[0056] In certain embodiments, the compound, e.g., an agent, such as an ARM, has Formula III: [ka] [During the ceremony, Each R 7 are independently hydrogen or C 1-6an optionally substituted group selected from aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a saturated or partially unsaturated 4-8 membered monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen or sulfur, or R attached to the same carbon atom 7 Groups and R 7’ groups may optionally together with the carbon atoms between them form an optionally substituted saturated or partially unsaturated 3-8 membered spirocyclic carbocyclic ring or an optionally substituted saturated or partially unsaturated 3-8 membered spirocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen or sulfur; Each R 7’ are independently hydrogen or optionally substituted C 1-3 It is aliphatic; Each R 8 are independently hydrogen or optionally substituted C 1-4 Aliphatic or: R 8 group and adjacent R 7 groups may optionally together with the atoms between them form an optionally substituted saturated or partially unsaturated 4-8 membered monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur; R 9 is hydrogen, optionally substituted C 1-3 Aliphatic or -C(O)-(optionally substituted C 1-3 aliphatic); L 3 teeth [ka] and TBT; TBT is the target binding moiety; o is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. or a pharma- ceutically acceptable salt thereof.
[0057] 2.Definition: The compounds of the present invention include those compounds generally described herein and are designated by the classes, subclasses and species described herein. As used herein, the following definitions shall apply unless otherwise indicated. For the purposes of this invention, chemical elements are defined as defined in the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75 th In addition, general principles of organic chemistry are described in "Organic Chemistry", Thomas Sorrell, University Science Books, Sausalito: 1999 and "March's Advanced Organic Chemistry", 5th Ed., Ed.: Smith, MB and March, J., John Wiley & Sons, New York: 2001, the entire contents of which are incorporated herein by reference.
[0058] Administration: As used herein, the term "administration" typically refers to the administration of a composition to a subject or system. Those skilled in the art will appreciate that in the appropriate circumstances, various routes may be used for administration to a subject, e.g., a human. For example, in some embodiments, administration may be ocular, oral, parenteral, topical, etc. In some particular embodiments, administration may be bronchial (e.g., bronchial instillation), buccal, transdermal (which may be or include one or more of topical administration to the skin, intradermal, subdermal, transdermal, etc.), enteral, intraarterial, intradermal, intragastric, intramedullary, intramuscular, intranasal, intraperitoneal, intrathecal, intravenous, intraventricular, in a particular organ (e.g., in the liver), mucosal, nasal, oral, rectal, subcutaneous, sublingual, topical, tracheal (e.g., by intratracheal instillation), vaginal, vitreous, etc. In some embodiments, administration may include administration that is intermittent (e.g., multiple administrations separated in time) and / or periodic (e.g., multiple independent administrations separated by a common period of time) administration. In some embodiments, administration can be continuous administration (eg, perfusion) for at least a selected period of time.
[0059] Agent: In general, the term "agent" as used herein may be used to refer to any chemical class of compound or substance, including, for example, polypeptides, nucleic acids, carbohydrates, lipids, small molecules, metals, or complexes thereof. In appropriate circumstances, as will be clear to the skilled artisan from the context, the term may be used to refer to a substance that is or includes a cell or organism, or a fragment, extract, or component thereof. Alternatively or additionally, as will be clear from the context, the term may be used to refer to a natural product found in nature and / or obtained from nature. In some instances, again as will be clear from the context, the term may be used to refer to one or more substances that are designed, developed, and / or manufactured by the hand of man, and / or are not found in nature. In some embodiments, the agent is used in an isolated or pure form; in some embodiments, the agent may be used in a crude form. In some embodiments, potential agents may be used as a collection or library, for example, a collection or library that can be screened to identify and characterize active agents therein. In some cases, the term "agent" refers to a compound or substance that is or comprises a polymer; in some cases, the term can refer to a compound or substance that does not comprise one or more polymer moieties. In some embodiments, the term "agent" can refer to a compound or substance that is not a polymer and / or does not comprise substantially any polymer and / or one or more specific polymer moieties. In some embodiments, the term can refer to a compound or substance that does not comprise a polymer moiety or does not comprise substantially any polymer moiety. In some embodiments, the agent is a compound. In some embodiments, the agent is an ARM as described herein.
[0060] Aliphatic: As used herein, "aliphatic" refers to a linear (i.e., unbranched) or branched, substituted or unsubstituted hydrocarbon chain that is fully saturated or contains one or more units of unsaturation, or a substituted or unsubstituted monocyclic, bicyclic, or polycyclic hydrocarbon ring that is fully saturated or contains one or more units of unsaturation, or a combination thereof. Unless otherwise specified, an aliphatic group contains 1-100 aliphatic carbon atoms. In some embodiments, an aliphatic group contains 1-20 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-10 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-9 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-8 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-7 aliphatic carbon atoms. In other embodiments, an aliphatic group contains 1-6 aliphatic carbon atoms. In still other embodiments, an aliphatic group contains 1-5 aliphatic carbon atoms, and in still other embodiments, an aliphatic group contains 1, 2, 3, or 4 aliphatic carbon atoms. Suitable aliphatic groups include, but are not limited to, linear or branched, substituted or unsubstituted alkyl, alkenyl, alkynyl groups, and combinations thereof.
[0061] Alkenyl: As used herein, the term "alkenyl" refers to an aliphatic group, as defined herein, having one or more double bonds.
[0062] Alkenylene: The term "alkenylene" refers to a divalent alkenyl group.
[0063] Alkyl: As used herein, the term "alkyl" is given its ordinary meaning in the art and may include saturated aliphatic groups, including straight chain alkyl groups, branched chain alkyl groups, cycloalkyl (alicyclic) groups, alkyl substituted cycloalkyl groups, and cycloalkyl substituted alkyl groups. In some embodiments, an alkyl has 1-100 carbon atoms. In certain embodiments, a straight or branched chain alkyl has about 1-20 carbon atoms in its backbone (e.g., C for straight chain). 1 -C 20 , C for branched chains2 -C 20 ), or about 1-10 carbon atoms. In some embodiments, cycloalkyl rings have from about 3-10 carbon atoms in their ring structure, and such rings are monocyclic, bicyclic or polycyclic, or have about 5, about 6 or about 7 carbons in the ring structure. In some embodiments, alkyl groups have 1-4 carbon atoms (e.g., C for straight chain lower alkyls, C for aryl ... 1 -C 4 ) may be a lower alkyl group.
[0064] Alkylene: The term "alkylene" refers to a divalent alkyl group.
[0065] Amino acid: In its broadest sense, as used herein, refers to a compound and / or substance that can be included in a polypeptide chain, for example, by the formation of one or more peptide bonds. In some embodiments, an amino acid comprises an amino group and a carboxylic acid group. In some embodiments, an amino acid has the general structure NH(R')-C(R') 2 In some embodiments, the amino acid has the general structure H 2 NC(R') 2 In some embodiments, the amino acid has the general structure H 2The amino acid has a NC(H)(R')-COOH, where each R' is as described herein. In some embodiments, the amino acid is a naturally occurring amino acid. In some embodiments, the amino acid is a non-natural amino acid; in some embodiments, the amino acid is a D-amino acid; in some embodiments, the amino acid is an L-amino acid. "Standard amino acid" refers to any of the 20 standard L-amino acids commonly found in naturally occurring peptides. "Non-standard amino acid" refers to any amino acid other than the standard amino acids, whether produced synthetically or obtained from a natural source. In some embodiments, the amino acids, including the carboxy- and / or amino-terminal amino acids in a polypeptide, may contain structural modifications compared to the general structures described above. For example, in some embodiments, the amino acids may be modified by methylation, amidation, acetylation, pegylation, glycosylation, phosphorylation, and / or substitution (e.g., of an amino group, a carboxylic acid, one or more protons, one or more hydrogens, and / or a hydroxyl group). In some embodiments, such modifications may, for example, alter the circulating half-life of a polypeptide comprising a modified amino acid, compared to a polypeptide comprising another identical unmodified amino acid. In some embodiments, such modifications do not significantly alter the relative activity of a polypeptide that contains a modified amino acid, compared to an otherwise identical, unmodified amino acid. As is clear from the context, in some embodiments, the term "amino acid" is used to refer to a free amino acid; in certain embodiments, it can be used to refer to an amino acid residue of a polypeptide.
[0066] Animal: As used herein, refers to any member of the animal kingdom. In some embodiments, "animal" refers to humans of either sex and at any stage of development. In some embodiments, "animal" refers to non-human animals at any stage of development. In certain embodiments, the non-human animal is a mammal (e.g., rodent, mouse, rat, rabbit, monkey, dog, cat, sheep, cow, primate and / or pig). In some embodiments, the animal includes, but is not limited to, mammals, birds, reptiles, amphibians, fish, insects and / or worms. In some embodiments, the animal can be a transgenic animal, a genetically engineered animal and / or a clone.
[0067] Antibody: As used herein, the term "antibody" refers to a polypeptide that contains sufficient standard immunoglobulin sequence elements to confer specific binding to a particular target antigen. As is known in the art, naturally produced intact antibodies are approximately 150 kD tetrameric entities consisting of two identical heavy chain polypeptides (each approximately 50 kD) and two identical light chain polypeptides (each approximately 25 kD) that bind to each other in what is commonly referred to as a "Y-shaped" structure. Each heavy chain consists of at least four domains (each 110 amino acids long) - an amino-terminal variable (VH) domain (located at the tip of the Y structure), followed by three constant domains: CH1, CH2, and a carboxy-terminal CH3 (located at the base of the Y system). A short region known as the "switch" links the heavy chain variable and constant regions. A "hinge" links the CH2 and CH3 domains to the rest of the antibody. Two disulfide bonds in this hinge region link the two heavy chain polypeptides to each other in the intact antibody. Each light chain consists of two domains separated from each other by another "switch" - an amino-terminal variable (VL) domain, a carboxy-terminal constant (CL) domain. An intact antibody tetramer consists of two heavy-light chain dimers in which the heavy and light chains are bound to each other by a single disulfide bond, and two other disulfide bonds link the heavy chain hinge regions together, so that the dimer regions are bound to each other and a tetramer is formed. Naturally produced antibodies are also typically glycosylated on the CH2 domain. Each domain in a natural antibody has a structure characterized by an "immunoglobulin fold" formed from two β-sheets (e.g., 3-, 4- or 5-stranded sheets) arranged together in a compressed antiparallel β-barrel. Each variable domain contains three hypervariable loops (CDR1, CDR2 and CDR3) known as "complement determining regions" and four partially invariant "framework" regions (FR1, FR2, FR3 and FR4). When a native antibody folds, the FR regions form a β-sheet that provides a structural framework for the domains, and the CDR loop regions from both the heavy and light chains come together in three dimensional space such that they form a single hypervariable antigen binding site located at the tip of a Y structure.The Fc region of a natural antibody binds elements of the complement system and also binds to receptors on effector cells, e.g., effector cells that mediate cytotoxicity. As is known in the art, the affinity and / or other binding attributes of the Fc region for an Fc receptor can be modulated by glycosylation or other modifications. In some embodiments, the antibodies produced and / or utilized according to the present invention comprise a glycosylated Fc domain, such as an Fc domain with modified or engineered such glycosylation. For purposes of the present invention, in certain embodiments, any polypeptide or complex of polypeptides that comprises a sufficient immunoglobulin domain sequence as found in a natural antibody may be referred to and / or used as an "antibody," regardless of whether such polypeptide is produced naturally (e.g., produced by an organism in response to an antigen) or produced by recombinant technology, chemical synthesis, or other artificial systems or methods. In some embodiments, the antibody is polyclonal; in some embodiments, the antibody is monoclonal. In some embodiments, the antibody has constant region sequences characteristic of mouse, rabbit, primate, or human antibodies. In some embodiments, the antibody sequence elements are humanized, primatized, chimeric, etc., as known in the art. Furthermore, the term "antibody" as used herein, in appropriate embodiments (unless otherwise specified or clear from the context), may refer to constructs or formats known or developed in the art for utilizing the structural and functional characteristics of antibodies in alternative presentations.For example, in some embodiments, antibodies utilized in accordance with the present invention include, but are not limited to, intact IgA, IgG, IgE or IgM antibodies; bi- or multispecific antibodies (e.g., Zybodies®, etc.); such as Fab fragments, Fab' fragments, F(ab')2 fragments, Fd' fragments, Fd fragments and isolated CDRs or combinations thereof; single chain Fv; polypeptide-Fc fusions; single domain antibodies (e.g., shark single domain antibodies or fragments thereof such as IgNAR); camelid antibodies; masked antibodies (e.g., Probodies®); small modular immunopharmaceuticals ("SMIPs." TM "); single chain or tandem bispecific antibodies (TandAb®); VHH; Anticalins®; Nanobodies®; Minibodies; BiTE®; Ankyrin repeat proteins or DARPIN®; Avimers®; DART; TCR-like antibodies; Adnectins®; Affilins®; Trans-bodies®; Affibodies®; TrimerX®; MicroProteins; Fynomers®, Centyrins®; KALBITOR®; CovX-Bodies; and CrossMabs. In some embodiments, the antibody may not have a covalent modification (e.g., attachment of a glycan) that it would have if it were naturally produced. In some embodiments, the antibody may include a covalent modification (e.g., attachment of a glycan, a payload (e.g., a detection moiety, a therapeutic moiety, a catalytic moiety, etc.) or other pendant group (e.g., polyethylene glycol, etc.).
[0068] Approximately: the term "approximately" or "about" used herein, which is applied to one or more target values, refers to a value similar to the reference value mentioned.In certain embodiments, the term "approximately" or "about" refers to a range that is within 25%, 20% or less, 19% or less, 18% or less, 17% or less, 16% or less, 15% or less, 14% or less, 13% or less, 12% or less, 11% or less, 10% or less, 9% or less, 8% or less, 7% or less, 6% or less, 5% or less, 4% or less, 3% or less, 2% or less, or 1% or less in either direction (greater or smaller), unless otherwise specified or clear from the context (except when such number exceeds 100% of possible values).
[0069] Aryl: The term "aryl" used alone or as part of a larger moiety such as in "aralkyl", "aralkoxy", "aryloxyalkyl", etc., refers to a monocyclic, bicyclic, or polycyclic ring system having 5 to 30 total ring members, in which at least one ring in the system is aromatic. In some embodiments, the aryl group is a monocyclic, bicyclic, or polycyclic ring system having 5 to 14 total ring members, in which at least one ring in the system is aromatic and each ring in the system contains 3 to 7 ring members. In some embodiments, the aryl group is a biaryl group. The term "aryl" may be used interchangeably with the term "aryl ring". In certain embodiments of the invention, "aryl" refers to an aromatic ring system including, but not limited to, phenyl, biphenyl, naphthyl, binaphthyl, anthracyl, etc., which may bear one or more substituents. In some embodiments, groups in which the radical or point of attachment is on the aryl ring, in which the aromatic ring is fused to one or more non-aromatic rings, such as indanyl, phthalimidyl, naphthomimidyl, phthalimidyl, phenanthridinyl, or tetrahydronaphthyl, are also included within the scope of the term "aryl" as used herein.
[0070] Related: As the term is used herein, if the presence, level and / or form of one correlates with that of the other, then two events or substances are "related" to each other. For example, a particular substance (e.g., nucleic acid (e.g., genomic DNA, transcript, mRNA, etc.), polypeptide, genetic characteristic, metabolite, microorganism, cell, etc.) is considered to be related to a particular disease, disorder or condition if its presence, level and / or form correlates (e.g., across a relevant population) with the occurrence of the disease, disorder or condition and susceptibility to the disease, disorder or condition.
[0071] Carrier: as used herein, refers to a diluent, adjuvant, excipient or vehicle that is administered with the composition.In some typical embodiments, carrier can comprise sterile liquid, such as water and oil, including oil of petroleum, animal, vegetable or synthetic origin, such as peanut oil, soybean oil, mineral oil, sesame oil, etc.In some embodiments, carrier is or comprises one or more solid components.
[0072] Comparable: As used herein, the term "comparable" refers to two or more agents, substances, situations, combinations of conditions, etc. that are not necessarily identical to each other, but are sufficiently similar to allow comparison between them so that a person skilled in the art will understand that conclusions can be reasonably drawn based on the observed differences and similarities. In some embodiments, comparable combinations of conditions, situations, individuals, or populations are characterized by multiple substantially identical features or one or a few different features. In context, a person skilled in the art will understand the degree of identity required in any given situation for two or more such agents, substances, situations, combinations of conditions, etc. to be considered comparable. For example, a person skilled in the art will understand that combinations of situations, individuals, or populations are comparable to each other when they are characterized by a sufficient number and type of substantially identical features to provide a basis for a reasonable conclusion that the differences in the results obtained or observed phenomena under or with the various combinations of situations, individuals, or populations are induced or derived from changes in those features that have changed.
[0073] Cycloaliphatic: As used herein, the term "cycloaliphatic" refers to a saturated or partially unsaturated aliphatic monocyclic, bicyclic, or polycyclic ring system, for example, having 3-30 ring members, where the aliphatic ring system may be optionally substituted. Cycloaliphatic groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cycloheptyl, cycloheptenyl, cyclooctyl, cyclooctenyl, norbornyl, adamantyl, and cyclooctadienyl. In some embodiments, the cycloalkyl has 3-6 carbons. The term "cycloaliphatic" can also include an aliphatic ring where the radical or point of attachment is on the aliphatic ring, fused with one or more aromatic or non-aromatic rings, for example, decahydronaphthyl or tetrahydronaphthyl. In some embodiments, the carbocyclic group is bicyclic. In some embodiments, the carbocyclic group is tricyclic. In some embodiments, the carbocyclic group is polycyclic. In some embodiments, "cycloaliphatic" (or "carbocycle" or "cycloalkyl") refers to a monocyclic C ring that is fully saturated or contains one or more units of unsaturation, but is not aromatic. 3 -C 6 Hydrocarbon or C 8 -C 10 Bicyclic hydrocarbons or C which are fully saturated or contain one or more unsaturated units but are not aromatic 9 -C 16 Tricyclic hydrocarbons.
[0074] Derivative: As used herein, the term "derivative" refers to a structural analogue of a reference substance. In other words, a "derivative" is a substance that shows significant structural similarity with a reference substance, e.g., has a core or common structure, but also differs in a specific and separate way. In some embodiments, a derivative is a substance that can be formed from a reference substance by chemical manipulation. In some embodiments, a derivative is a substance that can be formed by carrying out a synthetic process that is substantially similar (e.g., shares multiple steps) to the synthetic process that forms the reference substance.
[0075] Dosage form or unit dosage form: Those skilled in the art will understand that the term "dosage form" can be used to refer to a physically discrete unit of active agent (e.g., therapeutic or diagnostic agent) for administration to a subject. Typically, each such unit contains a predetermined amount of active agent. In some embodiments, such amount is a unit dosage (or a complete fraction thereof) appropriate for administration according to a dosing regimen determined to correlate with a desired or beneficial outcome when administered to a relevant population (i.e., in a therapeutic dosing regimen). Those skilled in the art will understand that the total amount of a therapeutic composition or agent administered to a particular subject is determined by one or more attending physicians and may include administration of multiple dosage forms.
[0076] Dosing regimen: Those skilled in the art will understand that the term "dosing regimen" can be used to refer to a set of unit doses (typically two or more) that are typically administered individually to a subject, separated by a period of time. In some embodiments, a given therapeutic agent has a recommended dosing regimen that can include one or more administrations. In some embodiments, the dosing regimen includes multiple administrations, each of which is separated in time from the other administrations. In some embodiments, the individual administrations are separated from each other by the same amount of time; in some embodiments, the dosing regimen includes multiple administrations and at least two different times that separate the individual administrations. In some embodiments, all administrations within the dosing regimen are the same unit dosage. In some embodiments, different administrations within the dosing regimen are different amounts. In some embodiments, the dosing regimen includes an initial administration at a first dosage amount, and one or more additional administrations at a second dosage amount that is different from the first dosage amount. In some embodiments, the dosing regimen includes an initial administration at a first dosage amount, and one or more additional administrations at a second dosage amount that is the same amount as the first dosage amount. In some embodiments, the dosing regimen correlates with a desired or beneficial outcome when administered to a relevant population (ie, is a therapeutic dosing regimen).
[0077] Halogen: The term “halogen” means F, Cl, Br or I.
[0078] Heteroaliphatic: The term "heteroaliphatic" is given its ordinary meaning in the art to refer to an aliphatic group, as described herein, in which one or more carbon atoms are replaced with one or more heteroatoms (e.g., oxygen, nitrogen, sulfur, silicon, phosphorous, etc.).
[0079] Heteroaryl: The terms "heteroaryl" and "heteroar-", used alone or as part of a larger moiety, e.g., "heteroaralkyl" or "heteroaralkoxy", "aralkyl", "aralkoxy", "aryloxyalkyl", refer to a monocyclic, bicyclic or polycyclic ring system having, e.g., 5 to 30, e.g., 5, 6, 9, 10, 14, etc., ring members in total, in which at least one ring in the system is aromatic and at least one aromatic ring atom is a heteroatom. In some embodiments, the heteroatom is nitrogen, oxygen or sulfur. In some embodiments, a heteroaryl group is a group having 5 to 14 ring atoms (i.e., monocyclic, bicyclic or polycyclic), in some embodiments, 5, 6, 9, 10 or 14 ring atoms. In some embodiments, a heteroaryl group has 6, 10 or 14 pi electrons shared in the ring arrangement; containing 1 to 5 heteroatoms in addition to the carbon atoms. Heteroaryl groups include, but are not limited to, thienyl, furanyl, pyrrolyl, imidazolyl, pyrazolyl, triazolyl, tetrazolyl, oxazolyl, isoxazolyl, oxadiazolyl, thiazolyl, isothiazolyl, thiadiazolyl, pyridyl, pyridazinyl, pyrimidinyl, pyrazinyl, indolizinyl, purinyl, naphthyridinyl, and pteridinyl. In some embodiments, heteroaryl is a heterobiaryl group, such as bipyridyl. As used herein, the terms "heteroaryl" and "heteroar-" also include groups in which a heteroaromatic ring is fused with one or more aryl, cycloaliphatic, or heterocyclyl rings, and the radical or point of attachment is on the heteroaromatic ring. Non-limiting examples include indolyl, isoindolyl, benzothienyl, benzofuranyl, dibenzofuranyl, indazolyl, benzimidazolyl, benzthiazolyl, quinolyl, isoquinolyl, cinnolinyl, phthalazinyl, quinazolinyl, quinoxalinyl, 4H-quinolizinyl, carbazolyl, acridinyl, phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, and pyrido[2,3-b]-1,4-oxazin-3(4H)-one.Heteroaryl groups can be monocyclic, bicyclic or polycyclic. The term "heteroaryl" can be used interchangeably with the terms "heteroaryl ring" or "heteroaryl group," both of which include rings that are optionally substituted. The term "heteroaralkyl" refers to an alkyl group substituted by a heteroaryl group, where the alkyl and heteroaryl portions independently are optionally substituted.
[0080] Heteroatom: The term "heteroatom" refers to an atom that is not carbon and is not hydrogen. In some embodiments, a heteroatom is oxygen, sulfur, nitrogen, phosphorus, boron, or silicon (any oxidized form of nitrogen, sulfur, phosphorus, or silicon; any basic nitrogen or substitutable nitrogen of a heterocyclic ring (e.g., N, as in 3,4-dihydro-2H-pyrrolyl), NH (as in pyrrolidinyl), or NR (as in N-substituted pyrrolidinyl). + (including quaternized forms of). In some embodiments, the heteroatom is boron, nitrogen, oxygen, silicon, sulfur, or phosphorus. In some embodiments, the heteroatom is nitrogen, oxygen, silicon, sulfur, or phosphorus. In some embodiments, the heteroatom is nitrogen, oxygen, sulfur, or phosphorus. In some embodiments, the heteroatom is nitrogen, oxygen, sulfur, or phosphorus. In some embodiments, the heteroatom is nitrogen, oxygen, or sulfur.
[0081] Heterocyclyl: As used herein, the terms "heterocycle", "heterocyclyl", "heterocyclic radical" and "heterocyclic ring" are used interchangeably and refer to a monocyclic, bicyclic or polycyclic (e.g., 3-30 membered) ring moiety that is saturated or partially unsaturated and contains one or more heteroatom ring atoms. In some embodiments, the heteroatom is boron, nitrogen, oxygen, silicon, sulfur or phosphorus. In some embodiments, the heteroatom is nitrogen, oxygen, silicon, sulfur or phosphorus. In some embodiments, the heteroatom is nitrogen, oxygen, sulfur or phosphorus. In some embodiments, the heteroatom is nitrogen, oxygen or sulfur. In some embodiments, the heterocyclyl group is a stable 3- to 7-membered monocyclic or 7- to 10-membered bicyclic heterocyclic moiety that is saturated or partially unsaturated and has one or more, preferably 1-4, heteroatoms in addition to the carbon atoms, as defined above. When used in reference to a ring atom of a heterocycle, the term "nitrogen" is a substituted nitrogen. For example, in a saturated or partially unsaturated ring having 0-3 heteroatoms selected from oxygen, sulfur or nitrogen, the nitrogen can be N (as in 3,4-dihydro-2H-pyrrolyl), N (as in pyrrolidinyl) or N-substituted pyrrolidinyl. +It may be NR. The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure, and any ring atom may be optionally substituted. Examples of such saturated or partially unsaturated heterocyclic radicals include, but are not limited to, tetrahydrofuranyl, tetrahydrothienyl, pyrrolidinyl, piperidinyl, pyrrolinyl, tetrahydroquinolinyl, tetrahydroisoquinolinyl, decahydroquinolinyl, oxazolidinyl, piperazinyl, dioxanyl, dioxolanyl, diazepinyl, oxazepinyl, thiazepinyl, morpholinyl and quinuclidinyl. The terms "heterocycle", "heterocyclyl", "heterocyclyl ring", "heterocyclic group", "heterocyclic moiety" and "heterocyclic radical" are used interchangeably herein and include groups in which a heterocyclyl ring is fused to one or more aryl, heteroaryl or cycloaliphatic rings and the radical or point of attachment is on the heteroaliphatic ring, e.g., indolinyl, 3H-indolyl, chromanyl, phenanthridinyl or tetrahydroquinolinyl. Heterocyclyl groups can be monocyclic, bicyclic or polycyclic. The term "heterocyclylalkyl" refers to an alkyl group substituted with a heterocyclyl, where the alkyl and heterocyclyl moieties independently may be optionally substituted.
[0082] "Improved", "increased" or "decreased": these terms or grammatically equivalent comparative terms as used herein refer to values compared to comparable reference measurements. For example, in some embodiments, the assessment value achieved with the agent of interest can be "improved" compared to the assessment value obtained with a comparable reference agent. Alternatively or additionally, in some embodiments, the assessment value achieved in a subject or system of interest can be "improved" compared to the assessment value obtained in the same subject or system under different conditions (e.g., before and after an event such as administration of the agent of interest) or in a different, comparable subject (e.g., a comparable subject or system different from the subject or system of interest in the presence of one or more indicators of a particular disease, disorder or condition of interest, or prior exposure to a condition or agent, etc.). In some embodiments, the comparative term refers to a statistically valid difference (e.g., probability and / or magnitude sufficient to achieve statistical validity). Those skilled in the art will understand and can easily determine the degree and / or probability required or sufficient to achieve such statistical significance in a given context.
[0083] Partially unsaturated: As used herein, the term "partially unsaturated" refers to a moiety that contains at least one double or triple bond. The term "partially unsaturated" is intended to encompass groups with multiple sites of unsaturation, but is not intended to include aryl or heteroaryl moieties.
[0084] Pharmaceutical composition: As used herein, the term "pharmaceutical composition" refers to an active agent, such as a compound, formulated with one or more pharma- ceutically acceptable carriers.In some embodiments, the active agent is present in a unit dose suitable for administration in a therapeutic regimen that, when administered to a relevant population, shows a statistically significant probability of achieving a predetermined therapeutic effect. In some embodiments, the pharmaceutical composition may be specially formulated for administration in solid or liquid form, including administration adapted for: oral administration, e.g., immersion (aqueous or non-aqueous solutions or suspensions), tablets, e.g., intended for buccal, sublingual and systemic absorption, boluses, powders, granules, pastes for application to the tongue; parenteral administration, e.g., as a sterile solution or suspension or sustained release formulation, e.g., subcutaneous, intramuscular, intravenous or epidural injection; topical application, e.g., as a cream, ointment or controlled release patch or spray for application to the skin, lung or oral cavity; vaginally or rectally, e.g., as a pessary, cream or foam; sublingually; ophthalmic; transdermal; or via the nasal, pulmonary and other mucosal surfaces.
[0085] Pharmaceutically acceptable: As used herein, the phrase "pharmacologically acceptable" refers to those compounds, substances, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for contact with human tissue without excessive toxicity, irritation, allergic response or other problem or complication, commensurate with a reasonable benefit / risk ratio.
[0086] Pharmaceutically acceptable carrier: As used herein, the term "pharmacologically acceptable carrier" refers to a pharma- ceutically acceptable substance, composition, or vehicle, such as a liquid or solid filler, diluent, excipient, or solvent encapsulant, involved in carrying or transporting the primary compound from one organ or part of the body to another. Each carrier must be "acceptable" in the sense of being compatible with the other ingredients of the formulation and not deleterious to the patient. Some examples of substances which serve as pharma- ceutically acceptable carriers include sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose and its derivatives, such as sodium carboxymethylcellulose, ethylcellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppositories; oils, such as peanut oil, cottonseed oil, sunflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffers, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen-free water; isotonic saline; Ringer's solution; ethyl alcohol; pH buffer solutions; polyesters, polycarbonates and / or polyanhydrides; and other non-toxic compatible substances used in pharmaceutical formulations.
[0087] Pharmaceutically acceptable salts: The term "pharmaceutical acceptable salts" as used herein refers to salts of such compounds that are suitable for use in a pharmaceutical sense, i.e., salts that are suitable for use in contact with humans and lower animals, within the scope of sound medical judgment, without excessive toxicity, irritation, allergic response, etc., and that are commensurate with a reasonable benefit / risk ratio. Pharmaceutically acceptable salts are known. For example, SM Berge et al. have described pharmaceutical acceptable salts in detail in J. Pharmaceutical Sciences, 66: 1-19 (1977). In some embodiments, pharmaceutical acceptable salts include non-toxic acid addition salts, which are salts of amino groups formed by inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid, or organic acids such as acetic acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid, or other known methods such as ion exchange. In some embodiments, the pharma- ceutically acceptable salt includes, but is not limited to, adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecyl sulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2-hydrogen phosphate, glycerol ... Salts include, but are not limited to, non-toxic base addition salts, such as salts formed with bases and acid groups of the acidic groups of the compounds provided herein.Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, etc. In some embodiments, the pharma- ceutically acceptable salt is an ammonium salt (e.g., -N(R). 3 + ). In some embodiments, the pharma- ceutically acceptable salt is a sodium salt. In some embodiments, the pharma- ceutically acceptable salt is a calcium salt. In some embodiments, the pharma- ceutically acceptable salt includes non-toxic ammonium, quaternary ammonium and amine cations formed with counterions such as halides, hydroxides, carboxyls, sulfates, phosphates, nitrates, alkyls having 1-6 carbon atoms, sulfonates and arylsulfonates, when appropriate. In some embodiments, the provided compounds are in the form of pharma- ceutically acceptable salts.
[0088] Protecting group: As used herein, the phrase "protecting group" or "protection group" refers to a temporary substituent that protects a potentially reactive functional group from undesired chemical transformations. Examples of such protecting groups include esters of carboxylic acids, silyl ethers of alcohols, and acetals and ketals of aldehydes and ketones, respectively. A "Si-protecting group" is a protecting group that contains a Si atom, Si-trialkyl (e.g., trimethylsilyl, tributylsilyl, t-butyldimethylsilyl), Si-triaryl, Si-alkyl-diphenyl (e.g., t-butyldiphenylsilyl) or Si-aryl-dialkyl (e.g., Si-phenyldialkyl). Generally, Si-protecting groups are attached to an oxygen atom. The field of protecting group chemistry has been reviewed (Greene, TW; Wuts, PGM Protective Groups in Organic Synthesis, 2nd ed.; Wiley: New York, 1991). Such protecting groups (and related protected moieties) are described in detail below.
[0089] Protected hydroxyl groups are known in the art and include those described in detail in Protecting Groups in Organic Synthesis, TW Greene and PGM Wuts, 3rd edition, John Wiley & Sons, 1999, which is incorporated herein by reference in its entirety. Examples of suitable protected hydroxyl groups further include, but are not limited to, esters, carbonates, sulfonates, allyl ethers, ethers, silyl ethers, alkyl ethers, arylalkyl ethers, and alkoxyalkyl ethers. Examples of suitable esters include formates, acetates, propionates, pentanoates, crotonates, and benzoates. Specific examples of suitable esters include formate, benzoylformate, chloroacetate, trifluoroacetate, methoxyacetate, triphenylmethoxyacetate, p-chlorophenoxyacetate, 3-phenylpropionate, 4-oxopentanoate, 4,4-(ethylenedithio)pentanoate, pivaloate (trimethylacetic acid), crotonate, 4-methoxy-crotonate, benzoate, p-benzylbenzoate, 2,4,6-trimethylbenzoate. Examples of suitable carbonates include 9-fluorenylmethyl, ethyl, 2,2,2-trichloroethyl, 2-(trimethylsilyl)ethyl, 2-(phenylsulfonyl)ethyl, vinyl, allyl and p-nitrobenzyl carbonate. Examples of suitable silyl ethers include trimethylsilyl, triethylsilyl, t-butyldimethylsilyl, t-butyldiphenylsilyl, triisopropylsilyl ether and other trialkylsilyl ethers. Examples of suitable alkyl ethers include methyl, benzyl, p-methoxybenzyl, 3,4-dimethoxybenzyl, trityl, t-butyl and allyl ethers or derivatives thereof. Alkoxyalkyl ethers include acetals such as methoxymethyl, methylthiomethyl, (2-methoxyethoxy)methyl, benzyloxymethyl, β-(trimethylsilyl)ethoxymethyl and tetrahydropyran-2-yl ether.Examples of suitable arylalkyl ethers include benzyl, p-methoxybenzyl (MPM), 3,4-dimethoxybenzyl, O-nitrobenzyl, p-nitrobenzyl, p-halobenzyl, 2,6-dichlorobenzyl, p-cyanobenzyl, 2-picolyl and 4-picolyl ethers.
[0090] Protected amines are known in the art and include those described in detail in Greene (1999). Suitable mono-protected amines further include, but are not limited to, aralkyl amines, carbamates, allyl amines, amides, and the like. Examples of suitable mono-protected amino moieties include t-butyloxycarbonylamino (-NHBOC), ethyloxycarbonylamino, methyloxycarbonylamino, trichloroethyloxycarbonylamino, allyloxycarbonylamino (-NHAlloc), benzyloxycarbonylamino (-NHCBZ), allylamino, benzylamino (-NHBn), fluorenylmethoxycarbonylamino (-NHFmoc), formamide, acetamide, chloroacetamide, dichloroacetamide, trichloroacetamide, phenylacetamide, trifluoroacetamide, benzamide, t-butyldiphenylsilyl, and the like. Suitable di-protected amines include amines substituted with two substituents independently selected from those listed above as mono-protected amines, and further include cyclic imides, such as phthalimides, maleimides, succinimides, etc. Suitable di-protected amines also include pyrroles, such as 2,2,5,5-tetramethyl-[1,2,5]azadisilolidine, etc., and azides.
[0091] Protected aldehydes are known in the art and include those described in detail in Greene (1999). Suitable protected aldehydes further include, but are not limited to, acyclic acetals, cyclic acetals, hydrazones, imines, and the like. Examples of such groups include dimethyl acetal, diethyl acetal, diisopropyl acetal, dibenzyl acetal, bis(2-nitrobenzyl) acetal, 1,3-dioxane, 1,3-dioxolane, semicarbazones and derivatives thereof.
[0092] Protected carboxylic acids are known in the art and include those described in detail in Greene (1999). Suitable protected carboxylic acids further include, but are not limited to, optionally substituted C 1-6 These include aliphatic esters, optionally substituted aryl esters, silyl esters, activated esters, amides, hydrazides, and the like. Examples of such ester groups include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, benzyl, and phenyl esters, each of which may be optionally substituted. Further suitable protected carboxylic acids include oxazolines and orthoesters.
[0093] Protected thiols are known in the art and include those described in detail in Greene (1999). Suitable protected thiols further include, but are not limited to, disulfides, thioethers, silyl thioethers, thioesters, thiocarbonates, and thiocarbamates, and the like. Examples of such groups include, but are not limited to, alkyl thioethers, benzyl and substituted benzyl thioethers, triphenylmethyl thioethers, and trichloroethoxycarbonyl thioesters, to name a few.
[0094] Reference: as used herein, describes the standard or control against which comparison is performed. For example, in some embodiments, the agent, animal, individual, population, sample, sequence or value of interest is compared with the agent, animal, individual, population, sample, sequence or value of reference or control. In some embodiments, the reference or control is tested and / or determined substantially simultaneously with the test or determination of interest. In some embodiments, the reference or control is a past reference or control, and is optionally embodied in a tangible medium of expression. Typically, as understood by those skilled in the art, the reference or control is determined or characterized under conditions or circumstances comparable to the conditions or circumstances under evaluation. Those skilled in the art will understand when there is sufficient similarity to justify reliance on and / or comparison to a specific possible reference or control.
[0095] Substituted: As used herein, the compounds of the present invention may be optionally substituted and / or may contain substituted moieties. In general, the term "substituted", whether preceded by the term "optionally", means that one or more hydrogens of the specified moiety are replaced with a suitable substituent. Unless otherwise specified, an "optionally substituted" group may have a suitable substituent at each substitutable position of the group, and when more than one position of any given structure may be substituted with more than one substituent selected from a specified group, the substituents may be the same or different at all positions. The combinations of substituents envisioned by the present disclosure are preferably those that result in the formation of stable or chemically feasible compounds. As used herein, the term "stable" refers to a compound that is substantially unchanged when subjected to conditions that allow the compound to be produced, detected, and in certain embodiments, recovered, purified, and used for one or more of the purposes described herein.
[0096] Suitable monovalent substituents are halogen; -(CH 2 ) 0-4 R 〇 ;-(CH 2 ) 0-4 OR 〇 ;-O(CH 2 ) 0-4 R 〇 , -O-(CH 2 ) 0-4 C(O)OR 〇 ;-(CH 2 ) 0-4 CH(OR 〇 ) 2 ;R 〇 may be substituted with -(CH 2 ) 0-4 Ph;R 〇 may be substituted with -(CH 2 ) 0-4 O(CH 2 ) 0-1 Ph;R 〇 may be substituted with -CH=CHPh; R 〇 may be substituted with -(CH 2) 0-4 O(CH 2 ) 0-1 -ピリジル;-NO 2 ;-CN;-N 3 ;-(CH 2 ) 0-4 N(R 〇 ) 2 ;-(CH 2 ) 0-4 N(R 〇 )C(O)R 〇 ;-N(R 〇 )C(S)R 〇 ;-(CH 2 ) 0-4 N(R 〇 )C(O)N(R 〇 ) 2 ;-N(R 〇 )C(S)N(R 〇 ) 2 ;-(CH 2 ) 0-4 N(R 〇 )C(O)OR 〇 ;-N(R 〇 )N(R 〇 )C(O)R 〇 ;-N(R 〇 )N(R 〇 )C(O)N(R 〇 ) 2 ;-N(R 〇 )N(R 〇 )C(O)OR 〇 ;-(CH 2 ) 0-4 C(O)R 〇 ;-C(S)R 〇 ;-(CH 2 ) 0-4 C(O)OR 〇 ;-(CH 2 ) 0-4 C(O)SR 〇 ;-(CH 2 ) 0-4 C(O)OSi(R 〇 ) 3 ;-(CH 2 ) 0-4 OC(O)R 〇 ;-OC(O)(CH 2 ) 0-4 SR 〇 、-(CH 2 )0-4 SC(O)R 〇 ;-(CH 2 ) 0-4 C(O)N(R 〇 ) 2 ;-C(S)N(R 〇 ) 2 ;-C(S)SR°;-SC(S)SR°、-(CH 2 ) 0-4 OC(O)N(R 〇 ) 2 ;-C(O)N(OR 〇 )R 〇 ;-C(O)C(O)R 〇 ;-C(O)CH 2 C(O)R 〇 ;-C(NOR 〇 )R 〇 ;-(CH 2 ) 0-4 SSR 〇 ;-(CH 2 ) 0-4 S(O) 2 R 〇 ;-(CH 2 ) 0-4 S(O) 2 OR 〇 ;-(CH 2 ) 0-4 OS(O) 2 R 〇 ;-S(O) 2 N(R 〇 ) 2 ;-(CH 2 ) 0-4 S(O)R 〇 ;-N(R 〇 )S(O) 2 N(R 〇 ) 2 ;-N(R 〇 )S(O) 2 R 〇 ;-N(OR 〇 )R 〇 ;-C(NH)N(R 〇 ) 2 ;-Si(R 〇 ) 3 ;-OSi(R 〇 ) 3 ;-OSi(OR 〇 ) 3 ;-P(R 〇 )2 ;-P(OR 〇 ) 2 ;-OP(R 〇 ) 2 ;-OP(OR 〇 ) 2 ;-N(R 〇 )P(R 〇 ) 2 ;-OP(O)(R 〇 ) 2 ;-OP(O)(OR 〇 ) 2 ;-N(R 〇 )P(O)(R 〇 ) 2 ;-N(R 〇 )P(O)(OR 〇 ) 2 ;-B(R 〇 ) 2 ;-OB(R 〇 ) 2 ;-OB(OR 〇 ) 2 ;-P(O)(R 〇 ) 2 ;-OP(O)(R 〇 ) 2 ;-(C 1-4 Linear or branched alkylene)ON(R 〇 ) 2 ; or -(C 1-4 Linear or branched alkylene)C(O)ON(R 〇 ) 2 where each R 〇 are as defined below and are independently hydrogen, C 1-20 C having 1 to 5 heteroatoms independently selected from aliphatic, nitrogen, oxygen, sulfur, silicon and phosphorus 1-20 Heteroaliphatic, -CH 2 -(C 6-14 Aryl), -O(CH 2 ) 0-1 (C 6-14 Aryl), -CH 2 -(5-14 membered heteroaryl ring), a 5-20 membered monocyclic, bicyclic or polycyclic, saturated, partially unsaturated or aryl ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, sulfur, silicon and phosphorus, or two independently occurring R〇 together with their atoms form a 3-20 membered monocyclic, bicyclic or polycyclic, saturated, partially unsaturated or aryl ring, optionally substituted as defined below, having 0-5 heteroatoms independently selected from nitrogen, oxygen, sulfur, silicon and phosphorus.
[0097] R 〇 (or two independently existing R 〇 Suitable monovalent substituents on the ring formed by (and together with the atoms between them) are independently halogen, -(CH 2 ) 0-2 R ● , -(Halo R ● ), -(CH 2 ) 0-2 OH, -(CH 2 ) 0-2 OR ● , -(CH 2 ) 0-2 CH(OR ● ) 2 ;-O(Halo R ● ), -CN, -N 3 , -(CH 2 ) 0-2 C(O)R ● , -(CH 2 ) 0-2 C(O)OH, -(CH 2 ) 0-2 C(O)OR ● , -(CH 2 ) 0-2 S.R. ● , -(CH 2 ) 0-2 SH, -(CH 2 ) 0-2 NH 2 , -(CH 2 ) 0-2 NHR ● , -(CH 2 ) 0-2 NR ● 2 , -NO 2 , -SiR ● 3 , -OSiR ● 3 , -C(O)SR ● , -(C1-4 Linear or branched alkylene)C(O)OR ● Or -SSR ● where each R ● is unsubstituted or, if preceded by "halo", is substituted only with one or more halogens, and independently, C 1-4 Aliphatic, -CH 2 Ph, -O(CH 2 ) 0-1 Ph, and a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen and sulfur. ● Suitable divalent substituents on a saturated carbon atom of include ═O and ═S.
[0098] Suitable divalent substituents, e.g., on suitable carbon atoms, nitrogen atoms, etc., are independently: =O, =S, =CR * 2 , =NNR * 2 , =NNHC(O)R * , =NNHC(O)OR * , =NNHS(O) 2 R * , =NR * , =NOR * , -O(C(R * 2 )) 2-3 O- or -S(C(R * 2 )) 2-3 S-, where each R * may be substituted as defined below and independently represent hydrogen, C 1-20 C having 1 to 5 heteroatoms independently selected from aliphatic, nitrogen, oxygen, sulfur, silicon and phosphorus 1-20 Heteroaliphatic, -CH 2 -(C 6-20 Aryl), -O(CH 2 ) 0-1 (C 6-20 Aryl), -CH 2-(5-20 membered heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, sulfur, silicon and phosphorus), 5-20 membered, monocyclic, bicyclic or polycyclic, saturated, partially unsaturated or aryl ring having 0-5 heteroatoms independently selected from nitrogen, oxygen, sulfur, silicon and phosphorus, or two independently present R * together with their atoms form a 3-20 membered monocyclic, bicyclic or polycyclic, saturated, partially unsaturated or aryl ring, which may be substituted as defined below, having 0-5 heteroatoms independently selected from nitrogen, oxygen, sulfur, silicon and phosphorus. Suitable divalent substituents attached to adjacent substitutable atoms of an "optionally substituted" group are -O(CR * 2 ) 2-3 Contains O-.
[0099] R * (or two independently existing R * Suitable monovalent substituents on the ring formed by (and together with the atoms between them) are independently halogen, -(CH 2 ) 0-2 R ● , -(Halo R ● ), -(CH 2 ) 0-2 OH, -(CH 2 ) 0-2 OR ● , -(CH 2 ) 0-2 CH(OR ● ) 2 ;-O(Halo R ● ), -CN, -N 3 , -(CH 2 ) 0-2 C(O)R ● , -(CH 2 ) 0-2 C(O)OH, -(CH 2 ) 0-2 C(O)OR ● , -(CH 2 ) 0-2 S.R. ● , -(CH 2 ) 0-2SH, -(CH 2 ) 0-2 NH 2 , -(CH 2 ) 0-2 NHR ● , -(CH 2 ) 0-2 NR ● 2 , -NO 2 , -SiR ● 3 , -OSiR ● 3 , -C(O)SR ● , -(C 1-4 Linear or branched alkylene)C(O)OR ● Or -SSR ● where each R ● is unsubstituted or, if preceded by "halo", is substituted only with one or more halogens, and independently, C 1-4 Aliphatic, -CH 2 Ph, -O(CH 2 ) 0-1 R is a 5-6 membered saturated, partially unsaturated or aryl ring having Ph and 0-4 heteroatoms independently selected from nitrogen, oxygen and sulfur. * Suitable divalent substituents of include ═O and ═S.
[0100] In some embodiments, a suitable substituent on a substitutable nitrogen of an "optionally substituted" group is -R † , -NR † 2 , -C(O)R † , -C(O)OR † , -C(O)C(O)R † , -C(O)CH 2 C(O)R † , -S(O) 2 R † , -S(O) 2 NR † 2 , -C(S)NR † 2 , -C(NH)NR † 2 or -N(R † )S(O) 2 R† where each R † are independently hydrogen, optionally substituted C as defined below 1-6 an aliphatic, unsubstituted -OPh or an unsubstituted 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or two independently occurring R † together with their atoms form a 3-12 membered saturated, partially unsaturated or aryl monocyclic or bicyclic ring having 0-4 heteroatoms independently selected from nitrogen, oxygen, sulfur, silicon and phosphorus.
[0101] In some embodiments, R † Suitable substituents on the aliphatic group are independently halogen, -R ● , -(Halo R ● ), -OH, -OR ● , -O(HaloR ● ), -CN, -C(O)OH, -C(O)OR ● , -NH 2 , -NHR ● , -NR ● 2 OR -NO 2 where each R ● is unsubstituted or, if preceded by "halo", is substituted only with one or more halogens, and independently, C 1-4 Aliphatic, -CH 2 Ph, -O(CH 2 ) 0-1 Ph is a 5-6 membered saturated, partially unsaturated or aryl ring having 0-4 heteroatoms independently selected from nitrogen, oxygen or sulfur.
[0102] Subject: As used herein, the term "subject" or "test subject" refers to any living organism to which the provided compound or composition is administered according to the present invention, for example, for experimental, diagnostic, prophylactic and / or therapeutic purposes. Typical subjects include animals (e.g., mammals such as mice, rats, rabbits, non-human primates and humans; insects; worms, etc.) and plants. In some embodiments, the subject may have and / or be susceptible to a disease, disorder and / or condition. In some embodiments, the subject is a human.
[0103] Susceptible to: An individual who is "susceptible to" a disease, disorder, and / or condition is an individual who is at a higher risk of developing the disease, disorder, and / or condition than the general population. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition may not have been diagnosed with the disease, disorder, and / or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition may show symptoms of the disease, disorder, and / or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition may not show symptoms of the disease, disorder, and / or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition progresses to the disease, disorder, and / or condition. In some embodiments, an individual who is susceptible to a disease, disorder, and / or condition does not progress to the disease, disorder, and / or condition.
[0104] Therapeutic agent: As used herein, the phrase "therapeutic agent" refers to an agent that has a therapeutic effect and / or elicits a desired biological and / or pharmacological effect when administered to a subject. In some embodiments, a therapeutic agent is any substance that can be used to alleviate, improve, alleviate, inhibit, prevent, delay the onset, reduce the severity, or reduce the occurrence of one or more symptoms or characteristics of a disease, disorder, and / or condition. In some embodiments, provided compounds are useful as therapeutic agents.
[0105] Therapeutic regimen: As used herein, the term "therapeutic regimen" refers to a dosing regimen whose administration to a relevant population can be correlated with a desired or beneficial therapeutic outcome.
[0106] Therapeutically effective amount: As used herein, the term "therapeutically effective amount" refers to a substance (e.g., a therapeutic agent, composition, and / or formulation) that elicits a desired biological response when administered as part of a treatment regimen. In some embodiments, a therapeutically effective amount of a substance is an amount sufficient to treat, diagnose, prevent, and / or delay the onset of a disease, disorder, and / or condition when administered to a subject having or susceptible to a disease, disorder, and / or condition. As will be appreciated by those skilled in the art, an effective amount of a substance may vary depending on factors such as the desired biological endpoint, the substance delivered, the target cell or tissue, and the like. For example, an effective amount of a compound in a formulation for treating a disease, disorder, and / or condition is an amount that relieves, improves, alleviates, inhibits, prevents, delays the onset, reduces the severity, or reduces the occurrence of one or more symptoms or characteristics of a disease, disorder, and / or condition. In some embodiments, a therapeutically effective amount is administered in a single dose; in some embodiments, multiple unit doses are required to deliver a therapeutically effective amount. In some embodiments, provided compounds are administered in a therapeutically effective amount, in a single dose or in multiple unit doses.
[0107] Treat: As used herein, the term "treat", "treatment" or "treating" refers to any method used to partially or completely relieve, ameliorate, alleviate, inhibit, prevent, delay the onset, reduce the severity, or reduce the occurrence of one or more symptoms or characteristics of a disease, disorder, and / or condition. Treatment may be administered to subjects who do not show signs of a disease, disorder, and / or condition. In some embodiments, treatment may be administered to subjects who show only early signs of a disease, disorder, and / or condition, for example, to reduce the risk of developing pathology associated with the disease, disorder, and / or condition.
[0108] Unit dose: As used herein, the expression "unit dose" refers to an amount administered as a single dose of a pharmaceutical composition and / or in a physically discrete unit. In many embodiments, a unit dose comprises a predetermined amount of active agent. In some embodiments, a unit dose comprises an entire single dose of a drug. In some embodiments, two or more unit doses are administered to achieve a total single dose. In some embodiments, administration of multiple unit doses is required or expected to be required to achieve a desired effect. A unit dose can be, for example, a volume of a liquid (e.g., an acceptable carrier) containing a predetermined amount of one or more therapeutic agents, a predetermined amount of one or more therapeutic agents in solid form, a sustained release formulation or a drug delivery device containing a predetermined amount of one or more therapeutic agents, etc. It is understood that a unit dose can be in a formulation that contains a variety of optional components in addition to one or more therapeutic agents. For example, acceptable carriers (e.g., pharma- ceutically acceptable carriers), diluents, stabilizers, buffers, preservatives, etc., can include those described below. Those skilled in the art understand that in many embodiments, the total appropriate daily dosage of a particular therapeutic agent can comprise a portion or a plurality of unit doses, and can be determined by the attending physician within the scope of sound medical judgment.In some embodiments, the specific effective dosage level for any particular subject or organism can depend on a variety of factors, including the disorder and the severity of the disorder that is treated; the specific active compound that is used; the specific composition that is used; the age, weight, general health, sex and diet of the subject; the administration time and the excretion rate of the specific active compound that is used; the duration of treatment; the drugs and / or additional therapies that are used in combination with or simultaneously with one or more specific compounds that are used, and factors that are known in the medical field.
[0109] Unsaturated: As used herein, the term "unsaturated" means that a moiety has one or more units of unsaturation.
[0110] Wild-type: As used herein, the term "wild-type" has its art-understood meaning of referring to a material having a structure and / or activity found in nature in a "normal" (as opposed to mutated, diseased, altered, etc.) state or situation. Those of skill in the art will appreciate that wild-type genes and polypeptides often exist in multiple alternative forms (e.g., alleles).
[0111] Unless otherwise specified, salts, e.g., pharma- ceutically acceptable acid or base addition salts, stereoisomeric forms, and tautomeric forms of the provided compounds (e.g., drugs, ARMs, etc.) are included. Unless otherwise specified, structures depicted herein also include various isotopes, e.g., replacement of hydrogen with deuterium or tritium, 13 C or 14 In some embodiments, the compositions comprising the compounds include isotopes enriched in the compounds at levels of the isotope. Such compounds and compositions are useful as analytical tools, probes in biological assays, or therapeutic agents, and the like.
[0112] Unless otherwise clear from the context, in the present invention, (i) the term "a" may be understood to mean "at least one"; (ii) the term "or" may be understood to mean "and / or"; (iii) the terms "comprising" and "including" may be understood to encompass the itemized components or steps present either by themselves or together with one or more additional components or steps; (iv) the terms "about" and "approximately" may be understood to allow for standard variations understood by those of skill in the art; and (v) when ranges are provided, the endpoints are included.
[0113] 3.Cellular immunotherapy A variety of immune cells, particularly NK cells, can be used with the agents described herein to treat a variety of conditions, disorders or diseases, including cancer. Such cells are administered before, simultaneously and / or sequentially with the agents described herein, such as ARM. In some embodiments, such cells, such as NK cells, are administered simultaneously with the agents, such as ARM, in the same composition that includes both NK cells and ARM. In some embodiments, such cells, such as NK cells, are administered simultaneously with the agents, such as ARM, in separate compositions, such as one composition that includes NK cells but does not include ARM and one composition that includes ARM but does not include NK cells.
[0114] As will be appreciated by those skilled in the art, useful immune cells such as NK cells can be derived from a variety of sources and / or engineered in numerous ways. For example, in some embodiments, the NK cells are derived from stem cells. In some embodiments, the NK cells are derived from an iPSC line. In some embodiments, the NK cells are derived from a clonal master iPSC line. In some embodiments, the NK cells are engineered to express a specific receptor, e.g., a high affinity, optionally uncleavable CD16 receptor. In some embodiments, the NK cells are engineered to express a chimeric antigen receptor (CAR), e.g., in some embodiments, the NK cells can be engineered to express an anti-CD19 CAR. In some embodiments, the NK cells are CAR-NK cells. In some embodiments, the NK cells are engineered to express a cytokine receptor. In some embodiments, the NK cells contain an IL-15 receptor fusion that enhances tolerance and expansion capabilities without the need for co-administration of cytokine support. In some embodiments, the NK cells are engineered to inhibit the expression of a specific cellular protein, e.g., a specific cell surface protein. In some embodiments, the NK cells are engineered to inhibit the expression of CD38. In some embodiments, the NK cells are derived from the placenta. In some embodiments, the NK cells are donor NK cells. In some embodiments, the NK cells are haploidentical donor NK cells. In some embodiments, the NK cells are mismatched donor NK cells. In some embodiments, the NK cells are related donor NK cells, e.g., mismatched related donor NK cells. In some embodiments, the NK cells are unrelated donor NK cells. In some embodiments, the NK cells are derived from a subject, e.g., a patient. In some embodiments, the technology provided includes natural cell engagers that bind to natural cells (e.g., NK cells and macrophages) and simultaneously bind to specific tumor cells. In some embodiments, the NK cells are derived from umbilical cord blood stem and progenitor cells.In some embodiments, NK cells are derived from regulating signaling pathways, such as the Notch signaling pathway. In some embodiments, nanoparticles are utilized to improve and / or maintain the proliferation of NK cells. In some embodiments, the NK cells described herein are produced ex vivo. In some embodiments, the NK cells are cryopreserved and stored as a ready-to-use cell therapy. Examples of certain such techniques include those utilized by Fate Therapeutics, NantKwest Inc., Celularity, Inc., GC Pharma, Sorrento Therapeutics, Inc., Affimed GmbH / MD Anderson Cancer Center, Gamida Cell Ltd., Nohla Therapeutics, Kiadis Pharma NV, and others. Those skilled in the art will understand that antibodies and / or CARs that may be optionally utilized against certain antigens utilized in certain such techniques may not be required for the techniques provided, including the ARMs described herein.
[0115] Cell populations / preparations In some embodiments, useful cells, e.g., NK cells, are processed prior to administration to a subject. In many embodiments, NK cells are enriched, preactivated, and / or expanded in vitro prior to administration to a subject. In some embodiments, a composition comprising NK cells for administration is enriched for NK cells compared to a reference composition, e.g., blood from a subject to which such composition is administered. In some embodiments, enrichment is or includes an increase in the number of cells per unit volume, e.g., mL. In some embodiments, enrichment is or includes an increase in the proportion of NK cells in such a composition. In some embodiments, enrichment is or includes an increase in the number of cells per unit volume and an increase in the proportion of NK cells in the composition. In some embodiments, the composition is a substantially pure composition of NK cells, in that non-NK cells in the composition are "impurities" derived from the manufacturing process (e.g., incomplete isolation, purification, etc.). As will be appreciated by those skilled in the art, chemical and biological processes rarely, if ever, run to completion and / or proceed completely, or achieve or avoid absolute results. Thus, the term "substantially" is used herein to capture the potential lack of completeness inherent in many biological and / or chemical phenomena.
[0116] A variety of techniques for enriching NK cells are available in the art and can be utilized according to the present invention.For example, in some embodiments, NK cells are isolated using leukapheresis, optionally with purification steps such as CD3 depletion and / or CD56 positive selection.In some embodiments, compared with a reference population of NK cells (e.g., NK cells in the blood of donor or subject), NK cells, for example, preactivated memory-like NK cells, are enriched for CD56 and depleted of CD3 expressing cells.
[0117] Prior to administration to a subject, the NK cells are typically preactivated with cytokines such as IL-12, IL-15, and IL-18 for an appropriate period of time (e.g., 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, or 25 hours or more, e.g., about 16 hours). In some embodiments, prior to administration, the NK cells are treated with cytokines. In some embodiments, NK cells are preactivated by treatment with an appropriate amount of IL-12 (e.g., about 10 ng / mL), IL-15 (e.g., 50 ng / mL), and IL-18 (e.g., 50 ng / mL) for an appropriate period of time (e.g., 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, 24 hours, or 25 hours or more, e.g., about 16 hours). NK cell preactivation conditions and preactivated NK cells can be assessed by evaluation of one or more markers, such as CD94, NKG2A, NKp46, CD25, NKp30, NKp44, CD62L, CD27, TRAIL, the cytotoxic molecules perforin, and granzyme B. Certain useful markers are described in Romee et al., Blood 120, 4751-4760, (2012); Leong et al., Biol. Blood Marrow Transplant. 20, 463-473 (2014); Romee et al., Sci Transl Med. 2016 Sep 21; 8(357):357ra123. doi: 10.1126 / scitranslmed.aaf2341, etc. In some embodiments, the NK cells are primary human NK cells differentiated in vitro into memory-like NK cells via full activation with preactivated IL-12, IL-15 and IL-18.
[0118] In particular, such cytokine-induced memory-like NK cells show enhanced response to cytokine or activating receptor restimulation for weeks to months after preactivation, and may be particularly useful for treating a variety of conditions, disorders or diseases, including cancer. In some embodiments, such preactivated memory-like NK cells have enhanced interferon-γ (IFN-γ) production and / or cytotoxicity against cancer cells. Exemplary methods of production and administration of such NK cells can be found in Romee et al., Blood 120, 4751-4760, (2012); Leong et al., Biol. Blood Marrow Transplant. 20, 463-473 (2014); Romee et al., Sci Transl Med. 2016 Sep 21; 8(357):357ra123. doi: 10.1126 / scitranslmed.aaf2341, etc. In some embodiments, such NK cells have enhanced proliferation following restimulation (e.g., with cytokines or via activating receptors, etc.), express high affinity or high levels of the IL-2 receptor αβγ, and / or provide increased IFN-γ production, compared to a comparable reference NK cell, e.g., an NK cell similarly produced but that has not been pre-activated (e.g., not treated with cytokines, treated only with low doses of IL-15, etc.).
[0119] Preactivated memory-like NK cells may have a significant difference in the number of protein expressions compared to reference NK cells, such as CD94, NKG2A, NKp46, CD25, NKp30, NKp44, CD62L, CD27, TRAIL, cytotoxic molecules perforin and granzyme B. In some embodiments, NK cells show a decrease in NKp80 expression. Such markers can be utilized separately or in combination to enrich, purify, and / or identify memory-like NK cells, among others. Exemplary useful markers can be identified using a variety of techniques, such as mass cytometry and multidimensional analysis. Exemplary methods for identifying proteins that can distinguish preactivated memory-like NK cells from reference (e.g., control) NK cells and exemplary such proteins are described in Romee et al., Sci Transl Med. 2016 Sep 21;8(357):357ra123. doi: 10.1126 / scitranslmed.aaf2341.
[0120] In some embodiments, immune cells, such as NK cells, are contacted with a GSK3α / β inhibitor. In some embodiments, such cells are preactivated with a GSK3α / β inhibitor.
[0121] In some embodiments, the immune cells are cytokine-induced memory-like NK cells. In some embodiments, the immune cells are IL-12, IL-15 and IL-18-preactivated NK cells. In some embodiments, the immune cells are allogeneic HLA-haplotype-matched IL-12, IL-15 and IL-18-activated NK cells. Without intending to be limited by any of them, memory-like NK cells after IL-12, IL-15 and IL-18 preactivation can result in a process including differentiation that gives long-term changes in functional capacity. Memory-like NK cells with such functional capacity can be produced by treatment with other agents (e.g., other cytokines or other small molecules, peptides, proteins, etc.). Techniques (e.g., protein markers, assays, etc.) for evaluating treatment with such agents and / or resulting NK cells are available in the art and may be utilized according to the present invention (e.g., techniques described in Romee et al., Sci Transl Med. 2016 Sep 21;8(357):357ra123. doi: 10.1126 / scitranslmed.aaf2341). In some embodiments, memory-like NK cells have increased expression of inhibitory and activating cytokine receptors (e.g., CD94 / NKG2A, NKp30, NKp44, NKp46, NKG2D, CD62L, and CD25, etc.) and / or decreased expression of certain proteins (e.g., NKp80). In some embodiments, the levels of certain receptors (e.g., KIR, CD57, NKG2C, DNAM-1, CD137, CD11b, etc.) are substantially unchanged. In some embodiments, changes in activation, inhibitory, cytokine, and adhesion receptors are consistent with differentiation. In some embodiments, cytokine preactivation provides epigenetic regulation of certain genes, such as IFN-γ. For example, in some embodiments, IL-12, IL-15 and IL-18 activation (e.g., for 5 days) results in reduced methylation of the IFN-γ conserved non-coding sequence 1 locus in human NK cells.In some embodiments, certain pre-activated NK cells (e.g., cytokine-induced) cells exist in an enhanced activation state without substantial differentiation.
[0122] In some embodiments, the NK cells are administered within 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks, 11 weeks, 12 weeks, 13 weeks, 14 weeks, 15 weeks, 16 weeks, 17 weeks, 18 weeks, 19 weeks, or 20 weeks, or within 4 months, 5 months, 6 months, 7 months, 8 months, 9 months, 10 months, 11 months, or months after preactivation.
[0123] In particular, the present invention encompasses the recognition that such NK cells with enhanced properties and / or activity that may enhance the inhibition or killing of cancer cells may result in more and / or more severe side effects and / or toxicity, such as off-target toxicity to normal cells. Thus, in some embodiments, the present invention provides techniques for reducing such side effects and / or toxicity, including administering one or more agents, particularly ARMs, that promote, increase, and / or enhance the interaction of NK cells with targets and reduce the side effects and / or toxicity associated with NK cell administration, among others.
[0124] In some embodiments, the NK cells are expanded before, during and / or after preactivation. In some embodiments, the NK cells are purified prior to administration, e.g., to remove certain mediators (or components thereof), activating cytokines, etc.
[0125] In some embodiments, the NK cells administered to the subject are isolated and / or expanded from the subject (autologous). In some embodiments, the NK cells administered to the subject are isolated and / or expanded from another subject (allogeneic; e.g., from a haploidentical donor).
[0126] In some embodiments, the NK cells are processed (e.g., isolated, purified, preactivated, etc.) prior to administration. In some embodiments, the NK cell composition for administration comprises a specific artificial medium or components thereof, such as complete RPMI-1640 medium containing L-glutamine, HEPES, NEAA, penicillin / streptomycin, and 10% human AB serum, optionally supplemented with rhIL-15 (1 ng / mL) to support survival.
[0127] Administration Immune cells, such as preactivated memory-like NK cells, are formulated into a variety of formats known in the art for administration to a subject. Depending on the subject and / or the condition, disorder or disease being treated, an appropriate amount of cells is administered to provide a clinical benefit. In some embodiments, the cell dose levels are 10,000-100 million, 100,000-50 million, 100,000-20 million, 100,000-10 million, 50,000, 100,000, 200,000, 300,000, 300,000, 500,000, 1 million, 2 million, 3 million, 4 million, 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 15 million, 20 million, 25 million, 30 million, 35 million, 40 million, 45 million, 50 million, 60 million, 70 million, 80 million, or 90 million per kilogram. In some embodiments, the dose levels are 0.5×10 per kg or 100,000 per kg. 6 In some embodiments, the dose level is 1×10 per kg. 6 In some embodiments, the dose level is 10×10 per kg. 6 As will be appreciated by one of skill in the art, preactivated memory-like NK cells may be administered at lower doses to achieve the same or more clinical benefit when administered in the same amount, or to provide more clinical benefit, when compared to unactivated NK cells or preactivated NK cells that are not memory-like (e.g., treated overnight with IL-2 or IL-15 alone).
[0128] In many embodiments, the cells are administered via intravenous infusion. In some embodiments, the composition comprising the cells, e.g., preactivated NK cells, is administered via infusion. In some embodiments, such a composition is administered by adoptive transfer.
[0129] In some embodiments, the subject, e.g., the AML patient, is preconditioned with a chemotherapy drug for administration of the cells (e.g., day 0). For example, in some embodiments, the AML patient is preconditioned with fludarabine / cyclophosphamide on day 0.
[0130] In some embodiments, the immune cells, e.g., preactivated NK cells, are administered prior to administration of an agent such as an ARM. In some embodiments, they are administered simultaneously with an agent such as an ARM. In some embodiments, they are administered sequentially with an agent such as an ARM. In some embodiments, when not administered simultaneously, the immune cells, e.g., preactivated NK cells, and an agent such as an ARM are administered in such a way that the subject is exposed to both. Particular techniques for administration of NK cells are described in Miller et al., Blood 105, 3051-3057 (2005) and can be utilized according to the present invention.
[0131] In some embodiments, after or at the same time as the administration of immune cells, specific cytokines are administered to support the administered immune cells.In some embodiments, rhIL-2 is administered, typically at a low dose, to support memory-like NK cells by inducing high affinity IL-2Rαβγ.For example, see Leong, et al., Biol. Blood Marrow Transplant, 20, 463-473 (2014).
[0132] In some embodiments, donor memory-like NK cells are tracked in the subject's blood using informative HLA, e.g., donor or patient-specific anti-HLA monoclonal antibodies. In some embodiments, such cells may be at a maximum frequency, e.g., 7-14 days after infusion, and decline in number after recipient T cell recovery. If desired, additional doses of such NK cells may be administered (in some embodiments, 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or more doses may be administered). In some embodiments, memory-like NK cells comprise less than about 10%, less than about 15%, less than about 20%, less than about 25%, less than about 30%, less than about 35%, less than about 40%, less than about 45%, less than about 50%, less than about 60%, less than about 70%, less than about 80%, or less than about 90% of blood NK cells at the time post-administration (e.g., at 7 days). In some embodiments, the level is greater than about 10%. In some embodiments, the level is greater than about 20%. In some embodiments, the level is greater than about 30%. In some embodiments, the level is greater than about 40%. In some embodiments, the level is greater than about 50%. In some embodiments, the level is greater than about 60%. In some embodiments, the level is greater than about 70%. In some embodiments, the level is greater than about 80%. In some embodiments, the level is greater than about 90%. In some embodiments, the total number of memory-like NK cells is increased in the blood by at least 50-fold, 100-fold, 150-fold, 200-fold, 250-fold, 300-fold, 350-fold, 400-fold, 450-fold, 500-fold, 550-fold, 600-fold, 650-fold, 700-fold, 750-fold, 800-fold, 850-fold, 900-fold, 950-fold, or 1000-fold, e.g., comparing day 1 and a subsequent time point (e.g., day 7). In some embodiments, the increase is at least 100-fold. In some embodiments, the increase is at least 200-fold. In some embodiments, the increase is at least 300-fold. In some embodiments, the increase is at least 400-fold. In some embodiments, the increase is at least 500-fold. In some embodiments, the increase is at least 600-fold.In some embodiments, the increase is at least 700-fold. In some embodiments, the increase is at least 800-fold. In some embodiments, the increase is at least 900-fold. In some embodiments, the increase is at least 1000-fold. Typically, the percentage and absolute number (count) of memory-like NK cells will also increase (e.g., at days 5, 6, 7, 8, 9, 10, 11, 12, 13, and / or 14) following administration of the memory-like NK cells, e.g., by a percentage as described above (e.g., less than about 10%, less than 15%, less than 20%, less than 25%, less than 30%, less than 35%, less than 40%, less than 45%, less than 50%, less than 60%, less than 70%, less than 80%, or less than 90%; some In some embodiments, the total number of copies is increased by at least 90%) and by up to 50-fold, 100-fold, 150-fold, 200-fold, 250-fold, 300-fold, 350-fold, 400-fold, 450-fold, 500-fold, 550-fold, 600-fold, 650-fold, 700-fold, 750-fold, 800-fold, 850-fold, 900-fold, 950-fold, or 1000-fold or more; in some embodiments, by 100-fold, 200-fold, 300-fold, 400-fold, 500-fold, 600-fold or more.
[0133] In some embodiments, following administration, the memory-like NK cells have enhanced function, for example, as demonstrated by increased IFN-γ production upon stimulation.
[0134] In some embodiments, memory-like NK cells expand (Ki-67 + ).
[0135] In some embodiments, the preactivated memory-like NK cells are cytokine-induced memory-like NK cells. In some embodiments, the memory-like NK cells express inhibitory KIR receptors. In some embodiments, such cells can perform one or more functions (e.g., inhibiting and / or killing target cells, such as cancer cells) regardless of KIR-ligand interaction.
[0136] In some embodiments, the administered immune cells, for example, memory-like NK cells, can be detected in the blood and bone marrow of the subject for 1 day, 2 days, 3 days, 4 days, 5 days, 6 days, 7 days, 8 days, 9 days, 10 days or 1 week, 2 weeks, 3 weeks, 4 weeks, 5 weeks, 6 weeks, 7 weeks, 8 weeks, 9 weeks, 10 weeks or more.In some embodiments, such cells proliferate and / or expand in vivo after administration to the subject.In some embodiments, such cells differentiate in vivo in the subject and show enhanced function against targets such as cancer cells (e.g., leukemia cells).
[0137] In some embodiments, the immune cells, e.g., preactivated NK cells, are administered simultaneously with the ARM. In some embodiments, they are administered in a single composition. In some embodiments, they are administered as separate compositions.
[0138] In some embodiments, an appropriate amount of an antibody may also be administered together with the ARM in the same composition or in a separate composition (and optionally may be administered prior to the ARM, simultaneously with the ARM or sequentially with the ARM). In some embodiments, a composition comprising an ARM, preactivated NK cells and optionally an antibody or fragment thereof is administered. In some embodiments, a composition comprising an ARM, preactivated NK cells and optionally IgM, comprising uABT, is administered. In some embodiments, a provided composition comprises a complex comprising an NK cell, an antibody or fragment thereof and an ARM. In some embodiments, in such complex A, the CD16a receptor of the NK cell interacts with an antibody or fragment thereof and the antibody binding portion of the ARM interacts with the same antibody or fragment thereof.
[0139] 4. Typical ARM drugs A variety of ARM agents may be utilized according to the present invention. In some embodiments, the ARM comprises an antibody binding portion that interacts with the Fab region, and may bind and recruit antibodies (and / or fragments thereof) that preferably comprise such Fab regions. In some embodiments, the ARM comprises an antibody binding portion that interacts with the Fc region (e.g., uABT as described herein), and may bind and recruit a variety of antibodies (and / or fragments thereof) that preferably comprise such Fc regions. As will be appreciated by those skilled in the art, the antibodies (and / or fragments thereof) recruited by such ARMs may comprise a variety of Fab regions and may have a variety of specificities. In some embodiments, an individual recruited antibody (or fragment thereof) does not exceed 1%, 2%, 3%, 4%, 5%, 6%, 7%, 8%, 9%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, or 90% of the total recruited antibodies and fragments thereof.
[0140] In certain embodiments, a useful ARM has formula I: [ka] [During the ceremony, ABT is the antibody binding moiety; L is a divalent linker moiety connecting ABT and TBT; TBT is the target binding moiety. or a pharma- ceutically acceptable salt thereof.
[0141] In some embodiments, a useful ARM is a compound of formula Ia or a salt thereof.In some embodiments, a useful ARM is a compound of formula Ib or a salt thereof.
[0142] In certain embodiments, a useful ARM is a compound of formula II or a pharma- ceutically acceptable salt thereof: R 1 , R 3 and R 5Each of is independently hydrogen or C 1-6 an optionally substituted group selected from aliphatic, 3- to 8-membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, 8- to 10-membered bicyclic aromatic carbocyclic ring, 4- to 8-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 5- to 6-membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 8- to 10-membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R 1 and R 1’ may optionally be joined together with the carbon atoms therebetween to form a 3- to 8-membered saturated or partially unsaturated spirocyclic carbocyclic ring or a 4- to 8-membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R 3 and R 3’ may optionally be joined together with the carbon atoms therebetween to form a 3- to 8-membered saturated or partially unsaturated spirocyclic carbocyclic ring or a 4- to 8-membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R attached to the same carbon atom 5 Groups and R 5’ the groups may optionally be joined together with the carbon atoms between them to form a 3- to 8-membered saturated or partially unsaturated spirocyclic carbocyclic ring or a 4- to 8-membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or; The Two R's 5 The groups, together with the atoms between them, may optionally be divalent C 1-10 It may form a linear or branched saturated or unsaturated hydrocarbon chain, where one to three methylene units of the chain may independently be selected from the group consisting of -S-, -SS-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -S(O)-, -S(O)2 -or- Cy 1 -, where each -Cy 1 - is independently a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R 1’ , R 3’ and R 5’ each independently represents hydrogen or C 1-3 It is aliphatic; R 2 , R 4 and R 6 each independently represents hydrogen or C 1-4 Aliphatic or: R 2 and R 1 may optionally be joined together with the atoms therebetween to form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur; R 4 and R 3 may optionally combine with the atoms therebetween to form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or; R 6 group and adjacent R 5 The groups may optionally, together with the atoms between them, form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; L 1 teeth, [ka] is a trivalent linker moiety linking L 2 is a covalent bond or a divalent linear or branched C 1-10A saturated or unsaturated hydrocarbon chain, wherein one to three methylene units of the chain are independently selected from the group consisting of -S-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -S(O)-, -S(O) 2 -, [ka] Or -Cy 1 -, where each -Cy 1 - is independently a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; TBT is the target binding moiety; Each of m and n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; or a pharma- ceutically acceptable salt thereof.
[0143] In certain embodiments, a useful ARM has formula III: [ka] [During the ceremony, Each R 7 are independently hydrogen or C 1-6 an optionally substituted group selected from aliphatic, 3- to 8-membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, 8- to 10-membered bicyclic aromatic carbocyclic ring, 4- to 8-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 5- to 6-membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 8- to 10-membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R attached to the same carbon atom 7 Groups and R 7’groups may optionally be joined together with the carbon atoms between them to form a 3- to 8-membered saturated or partially unsaturated spirocyclic carbocyclic ring or a 4- to 8-membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Each R 7’ are independently hydrogen or C 1-3 It is aliphatic; Each R 8 are independently hydrogen or C 1-4 Aliphatic or: R 8 group and adjacent R 7 The groups may optionally, together with the atoms between them, form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R 9 is hydrogen, C 1-3 Aliphatic or -C(O)C 1-3 It is aliphatic; L 3 teeth [ka] and TBT; TBT is the target binding moiety; o is 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. or a pharma- ceutically acceptable salt thereof.
[0144] antibody binding site A wide variety of antibody binding moieties are known in the art and can be utilized in accordance with the present invention.
[0145] In some embodiments, the antibody binding moiety interacts primarily with the Fab region. In some embodiments, the antibody binding moiety interacts primarily with antibodies and / or fragments thereof that contain a particular Fab structure and / or are directed to a particular antigen.
[0146] In some embodiments, the antibody binding moiety interacts with the Fc region. In some embodiments, the antibody binding moiety described herein, such as uABT, can interact with the Fc region and recruit Fc regions bound to Fab regions with diverse structures and / or antigen specificities. In some embodiments, the useful agent comprises a universal antibody binding moiety that can bind to antibodies with different Fab regions and different specificities. In some embodiments, the antibody binding moiety is a universal antibody binding moiety that binds to the Fc region. In some embodiments, the binding of the antibody binding moiety to an antibody (or fragment thereof), such as the binding of uABT to an Fc region, can occur simultaneously with the binding of an Fc receptor, such as CD16a, to the same antibody (or fragment thereof) (e.g., when uABT binds to Fc, it can occur at different positions / amino acid residues of the same Fc region). In some embodiments, even with the universal antibody binding moiety bound, the Fc region is still able to interact with an Fc receptor and carry out one or more or all of its immune activities, including recruiting immune cells (e.g., effector cells such as NK cells) and / or inducing, generating, promoting, and / or enhancing immune system activity, e.g., antibody-dependent cellular cytotoxicity (ADCC) and / or ADCP, against a target cell, tissue, subject, and / or substance.
[0147] A wide variety of universal antibody binding moieties may be utilized in accordance with the present invention, and numerous techniques are available for the identification and evaluation of universal antibody binding moieties, such as those described in the Examples. In some embodiments, a universal antibody binding moiety comprises one or more amino acid residues, each of which is independently natural or non-natural. In some embodiments, a universal antibody binding moiety comprises: [ka] or a salt form thereof. In some embodiments, the universal antibody binding moiety has the structure: [ka] or a salt form thereof. In some embodiments, the universal antibody binding moiety is a peptide moiety, e.g., R c In some embodiments, the universal antibody binding moiety is a cyclic peptide moiety, e.g., [ka] In some embodiments, the universal antibody binding moiety is or comprises a moiety having the structure R c -(Xaa)z- or [ka] and is or comprises a peptide unit. In some embodiments, -(Xaa)z- is or comprises a peptide unit. In some embodiments, a peptide unit is an amino acid residue, e.g., a peptide unit having a positively charged side chain (e.g., a "positively charged amino acid residue", Xaa P In some embodiments, the peptide unit comprises an amino acid residue of formula AI having a side chain that includes an aromatic group (an "aromatic amino acid residue", Xaa A In some embodiments, the peptide unit comprises a positively charged amino acid residue and an aromatic amino acid residue. In some embodiments, the peptide unit comprises a W. In some embodiments, the peptide unit comprises a positively charged amino acid residue and an aromatic amino acid residue. In some embodiments, the peptide unit comprises a Xaa A XaaXaa P Xaa P In some embodiments, the peptide unit is or comprises XaaP Xaa P XaaXaa A In some embodiments, the peptide unit is or comprises Xaa P Xaa A Xaa P In some embodiments, the peptide unit is or comprises two or more Xaa P Xaa A Xaa P In some embodiments, the peptide unit is or comprises Xaa P Xaa A Xaa P XaaXaa P Xaa A Xaa P In some embodiments, the peptide unit is or comprises Xaa P Xaa P Xaa A Xaa A Xaa P In some embodiments, the peptide unit is or comprises Xaa P Xaa P Xaa P Xaa A In some embodiments, the peptide unit is or comprises two or more Xaa A Xaa A Xaa PIn some embodiments, the peptide unit is or comprises HWRGWA. In some embodiments, the peptide unit is or comprises WGRR. In some embodiments, the peptide unit is or comprises RRGW. In some embodiments, the peptide unit is or comprises NRFRGKYK. In some embodiments, the peptide unit is or comprises NARKFYK. In some embodiments, the peptide unit is or comprises positively charged amino acid residues, aromatic amino acid residues, and amino acid residues, such as amino acid residues of formula AI having a negatively charged side chain (e.g., "negatively charged amino acid residue", Xaa, Xb, Xc, Xd, Xe, Xf, Xg, Xh, Xi, Xj ... N). In some embodiments, the peptide residue is RHRFNKD. In some embodiments, the peptide unit is TY. In some embodiments, the peptide unit is TYK. In some embodiments, the peptide unit is RTY. In some embodiments, the peptide unit is RTYK. In some embodiments, the peptide unit is or comprises a sequence selected from PAM. In some embodiments, the peptide unit is WHL. In some embodiments, the peptide unit is ELVW. In some embodiments, the peptide unit is or comprises a sequence selected from AWHLGELVW. In some embodiments, the peptide unit is or comprises a sequence selected from DCAWHLGELVWCT, where the two cysteine residues are capable of forming a disulfide bond as found in natural proteins. In some embodiments, the peptide unit is or comprises a sequence selected from Fc-III. In some embodiments, the peptide unit is or comprises a sequence selected from DpLpAWHLGELVW. In some embodiments, the peptide unit is or comprises a sequence selected from FcBP-1. In some embodiments, the peptide unit is or comprises a sequence selected from DpLpDCAWHLGELVWCT. In some embodiments, the peptide unit is or comprises a sequence selected from FcBP-2. In some embodiments, the peptide unit is or comprises a sequence selected from CDCAWHLGELVWCTC, where the first and last cysteines and the two central cysteines are each independently capable of forming a disulfide bond as found in the native protein. In some embodiments, the peptide unit is or comprises a sequence selected from Fc-III-4c. In some embodiments, the peptide unit is or comprises a sequence selected from FcRM. In some embodiments, the peptide unit is or comprises a sequence selected from cyclic peptide units.In some embodiments, the cyclic peptide unit comprises an amide group formed by a side chain amino group and a C-terminal -COOH.
[0148] In some embodiments, -(Xaa)z- is [X 1 ] p1 [X 2 ] p2 -X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 -[X 13 ] p13 -[X 14 ] p14 [X 15 ] p15 [X 16 ] p16 is or includes, where X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 and X 13 Each of p1, p2, p13, p14, p15, and p16 is independently 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. In some embodiments, X 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 and X 13 Each of X is independently an amino acid residue of an amino acid of formula AI.1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 and X 13 Each of X is independently a naturally occurring amino acid residue. 1 , X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 and X 13 One or more of are independently a non-natural amino acid residue as described herein.
[0149] In some embodiments, the peptide unit comprises an amino acid residue having a functional group capable of reacting with a functional group of another amino acid residue. In some embodiments, the peptide unit comprises an amino acid residue having a side chain that comprises a functional group capable of reacting with another functional group of the side chain of another amino acid residue to form a bond (see, for example, the compounds in Table 1). In some embodiments, a functional group of an amino acid residue is bonded to a functional group of another amino acid residue to form a bond (or crosslink). The bond is bonded to a backbone atom of the peptide unit and does not include a backbone atom. In some embodiments, the peptide unit comprises a bond formed by the side chains of two non-adjacent amino acid residues. In some embodiments, the bond is bonded to two backbone atoms of two non-adjacent amino acid residues. In some embodiments, both backbone atoms bonded to the bond are carbon atoms. In some embodiments, the bond is L. b where L b is L as described herein. a where L a is not a covalent bond. In some embodiments, La In some embodiments, L comprises -Cy-. a In some embodiments, -Cy- is an optionally substituted heteroaryl. [ka] In some embodiments, L a teeth, [ka] In some embodiments, such L a is the -N of the side chain of an amino acid residue. 3 In some embodiments, the bond is formed by the linkage of two thiol groups, e.g., cysteic acid groups. In some embodiments, L a In some embodiments, L includes -SS-. a Ha-CH 2 -SS-CH 2 In some embodiments, the linkage is an amino group (e.g., —NH 2 ) and a carboxylic acid group (e.g., —COOH in the side chain of an aspartic acid or glutamic acid residue). a In some embodiments, L comprises -C(O)-N(R')-. a In some embodiments, L a Ha-CH 2 CONH-(CH 2 ) 3 In some embodiments, L a comprises -C(O)-N(R')-, where R' is R, which together with the R groups on the peptide backbone form a ring (e.g., the ring of I-27). a Ha-(CH 2 ) 2 -N(R')-CO--(CH 2 ) 2In some embodiments, -Cy- is optionally substituted phenylene. In some embodiments, -Cy- is optionally substituted 1,2-phenylene. In some embodiments, L a teeth, [ka] In some embodiments, L a teeth, [ka] In some embodiments, L a is an optionally substituted divalent C 2 - 20 In some embodiments, L a is an optionally substituted -(CH 2 ) 9 -CH=CH-(CH 2 ) 9 In some embodiments, L a Ha-(CH 2 ) 3 -CH=CH-(CH 2 ) 3 -It is.
[0150] In some embodiments, the two amino acid residues attached to the bond are separated by 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or more than 15 amino acid residues therebetween (excluding the two amino acid residues attached to the bond). In some embodiments, the number is 1. In some embodiments, the number is 2. In some embodiments, the number is 3. In some embodiments, the number is 4. In some embodiments, the number is 5. In some embodiments, the number is 6. In some embodiments, the number is 7. In some embodiments, the number is 8. In some embodiments, the number is 9. In some embodiments, the number is 10. In some embodiments, the number is 11. In some embodiments, the number is 12. In some embodiments, the number is 13. In some embodiments, the number is 14. In some embodiments, the number is 15.
[0151] In some embodiments, each of p1, p2, p13, p14, p15 and p16 is 0. In some embodiments, -(Xaa)z- is -X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 - is or contains: X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 and X 12 each is independently an amino acid residue; X 6 is Xaa A or Xaa Pand; X 9 is Xaa N and; X 12 is Xaa A or Xaa P It is. In some embodiments, X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 and X 12 Each of X is independently an amino acid residue of an amino acid of formula AI described herein. 5 is Xaa A or Xaa P In some embodiments, X 5 is Xaa A In some embodiments, X 5 is Xaa P In some embodiments, X 5 is an amino acid residue whose side chain contains a saturated, partially saturated or aromatic ring, which may be optionally substituted. In some embodiments, X 5 teeth [ka] In some embodiments, X 5 teeth [ka] In some embodiments, X 6 is Xaa A In some embodiments, X 6 is Xaa P In some embodiments, X 6 is His. In some embodiments, X 12 is Xaa A In some embodiments, X 12 is XaaP In some embodiments, X 9 is Asp. In some embodiments, X 9 is Glu. In some embodiments, X 12 teeth [ka] In some embodiments, X 12 teeth [ka] In some embodiments, X 7 , X 10 and X 11 each independently represents an amino acid residue having a hydrophobic side chain ("hydrophobic amino acid residue", Xaa H In some embodiments, X 7 is Xaa H In some embodiments, X 7 teeth [ka] In some embodiments, X 7 In some embodiments, X is Val. 10 is Xaa H In some embodiments, X 10 is Met. In some embodiments, X 10 teeth [ka] In some embodiments, X 11 is Xaa H In some embodiments, X 11 teeth [ka] In some embodiments, X 8 In some embodiments, X is Gly. 4is Pro. In some embodiments, X 3 In some embodiments, X is Lys. 12 The -COOH of Lys(X 3 ) to form an amide bond with the side chain amino group of Lys(X 3 The other amino group of the ) is attached to a linker moiety which is then attached to the target binding moiety.
[0152] In some embodiments, -(Xaa)z- is -X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 - is or contains, X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 and X 12 each is independently an amino acid residue; At least two amino acid residues have one or more bonds L b Connected by; L b is C 1 -C 20 Aliphatic or C with 1-5 heteroatoms 1 -C 20 heteroaliphatic, wherein one or more methylene units of said group are optionally independently selected from -C(R') 2 -, -Cy-, -O-, -S-, -SS-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O) 2 -, -S(O) 2 may be substituted by -N(R')-, -C(O)S- or -C(O)O-, where Lb is attached to a backbone atom of one amino acid residue and to a backbone atom of another amino acid residue, but not including the backbone atom; X 6 is Xaa A or Xaa P and; X 9 is Xaa N and; X 12 is Xaa A or Xaa P It is. In some embodiments, X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 and X 12 is independently an amino acid residue of the amino acid formula AI described herein. In some embodiments, the two non-adjacent amino acid residues are b In some embodiments, X 5 and X 10 L b In some embodiments, one bond L b In some embodiments, X 6 is Xaa A In some embodiments, X 6 is Xaa P In some embodiments, X 6 In some embodiments, X is His. 9 is Asp. In some embodiments, X 9 is Glu. In some embodiments, X 12 is Xaa A In some embodiments, X 12 teeth [ka] In some embodiments, X 12teeth [ka] In some embodiments, X 12 teeth [ka] In some embodiments, X 4 , X 7 and X 11 each independently represents Xaa H In some embodiments, X 4 is Xaa H In some embodiments, X 4 In some embodiments, X is Ala. 7 is Xaa H In some embodiments, X 7 teeth [ka] In some embodiments, X 11 is Xaa H In some embodiments, X 11 teeth [ka] In some embodiments, X 8 In some embodiments, X is Gly. 3 In some embodiments, X is Lys. 12 -COOH is Lys(X 3 ) to form an amide bond with the side chain amino group of Lys(X 3 The other amino group of L is attached to a linker moiety, which is then attached to a target binding moiety. b teeth [ka] In some embodiments, L b teeth [ka] In some embodiments, L b links two α carbon atoms of two different amino acid residues. 5 and X 10 Both of the amino acids are Cys, and the two -SH groups of these side chains form -SS- (L b -CH 2 -SS-CH 2 -).
[0153] In some embodiments, -(Xaa)z- is -X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 - is or contains, X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 and X 12 each is independently an amino acid residue; At least two amino acid residues have one or more bonds L b Connected by; L b is C 1 -C 20 Aliphatic or C with 1-5 heteroatoms 1 -C 20 heteroaliphatic, wherein one or more methylene units of said group are optionally independently selected from -C(R') 2-, -Cy-, -O-, -S-, -SS-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O) 2 -, -S(O) 2 may be substituted by -N(R')-, -C(O)S- or -C(O)O-, where L b is attached to a backbone atom of one amino acid residue and to a backbone atom of another amino acid residue, but not including the backbone atom; X 4 is Xaa A and; X 5 is Xaa A or Xaa P and; X 8 is Xaa N and; X 11 is Xaa A It is. In some embodiments, X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 and X 12 is independently an amino acid residue of the amino acid formula AI described herein. In some embodiments, the two non-adjacent amino acid residues are b In some embodiments, one bond L b In some embodiments, X 2 and X 12 L b In some embodiments, L b Ha-CH 2 -SS-CH 2 In some embodiments, L b Ha-CH 2 -CH 2 -S-CH 2In some embodiments, L b teeth [ka] In some embodiments, L b teeth [ka] In some embodiments, L b Ha-CH 2 CH 2 CO-N(R')-CH 2 CH 2 In some embodiments, R' is -N(R')-CH 2 CH 2 - together with the R group on the backbone atom to which it is attached forms a ring, e.g., the ring of I-27. In some embodiments, the ring formed is 3-, 4-, 5-, 6-, 7- or 8-membered. In some embodiments, the ring formed is monocyclic. In some embodiments, the ring formed is saturated. In some embodiments, L b teeth [ka] In some embodiments, L b links two α carbon atoms of two different amino acid residues. 4 is Xaa A In some embodiments, X 4 is Tyr. In some embodiments, X 5 is Xaa A In some embodiments, X 5 is Xaa P In some embodiments, X 5 is His. In some embodiments, X 8 is Asp. In some embodiments, X 8 is Glu. 11 is Tyr. In some embodiments, X2 and X 12 Both of the amino acids are Cys, and the two -SH groups of these side chains form -SS- (L b is -CH 2 -SS-CH 2 In some embodiments, X 3 , X 6 , X 9 , and X 10 each independently represents Xaa H In some embodiments, X 3 is Xaa H In some embodiments, X 3 In some embodiments, X is Ala. 6 is Xaa H In some embodiments, X 6 In some embodiments, X is Leu. 9 is Xaa H In some embodiments, X 9 In some embodiments, X is Leu. 9 teeth [ka] In some embodiments, X 10 is Xaa H In some embodiments, X 10 In some embodiments, X is Val. 10 teeth [ka] In some embodiments, X 7 In some embodiments, p1 is 1. In some embodiments, X 1 is Asp. In some embodiments, p13 is 1. In some embodiments, p14, p15 and p16 are 0. In some embodiments, X 13 is an amino acid residue having a polar uncharged side chain (e.g., at physiological pH, a "polar uncharged amino acid residue", XaaL In some embodiments, X 13 In some embodiments, p13 is 0. In some embodiments, R c Ha-NHCH 2 CH(OH)CH 3 In some embodiments, R c is (R)-NHCH 2 CH(OH)CH 3 In some embodiments, R c (S)-NHCH 2 CH(OH)CH 3 It is.
[0154] In some embodiments, -(Xaa)z- is -X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 - is or contains, X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 and X 12 each is independently an amino acid residue; At least two amino acid residues are linked to one or more bonds L b Connected by; L b is C 1 -C 20 Aliphatic or C with 1-5 heteroatoms 1 -C 20 heteroaliphatic, wherein one or more methylene units of said group are optionally independently selected from -C(R') 2-, -Cy-, -O-, -S-, -SS-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O) 2 -, -S(O) 2 may be substituted by -N(R')-, -C(O)S- or -C(O)O-, where L b is attached to a backbone atom of one amino acid residue and to a backbone atom of another amino acid residue, but not including the backbone atom; X 5 is Xaa A or Xaa P and; X 8 is Xaa N and; X 11 is Xaa A It is. In some embodiments, X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 and X 12 is independently an amino acid residue of the amino acid formula AI described herein. In some embodiments, the two non-adjacent amino acid residues are b In some embodiments, one bond L b In some embodiments, two or more bonds L b In some embodiments, there are two bonds L b In some embodiments, X 2 and X 12 L b In some embodiments, X 4 and X 9 L b In some embodiments, X 4 and X 10 L bIn some embodiments, L b Ha-CH 2 -SS-CH 2 In some embodiments, L b teeth [ka] In some embodiments, L b teeth [ka] In some embodiments, X 2 and X 12 Both of the amino acids are Cys, and the two -SH groups of these side chains form -SS- (L b -CH 2 -SS-CH 2 In some embodiments, X 4 and X 10 Both of the amino acids are Cys, and the two -SH groups of these side chains form -SS- (L b -CH 2 -SS-CH 2 In some embodiments, X 4 and X 9 L b where L b teeth [ka] In some embodiments, X 4 and X 9 L b where L b teeth [ka] It is. In some embodiments, X 5 is Xaa A In some embodiments, X 5 is Xaa PIn some embodiments, X 5 In some embodiments, X is His. 8 is Asp. In some embodiments, X 8 is Glu. In some embodiments, X 11 is Tyr. In some embodiments, X 11 teeth [ka] In some embodiments, X 2 and X 12 L b where L b Ha-CH 2 -S-CH 2 CH 2 In some embodiments, L b links two α carbon atoms of two different amino acid residues. 3 , X 6 and X 9 each independently represents Xaa H In some embodiments, X 3 is Xaa H In some embodiments, X 3 In some embodiments, X is Ala. 6 is Xaa H In some embodiments, X 6 In some embodiments, X is Leu. 6 teeth [ka] In some embodiments, X 9 is Xaa H In some embodiments, X 9 In some embodiments, X is Leu. 9 teeth [ka] In some embodiments, X 10 is Xaa H In some embodiments, X 10 In some embodiments, X is Val. 7 In some embodiments, p1 is 1. In some embodiments, X 1 is Xaa N In some embodiments, X 1 is Asp. In some embodiments, X 1 is Glu. In some embodiments, p13 is 1. In some embodiments, p14, p15 and p16 are 0. In some embodiments, X 13 is Xaa L In some embodiments, X 13 is Val.
[0155] In some embodiments, -(Xaa)z- is -X 2 X 3 X 4 X 5 X 6 X 7 X 8 X 9 X 10 X 11 X 12 X 13 X 14 X 15 X 16 - is or contains, X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 , X 12 , X 13 , X 14 , X 15 and X 16 each is independently an amino acid residue; At least two amino acid residues have one or more bonds Lb Connected by; L b is C 1 -C 20 Aliphatic or C with 1-5 heteroatoms 1 -C 20 heteroaliphatic, wherein one or more methylene units of said group are optionally independently selected from -C(R') 2 -, -Cy-, -O-, -S-, -SS-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O) 2 -, -S(O) 2 may be substituted by -N(R')-, -C(O)S- or -C(O)O-, where L b is attached to a backbone atom of one amino acid residue and to a backbone atom of another amino acid residue, but not including the backbone atom; X 3 is Xaa N and; X 6 is Xaa A and; X 7 is Xaa A or Xaa P and; X 9 is Xaa N and; X 13 is Xaa A It is. In some embodiments, X 2 , X 3 , X 4 , X 5 , X 6 , X 7 , X 8 , X 9 , X 10 , X 11 and X 12 is independently an amino acid residue of the amino acid formula AI described herein. In some embodiments, the two non-adjacent amino acid residues are bIn some embodiments, one bond L b In some embodiments, two or more bonds L b In some embodiments, there are two bonds L b In some embodiments, X 2 L b By X 16 In some embodiments, X 4 L b By X 14 In some embodiments, X 2 and X 16 Both of the amino acids are Cys, and the two -SH groups of these side chains form -SS- (L b is -CH 2 -SS-CH 2 In some embodiments, X 4 and X 14 Both of the amino acids are Cys, and the two -SH groups of these side chains form -SS- (L b is -CH 2 -SS-CH 2 In some embodiments, L b links two α carbon atoms of two different amino acid residues. 3 is Asp. In some embodiments, X 3 is Glu. In some embodiments, X 5 is Xaa H In some embodiments, X 5 In some embodiments, X is Ala. 6 is Xaa A In some embodiments, X 6 is Tyr. In some embodiments, X 7 is Xaa A In some embodiments, X 7 is Xaa P In some embodiments, X 7 In some embodiments, X is His.8 is Xaa H In some embodiments, X 8 In some embodiments, X is Ala. 9 In some embodiments, X is Gly. 10 is Asp. In some embodiments, X 10 is Glu. In some embodiments, X 11 is Xaa H In some embodiments, X 11 In some embodiments, X is Leu. 12 is Xaa H In some embodiments, X 12 In some embodiments, X is Val. 13 is Xaa A In some embodiments, X 13 is Tyr. In some embodiments, X 15 is an amino acid residue that contains a polar, uncharged side chain (e.g., at physiological pH, a "polar, uncharged amino acid residue", Xaa L In some embodiments, X 15 In some embodiments, p1 is 1. In some embodiments, X 1 is Xaa N In some embodiments, X 1 is Asp. In some embodiments, X 1 is Glu.
[0156] As will be appreciated by those of skill in the art, an amino acid residue may be replaced by another amino acid residue having similar properties. H (e.g., Val, Leu, etc.) is replaced by another Xaa H (e.g., Leu, Ile, Ala, etc.), and a certain Xaa A is another Xaa A can be replaced with Xaa P is Xaa P can be replaced by a certain Xaa Nis another Xaa N can be replaced with Xaa L is another Xaa L etc. can be substituted.
[0157] In some embodiments, the antibody binding moiety, e.g., a universal antibody binding moiety, is a universal antibody binding moiety of a compound of Table 1. In some embodiments, the antibody binding moiety, e.g., a universal antibody binding moiety, is or includes the following structure, optionally substituted: [Table 1-1] [Table 1-2] [Table 1-3] [Table 1-4] [Table 1-5] [Table 1-6] [Table 1-7] [Table 1-8] [Table 1-9] [Table 1-10] [Table 1-11] [Table 1-12]
[0158] In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-1. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-2. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-3. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-4. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-5. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-6. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-7. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-8. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-9. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-10. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-11. In some embodiments, the universal antibody binding moiety is or comprises an optionally substituted A-12. In some embodiments, the universal antibody binding moiety is or comprises an optionally substituted A-13. In some embodiments, the universal antibody binding moiety is or comprises an optionally substituted A-14. In some embodiments, the universal antibody binding moiety is or comprises an optionally substituted A-15. In some embodiments, the universal antibody binding moiety is or comprises an optionally substituted A-16.In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-17. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-18. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-19. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-20. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-21. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-22. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-23. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-24. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-25. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-26. In some embodiments, the universal antibody binding moiety is or comprises an optionally substituted A-27. In some embodiments, the universal antibody binding moiety is or comprises an optionally substituted A-28. In some embodiments, the universal antibody binding moiety is or comprises an optionally substituted A-29. In some embodiments, the universal antibody binding moiety is or comprises an optionally substituted A-30. In some embodiments, the universal antibody binding moiety is or comprises an optionally substituted A-31. In some embodiments, the universal antibody binding moiety is or comprises an optionally substituted A-32.In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-33. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-34. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-35. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-36. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-37. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-38. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-39. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-40. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-41. In some embodiments, the universal antibody binding portion is or comprises an optionally substituted A-42. In some embodiments, the universal antibody binding moiety is or comprises an optionally substituted A-43. In some embodiments, the universal antibody binding moiety is or comprises an optionally substituted A-44. In some embodiments, the universal antibody binding moiety is or comprises an optionally substituted A-45. In some embodiments, the universal antibody binding moiety is or comprises an optionally substituted A-46. In some embodiments, the universal antibody binding moiety is or comprises an optionally substituted A-47. In some embodiments, the universal antibody binding moiety is or comprises an optionally substituted A-48.In some embodiments, the universal antibody binding moiety is or comprises an optionally substituted A-49. In some embodiments, it is unsubstituted. In some embodiments, it is substituted.
[0159] In some embodiments, the universal antibody binding moiety comprises a peptide unit and is linked to the linker moiety by the C-terminus of the peptide unit. In some embodiments, it is linked to the linker moiety by the N-terminus of the peptide unit. In some embodiments, it is linked to the linker moiety through a side group of the peptide unit.
[0160] In some embodiments, the antibody binding moiety, e.g., a universal antibody binding moiety, comprises a small molecule agent, e.g., having a molecular weight of less than 10000, less than 9000, less than 8000, less than 7000, less than 6000, less than 5000, less than 4000, less than 3000, less than 2000, less than 1500, less than 1000, etc. Suitable such antibody binding moieties include small molecule Fc binding moieties, e.g., those described in U.S. Patent No. 9,745,339, U.S. Patent No. 20130131321, etc.
[0161] As will be appreciated by those skilled in the art, antibodies of diverse properties and activities (e.g., antibodies recognizing different antigens, with any modifications, etc.) can be recruited by the antibody binding moieties described herein. In some embodiments, such antibodies include, for example, antibodies administered to a subject for therapeutic purposes. In some embodiments, the antibodies recruited by the antibody binding moieties include antibodies against different antigens. In some embodiments, the antibodies recruited by the antibody binding moieties include antibodies whose antigens are not present on the surface or cell membrane of a target cell (e.g., a target cell such as a cancer cell). In some embodiments, the antibodies recruited by the antibody binding moieties include antibodies that do not target antigens present on the surface or cell membrane of a target cell (e.g., a target cell such as a cancer cell). In some embodiments, an antigen on the surface of a target cell may interfere with the structure, conformation, and / or one or more properties and / or activities of the recruited antibody that binds to such antigen. In some embodiments, as will be appreciated by one of skill in the art, the provided technology includes universal antibody binding moieties that recruit antibodies of diverse specificity, where 1% or less, 2% or less, 5% or less, 10% or less, 15% or less, 20% or less, 25% or less, 30% or less, 35% or less, 40% or less, 45% or less, 50% or less, 55% or less, 60% or less, 65% or less, 70% or less, 75% or less, 80% or less, 85% or less, 90% or less, 95% or less, or 99% or less of the recruited antibodies are directed against the same antigen, protein, lipid, carbohydrate, etc. Among other advantages, one advantage of the present invention is that the provided technology including universal antibody binding moieties can take advantage of the diverse pool of antibodies such as those present in serum. In some embodiments, a universal antibody binding moiety of the invention (e.g., in an ARM) is contracted with a plurality of antibodies, where 1% or less, 2% or less, 5% or less, 10% or less, 15% or less, 20% or less, 25% or less, 30% or less, 35%, 40% or less, 45% or less, 50% or less, 55% or less, 60% or less, 65% or less, 70% or less, 75% or less, 80% or less, 85% or less, 90% or less, 95% or less, or 99% or less of the plurality of antibodies are antibodies to the same antigen, protein, lipid, carbohydrate, etc.
[0162] amino acid In some embodiments, useful compounds and, for example, ARM agents, can include one or more amino acid moieties, for example, universal antibody binding moieties, linker moieties, etc. In some embodiments, the amino acid is represented by the formula AI: [ka] or a salt thereof, wherein each variable is independently as described herein. In some embodiments, the amino acid residue is -N(R a1 )-L a1 -C(R a2 )(R a3 )-L a2 It has the structure -CO-.
[0163] In some embodiments, L a1 is a covalent bond. In some embodiments, the compound of formula AI has the structure NH(R a1 )-C(R a2 )(R a3 )-L a2 -COOH.
[0164] In some embodiments, L a2 is a covalent bond. In some embodiments, the compound of formula AI has the structure NH(R a1 )-C(R a2 )(R a3 )-L a2 -COOH.
[0165] In some embodiments, L a1 is a covalent bond, and L a2 is a covalent bond. In some embodiments, the compound of formula AI has the structure NH(R a1 )-C(R a2 )(R a3 )-COOH.
[0166] In some embodiments, L a is a covalent bond. In some embodiments, La is an optionally substituted divalent C 1-6 In some embodiments, L a is optionally substituted C 1-6 In some embodiments, L is alkylene. a Ha-CH 2 In some embodiments, L a Ha-CH 2 CH 2 In some embodiments, L a Ha-CH 2 CH 2 CH 2 -It is.
[0167] In some embodiments, R' is R. In some embodiments, R a1 is R, where R is as described herein. In some embodiments, R a2 is R, where R is as described herein. In some embodiments, R a3 is R, where R is as described herein. In some embodiments, R a1 , R a2 and R a3 Each of is independently R, where R is as described herein.
[0168] In some embodiments, R a1 is hydrogen. In some embodiments, R a2 is hydrogen. In some embodiments, R a3 is hydrogen. In some embodiments, R a1 is hydrogen, and R a2 and R a3 At least one of R is hydrogen. a1 is hydrogen, R a2 and R a3 One of the is hydrogen and the other is not hydrogen.
[0169] In some embodiments, Ra2 -L a -R, where R is as described herein. In some embodiments, R a2 -L a -R, where R is C 3-30 Cycloaliphatic, C 5-30 R is an optionally substituted group selected from aryl, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon. a2 -L a -R, where R is C 6-30 R is an optionally substituted group selected from aryl and 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon. a2 is the side chain of an amino acid. In some embodiments, R a2 is the side chain of a standard amino acid.
[0170] In some embodiments, R a3 -L a -R, where R is as described herein. In some embodiments, R a3 -L a -R, where R is C 3-30 Cycloaliphatic, C 5-30 R is an optionally substituted group selected from aryl, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon. a3 -L a -R, where R is C 6-30R is an optionally substituted group selected from aryl and 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon. a3 is the side chain of an amino acid. In some embodiments, R a3 is the side chain of a standard amino acid.
[0171] In some embodiments, R is a cyclic group. In some embodiments, R is an optionally substituted C 3-30 In some embodiments, R is cycloaliphatic.
[0172] In some embodiments, R is an aromatic group and the amino acid residue of the amino acid of formula AI is A In some embodiments, R is an optionally substituted phenyl. In some embodiments, R is a phenyl. In some embodiments, R is an optionally substituted phenyl. In some embodiments, R is 4-trifluoromethylphenyl. In some embodiments, R is 4-phenylphenyl. In some embodiments, R is an optionally substituted 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, R is an optionally substituted 5-14 membered heteroaryl having 1-5 heteroatoms independently selected from oxygen, nitrogen and sulfur. In some embodiments, R is [ka] In some embodiments, R is an optionally substituted pyridinyl. In some embodiments, R is 1-pyridinyl. In some embodiments, R is 2-pyridinyl. In some embodiments, R is pyridinyl. In some embodiments, R is [ka] It is.
[0173] In some embodiments, R' is -COOH. In some embodiments, the amino acid residue of the compound and the amino acid of formula AI is Xaa N It is.
[0174] In some embodiments, R' is -NH 2 In some embodiments, the amino acid residue of the compound and the amino acid of the AI is Xaa P It is.
[0175] In some embodiments, R a2 or R a3 is R, where R is a C 1-20 In some embodiments, the amino acid residues of the amino acids of the compounds and the AIs are Xaa H In some embodiments, R is -CH 3 In some embodiments, R is ethyl. In some embodiments, R is propyl. In some embodiments, R is cyclopropyl.
[0176] In some embodiments, R a1 , R a2 and R a3 Two or more of are R and, together, form an optionally substituted aryl group as described herein.
[0177] In some embodiments, R a1 And R a2 and R a3 One of them is R, and together they form R a1 forms an optionally substituted 3- to 6-membered ring with no additional ring heteroatoms other than the nitrogen atom to which it is attached. In some embodiments, the ring formed is a 5-membered ring such as that present in proline.
[0178] In some embodiments, R a2 and R a3 is R and together form a 3- to 6-membered ring, which may be optionally substituted as described herein. In some embodiments, R a2 and R a3 is R and together form an optionally substituted 3- to 6-membered ring having one or more nitrogen ring atoms. In some embodiments, R a2 and R a3 is R and forms an optionally substituted 3-6 membered ring having up to one ring heteroatom that is a nitrogen atom. In some embodiments, the ring is a saturated ring.
[0179] In some embodiments, the amino acid is a natural amino acid. In some embodiments, the amino acid is a non-natural amino acid. In some embodiments, the amino acid is an α-amino acid. In some embodiments, the amino acid is a β-amino acid.
[0180] target In some embodiments, the present invention provides techniques for selectively directing agents, including target binding moieties (e.g., ARM compounds), antibodies, and immune cells, such as NK cells, to a desired target site, including one or more targets. As one of skill in the art will appreciate, the techniques provided are useful for a variety of types of targets.
[0181] In some embodiments, the target is a damaged or defective tissue. In some embodiments, the target is a damaged tissue. In some embodiments, the target is a defective tissue. In some embodiments, the target is associated with a disease, disorder or condition, e.g., cancer, wounds, etc. In some embodiments, the target is a tumor. In some embodiments, the target is or comprises a diseased cell. In some embodiments, the target is or comprises a cancer cell. In some embodiments, the target is a foreign substance. In some embodiments, the target is or comprises an infectious agent. In some embodiments, the target is a microorganism. In some embodiments, the target is or comprises a bacterium. In some embodiments, the target is or comprises a virus.
[0182] In many embodiments, the target is a tissue and / or cell associated with a disease, disorder or condition, particularly various types of cancer.In some embodiments, the target comprises a cancer cell.In particular, the present invention provides a particularly useful technique for selectively targeting cancer cells by the immune system, for example, via recruiting antibodies (e.g., endogenous antibodies) and immune cells, such as NK cells, by using ARM.
[0183] In many embodiments, the target is a cancer cell or a proliferative condition, disorder or disease. In some embodiments, the cancer or proliferative condition, disorder or disease is a benign tumor, a malignant tumor, a solid tumor, a brain carcinoma, a kidney cancer, a liver cancer, an adrenal cancer, a bladder cancer, a breast cancer, a stomach cancer, a stomach tumor, an ovarian cancer, a colon cancer, a rectal cancer, a prostate cancer, a pancreatic cancer, a lung cancer, a vaginal cancer, a cervical cancer, a testicular cancer, a genitourinary tract cancer, an esophageal cancer, a laryngeal cancer, a skin cancer, a bone cancer or a thyroid cancer, a sarcoma, a glioblastoma, a neuroblastoma, a multiple myeloma. , gastrointestinal cancers, in particular colon cancer or colorectal adenoma, tumors of the head and neck, epithelial hyperproliferation, psoriasis, prostatic hyperplasia, epithelial neoplasms, adenoma, adenocarcinoma, keratoacanthoma, epidermoid carcinoma, large cell carcinoma, non-small cell lung cancer, lymphoma, Hodgkin and non-Hodgkin, breast cancer, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, hematological tumors including leukemia, diffuse large B-cell lymphoma (DLBCL), ABC DLBCL, chronic lymphocytic leukemia (CLL), chronic lymphocytic lymphoma, primary effusion lymphoma, Burkitt's lymphoma / leukemia, acute lymphocytic leukemia, B-cell prolymphocytic leukemia, lymphocytic lymphoma, Waldenstrom's macroglobulinemia (WM), splenic marginal zone lymphoma, multiple myeloma, plasmacytoma and intravascular large B-cell lymphoma.
[0184] The targeting moiety typically comprises one or more physical, chemical and / or biological markers that can be utilized by the target binding portion of a compound (e.g., an ARM) to selectively recruit antibodies and / or fragments thereof and / or immune cells to the target.
[0185] In some embodiments, the cells of the target site may contain one or more characteristic factors that are useful for targeting.In some embodiments, such factors are proteins and / or their fragments.In some embodiments, such factors are antigens that are specifically associated with disease, disorder or condition.
[0186] For example, in some embodiments, cancer cells may contain one or more tumor-specific or tumor-associated antigens. The target binding moiety described herein can selectively bind to such markers. In some embodiments, the target binding moiety of the present invention is a small molecule that is useful for binding to cell surface protein and / or intracellular protein.
[0187] In some embodiments, the characteristic factor, e.g., of a cell at a target site, is or includes a carbohydrate, e.g., a cell surface carbohydrate, e.g., on a glycosylated protein, etc. In some embodiments, the characteristic factor is or includes a lipid.
[0188] In some embodiments, the characteristic factor is extracellular, for example, the cells of the target site. In some embodiments, the characteristic factor is an extracellular protein. In some embodiments, the characteristic factor is present on the cell surface. In some embodiments, the characteristic factor is a protein present on the cell surface. For example, in many tumor tissues, cell surface and / or extracellular mucins show different glycosylation levels and patterns, which can be utilized for targeting.
[0189] In some embodiments, a target site, such as a diseased tissue, has one or more physical, biological and / or chemical properties that can be exploited by a target binding moiety. In some embodiments, such a property is pH. In some embodiments, such a property is the concentration of one or more chemical substances. For example, the tumor microenvironment is often hypoxic and / or acidic (e.g., pH 6.5-6.9 vs. 7.2-7.4).
[0190] In some embodiments, the target is or comprises a peptide or a fragment thereof. In some embodiments, the target is or comprises a protein or a fragment thereof. In some embodiments, the target is avidin. In some embodiments, the target is streptavidin. In some embodiments, the target is or comprises an antigen. In some embodiments, the target is a tumor-specific antigen. In some embodiments, the target is or comprises a tumor-associated antigen (TAA).
[0191] In some embodiments, the tumor-associated antigen is or comprises a carbohydrate. In some embodiments, the target binding moiety provided comprises such a TAA. In some embodiments, the carbohydrate is part of a glycoprotein. In some embodiments, the carbohydrate is a glycolipid. Many conditions, disorders and diseases, such as various types of cancer, are associated with abnormal glycosylation. In some embodiments, the tumor-associated carbohydrate antigen (TACA) comprises and / or is associated with altered sialic acid expression, altered Lewis carbohydrate antigen expression, altered ganglioside expression, etc. In some embodiments, the target binding moiety of the present invention can target various types of TACAs, including those described in the art, for example, Chua and Durrant, Monoclonal Antibodies Against Tumour-Associated Carbohydrate Antigens, Carbohydrate Mahmut Caliskan, IntechOpen, DOI: 10.5772 / 66996.
[0192] In some embodiments, the tumor-associated antigen is a cell surface receptor. In some embodiments, the TAA is selected from the group consisting of BMPR1B (bone morphogenetic protein receptor type IB, Genbank accession number NM_001203), E16 (LAT1, SLC7A5, Genbank accession number NM_003486), STEAP1 (six-transmembrane epithelial antigen of the prostate, Genbank accession number NM_012449), 0772P (CA125, MUC16, Genbank accession number AF361486), MPF (MPF, MSLN, SMR, megakaryocyte potentiating factor, mesothelin, Genbank accession number NM.sub.-005823), Napi3b (NAPI-3B, NPTIIb, SLC34A2, solute carrier family 34 (sodium phosphate), member 2, type II sodium-dependent phosphate transporter 3b, Genbank accession number NM_006424), Sema 5b (FLJ10372, KIAA1445, Mm.42015, SEMA5B, SEMAG, semaphorin 5b Hlog, semadomain, seven thrombospondin repeats (type 1 and type 1-like), transmembrane domain (TM) and short cytoplasmic domain (semaphorin 5B, Genbank accession number AB040878), PSCA hlg (2700050C12Rik, C530008016Rik, RIKEN cDNA 2700050C12, RIKEN cDNA 2700050C12 gene, Genbank accession number AY358628), ETBR (endothelin type B receptor, Genbank accession number AY275463), MSG783 (RNF124, hypothetical protein FLJ20315, Genbank accession number NM_017763), STEAP2 (HGNC_8639, IPCA-1, PCANAP1, STAMPI, STEAP2, STMP, prostate cancer associated gene 1, prostate cancer associated protein 1, prostate six transmembrane epithelial antigen 2, six transmembrane protein, Genbank accession number AY275463), session number AF455138), TrpM4 (BR22450, FLJ20041, TRPM4, TRPM4B, transient receptor potential type cation channel, subfamily M, member 4, Genbank accession number NM_017636), CRIPTO (CR, CR1, CRGF, CRIPTO, TDGF1, teratocarcinoma-derived growth factor, Genbank accession number NP_003203 or NM_003212), CD21 (CR2 (complement receptor 2) or C3DR (C3d / Epstein-Barr virus receptor) or Hs.73792 Genbank accession number M26004), CD79b (CD79B, CD79.β., IGb (immunoglobulin-related beta), B29, Genbank accession number NM_000626), FcRH2 (IFGP4, IRTA4, SPAP1A (phosphatase anchor protein 1a SH2 domain containing), SPAP1B, SPAP1C, Genbank accession number NM_030764), HER2 (Genbank accession number M1730), NCA (Genbank accession number M18728), MDP (Genbank accession number BC017023), IL20Rα (Genbank accession number AF184971), brevican (Genbank accession number AF229053, EphB2R (Genbank accession number NM_004442), ASLG659 (Genbank accession number AX092328), PSCA (Genbank accession number AJ297436), GEDA (Genbank accession number NM_004442), and IL20Rα (Genbank accession number AF184971). Accession number AY260763, BAFF--R (B cell activating factor receptor, BLyS receptor 3, BR3, NP_443177.1), CD22 (B cell receptor CD22-B isoform, NP_001762.1), CD79a (CD79A, CD79.α., immunoglobulin-related alpha, a B cell-specific protein that covalently interacts with Igβ (CD79B) and forms a complex with IgM molecules on the surface, transducing signals involved in B cell differentiation, Genbank accession number NP_001774.1), CXCR5 (Burkitt's lymphoma receptor 1, a G protein-coupled receptor that is activated by the CXCL13 chemokine, functions in lymphocyte migration and humoral defense, and plays a role in HIV-2 infection and possibly in the development of AIDS, lymphoma, myeloma and leukemia, Genbank accession number NP_001707.1), HLA-DOB (binding peptides and promoting them to CD4+ β subunit of MHC class II molecule (Ia antigen) presented to T lymphocytes, Genbank accession number NP_002111.1), P2X5 (purinergic receptor P2X ligand-gated ion channel 5, an ion channel gated by extracellular ATP, may be involved in neurotransmission and neurogenesis, and its deficiency may contribute to the pathophysiology of idiopathic detrusor instability, Genbank accession number NP_002552.2), CD72 (B-cell differentiation antigen CD72, Lyb-2, Genbank accession number NP_001773.1), LY64 (Lymphocyte antigen 64 (RP105), a type I membrane protein of the leucine-rich repeat (LRR) family, regulates B-cell activation and apoptosis; loss of function is associated with increased disease activity in patients with systemic lupus erythematosus. Genbank accession number NP_005573.1), FcRH1 (Fc receptor-like protein 1, a putative receptor for immunoglobulin Fc domains containing C2-type Ig-like and ITAM domains, may have a role in B-lymphocyte differentiation. Genbank accession number NP_443170.1), IRTA2 (Immunoglobulin superfamily receptor rearrangement-associated 2, a putative immune receptor with a possible role in B-cell development and lymphomagenesis; deregulation of the gene by rearrangement occurs in several B-cell malignancies. Genbank Accession no. NP_112571.1); and TENB2 (a putative transmembrane proteoglycan related to the EGF / Heregulin family of growth factors and follistatin, selected from Genbank Accession no. AF179274.
[0193] In some embodiments, the target is or comprises a nucleic acid.
[0194] In some embodiments, the target is or comprises a lipid.
[0195] In some embodiments, the target is or comprises a carbohydrate. In some embodiments, the target is or comprises a carbohydrate associated with a disease, disorder or condition. In some embodiments, the target is or comprises a carbohydrate associated with cancer, for example, a carbohydrate as a glycan modification of a protein on the surface or outside of a cancer cell.
[0196] target binding site A wide variety of types of target-binding moieties and chemical classes can be utilized by the present invention, and many techniques (e.g., assays, reagents, kits, etc.) for identifying and / or evaluating the properties of target-binding moieties can be utilized by the present invention. In general, target-binding moieties interact with target sites through one or more physical, biological, and / or chemical properties. In some embodiments, the target-binding moiety binds to a characteristic factor described herein. In some embodiments, the target-binding moiety binds to a surface, extracellular and / or intracellular protein, carbohydrate, and / or nucleic acid. In some embodiments, the target-binding moiety binds to a surface protein of a target cell. In some embodiments, the target-binding moiety is a small molecule moiety. In some embodiments, the target-binding moiety is an antibody drug. In some embodiments, the target-binding moiety is a nucleic acid drug, such as an aptamer. In some embodiments, the target-binding moiety is a lipid moiety. Particular types of target-binding moieties are described below; one skilled in the art will understand that other types of target-binding moieties, including many known in the art, can also be utilized by the present invention.
[0197] In some embodiments, the target binding moiety binds to the target by one or more proteins, lipids, nucleic acids, carbohydrates, small molecules, etc. of the target. For example, in some embodiments, the target binding moiety binds to a tumor-specific antigen of the target cancer cell. In some embodiments, the tumor-specific antigen is or comprises a carbohydrate or a fragment thereof. In some embodiments, the tumor-specific antigen is or comprises a protein or a fragment thereof.
[0198] In some embodiments, the target binding moiety binds to a cell surface protein, carbohydrate, or lipid. In some embodiments, the target binding moiety binds to CD19. In some embodiments, the target binding moiety binds to CD20. In some embodiments, the target binding moiety binds to CD22. In some embodiments, the target binding moiety binds to CD30. In some embodiments, the target binding moiety binds to CD33. In some embodiments, the target binding moiety binds to CD123.
[0199] a. Small molecules In some embodiments, the target binding moiety is a small molecule moiety. In some embodiments, the small molecule moiety has a molecular weight of 8000 or less, 7000 or less, 6000 or less, 5000 or less, 4000 or less, 3000 or less, 2000 or less, 1500 or less, 1000 or less, 900 or less, 800 or less, 700 or less, or 600 or less. In some embodiments, the small molecule moiety has a molecular weight of 8000 or less. In some embodiments, the small molecule moiety has a molecular weight of 7000 or less. In some embodiments, the small molecule moiety has a molecular weight of 6000 or less. In some embodiments, the small molecule moiety has a molecular weight of 5000 or less. In some embodiments, the small molecule moiety has a molecular weight of 4000 or less. In some embodiments, the small molecule moiety has a molecular weight of 3000 or less. In some embodiments, the small molecule moiety has a molecular weight of 2000 or less. In some embodiments, the small molecule moiety has a molecular weight of 1500 or less. In some embodiments, the small molecule moiety has a molecular weight of 1000 or less. In some embodiments, the small molecule moiety has a molecular weight of 900 or less. In particular, the present invention encompasses the recognition that small molecule target binding moieties may be capable of binding to markers on the outside, on the surface and / or inside of a target, such as a cancer cell.
[0200] In some embodiments, the small molecule target binding moiety is or comprises a protein or a fragment thereof, such as a moiety that selectively binds to a cancer antigen. For example, in some embodiments, the target binding moiety is or comprises a moiety that selectively binds to prostate specific membrane antigen (PSMA). In some embodiments, the target binding moiety is [ka] is or contains
[0201] In some embodiments, the small molecule target binding moiety is or comprises a biotin moiety. [ka] In some embodiments, the small molecule target binding moiety is or comprises: [ka] is or contains
[0202] B. Peptide drugs In some embodiments, the target binding moiety is or comprises a peptide drug. In some embodiments, the target binding moiety is a peptide moiety. In some embodiments, the peptide moiety can be linear or cyclic. In some embodiments, the target binding moiety is or comprises a cyclic peptide moiety. A variety of peptide target binding moieties are known in the art and can be utilized in accordance with the present invention.
[0203] In some embodiments, the target binding moiety is or includes a peptide aptamer drug.
[0204] C. Aptamer drugs In some embodiments, the target binding moiety is or comprises a nucleic acid drug. In some embodiments, the target binding moiety is or comprises an oligonucleotide moiety. In some embodiments, the target binding moiety is or comprises an aptamer drug. A variety of aptamer drugs are known in the art and can be easily developed using common techniques and utilized in the technology provided by the present invention.
[0205] Linker part In some embodiments, the antibody binding moiety may optionally be linked to the target binding moiety by a linker moiety. Linker moieties of various types and / or for various purposes, such as those utilized in antibody drug conjugates, may be utilized in the present invention.
[0206] The linker moiety can be divalent or multivalent. In some embodiments, the linker moiety is divalent. In some embodiments, the linker is multivalent and links three or more moieties.
[0207] In some embodiments, the linker moiety is L. In some embodiments, L is a covalent bond or an optionally substituted divalent or polyvalent linear or branched chain C that contains one or more aliphatic, aryl, heteroaliphatic having 1-20 heteroatoms, heteroaromatic having 1-20 heteroatoms, or any combination thereof. 1-100 group, wherein one or more methylene units of said group are optionally independently selected from the group C 1-6 Alkylene, C 1-6 Alkenylene, divalent C with 1-5 heteroatoms 1-6 Heteroaliphatic groups, -C≡C-, -Cy-, -C(R') 2 -, -O-, -S-, -SS-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -C(O)C(R') 2 N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O)2 -, -S(O) 2 N(R')-, -C(O)S-, -C(O)O-, -P(O)(OR')-, -P(O)(SR')-, -P(O)(R')-, -P(O)(NR')-, -P(S)(OR')-, -P(S)(SR')-, -P(S)(R')-, -P(S)(NR')-, -P(R')-, -P(OR')-, -P(SR')-, -P(NR')-, or -[(-OC(R') 2 -C(R') 2 -) n ]-, where n is 1 to 20.
[0208] In some embodiments, L is divalent. In some embodiments, L is divalent or C 1-00 Aliphatic and C with 1-50 heteroatoms 1-100 heteroaliphatic, wherein one or more methylene units of said group are optionally independently selected from C 1-6 Alkylene, C 1-6 Alkenylene, divalent C with 1-5 heteroatoms 1-6 Heteroaliphatic groups, -C≡C-, -Cy-, -C(R') 2 -, -O-, -S-, -SS-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -C(O)C(R') 2 N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O) 2 -, -S(O) 2 N(R')-, -C(O)S-, -C(O)O-, -P(O)(OR')-, -P(O)(SR')-, -P(O)(R')-, -P(O)(NR')-, -P(S)(OR')-, -P(S)(SR')-, -P(S)(R')-, -P(S)(NR')-, -P(R')-, -P(OR')-, -P(SR')-, -P(NR')- or -[(-OC(R') 2 -C(R') 2 -) n ]- may be substituted.
[0209] In some embodiments, L is a covalent bond. In some embodiments, L is an optionally substituted divalent straight or branched chain C 1-100 In some embodiments, L is an optionally substituted linear or branched chain C 6-100 In some embodiments, L is an optionally substituted divalent linear or branched chain C alkyl group having 1 to 20 heteroatoms. 5-100 In some embodiments, L is an optionally substituted divalent linear or branched chain C alkyl group having 1 to 20 heteroatoms. 1-100 Heteroaliphatic groups, wherein one or more methylene units of said group are optionally and independently substituted.
[0210] In some embodiments, the linker moiety (e.g., L) is or comprises one or more polyethylene glycol units. 2 CH 2 O) n -, where n is as described herein. In some embodiments, one or more methylene units of L are independently -(CH 2 CH 2 O) n-. In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6. In some embodiments, n is 7. In some embodiments, n is 8. In some embodiments, n is 9. In some embodiments, n is 10. In some embodiments, n is 11. In some embodiments, n is 12. In some embodiments, n is 13. In some embodiments, n is 14. In some embodiments, n is 15. In some embodiments, n is 16. In some embodiments, n is 17. In some embodiments, n is 18. In some embodiments, n is 19. In some embodiments, n is 20.
[0211] In some embodiments, the linker moiety comprises one or more moieties that can be utilized for linking to other moieties, such as amino, carbonyl, etc. In some embodiments, the linker moiety comprises one or more -NR'-, where R' is as described herein. In some embodiments, -NR'- improves solubility. In some embodiments, -NR'- serves as a point of attachment to another moiety. In some embodiments, R' is -H. In some embodiments, one or more methylene units of L are independently replaced with -NR'-, where R' is as described herein.
[0212] In some embodiments, a linker moiety, e.g., L, comprises a -C(O)- group that can be used for linking to a moiety. In some embodiments, one or more methylene units of L are independently replaced with -C(O)-.
[0213] In some embodiments, the linker moiety comprises one or more ring moieties, e.g., one or more methylene units of L are replaced with -Cy-. In some embodiments, the linker moiety, e.g., L, comprises an aryl ring. In some embodiments, the linker moiety, e.g., L, comprises a heteroaryl ring. In some embodiments, the linker moiety, e.g., L, comprises an aliphatic ring. In some embodiments, the linker moiety, e.g., L, comprises a heterocyclyl ring. In some embodiments, the linker moiety, e.g., L, comprises a polycyclic ring. In some embodiments, the ring in the linker moiety, e.g., L, is 3-20 membered. In some embodiments, the ring is 5 membered. In some embodiments, the ring is 6 membered. In some embodiments, the ring in the linker is the product of a ring addition reaction (e.g., click chemistry and variations thereof) utilized to bond different moieties together.
[0214] In some embodiments, the linker moiety (e.g., L) is [ka] In some embodiments, the methylene unit of L is or comprises [ka] In some embodiments, -Cy- is substituted with [ka] It is.
[0215] In some embodiments, the linker moiety is as described in Table 1. Additional linker moieties include, for example, L 2 In some embodiments, L comprises a linker as described for the L 1 In some embodiments, L is as described herein. 2 In some embodiments, L is as described herein. 3In some embodiments, L is as described herein. b It is.
[0216] In some embodiments, L is [ka] It is.
[0217] Specific embodiments of variables By way of example, exemplary embodiments of variables are described throughout the specification. As will be appreciated by one of skill in the art, embodiments for the various variables may optionally be combined.
[0218] As defined above and described herein, ABT is an antibody binding moiety.
[0219] In some embodiments, the ABT is an antibody binding moiety.
[0220] In some embodiments, the ABT is selected from those shown in Table 1 below.
[0221] As defined above and described herein, L is a divalent linker moiety that connects ABT and TBT.
[0222] In some embodiments, L is a divalent linker moiety connecting ABT and TBT.
[0223] In some embodiments, L is selected from those shown in Table 1 below.
[0224] As defined above and described herein, TBT is a target binding moiety.
[0225] In some embodiments, TBT is the target binding moiety.
[0226] In some embodiments, the TBT is selected from those shown in Table 1 below.
[0227] R, as defined above and described herein, 1 , R 3 and R 5 Each of is independently hydrogen or C 1-6 or R is optionally substituted, selected from an aliphatic, 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen or sulfur; 1 and R 1’ may optionally be joined together with the carbon atoms therebetween to form a 3- to 8-membered saturated or partially unsaturated spirocyclic carbocyclic ring or a 4- to 8-membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R 3 and R 3’ may optionally be joined together with the carbon atom therebetween to form a 3- to 8-membered saturated or partially unsaturated spirocyclic carbocyclic ring, a 4- to 8-membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R bound to the same carbon atom 5 Groups and R 5’ groups optionally together with the carbon atoms between them form a 3- to 8-membered saturated or partially unsaturated spirocyclic carbocyclic ring or a 4- to 8-membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or two R 5 The groups, together with the atoms between them, form a divalent C 1-10forming a linear or branched saturated or unsaturated hydrocarbon chain, wherein one to three methylene units of the chain are independently selected from the group consisting of -S-, -SS-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -S(O)-, -S(O) 2 -or- Cy 1 -, where each -Cy 1 - is independently a 5-6 membered heteroarylenyl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0228] In some embodiments, R 1 is hydrogen. In some embodiments, R 1 is C 1-6 An optionally substituted group selected from aliphatic, 3- to 8-membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, 8- to 10-membered bicyclic aromatic carbocyclic ring, 4- to 8-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 5- to 6-membered monocyclic heteroaromatic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 8- to 10-membered bicyclic heteroaromatic ring having 1 to 5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 1 is an optionally substituted C 1-6 In some embodiments, R 1 is an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, R 1 is an optionally substituted phenyl. In some embodiments, R 1 is an optionally substituted 8-10 membered bicyclic aromatic carbocyclic ring. In some embodiments, R 1 is an optionally substituted 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.1 is an optionally substituted 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 1 is an optionally substituted 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen or sulfur.
[0229] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] It is.
[0230] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] In some embodiments, R1 teeth [ka] It is.
[0231] In some embodiments, R 1 teeth [ka] In some embodiments, R 1 teeth [ka] It is.
[0232] In some embodiments, R 1 and R 1’ may optionally be joined together with the carbon atoms between them to form a 3-8 membered saturated or partially unsaturated spirocyclic carbocyclic ring. 1 and R 1’ may optionally be joined together with the carbon atoms therebetween to form a 4-8 membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0233] In some embodiments, R 1 is selected from those shown in Table 1 below.
[0234] In some embodiments, R is R 1 In some embodiments, R a2 is R as described herein. 1 In some embodiments, R a3 is R as described herein. 1 It is.
[0235] In some embodiments, R 3 is hydrogen. In some embodiments, R 3 is C1-6 An optionally substituted group selected from aliphatic, 3- to 8-membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, 8- to 10-membered bicyclic aromatic carbocyclic ring, 4- to 8-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 5- to 6-membered monocyclic heteroaromatic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 8- to 10-membered bicyclic heteroaromatic ring having 1 to 5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 3 is an optionally substituted C 1-6 In some embodiments, R 3 is an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, R 3 is an optionally substituted phenyl. In some embodiments, R 3 is an optionally substituted 8-10 membered bicyclic aromatic carbocyclic ring. In some embodiments, R 3 is an optionally substituted 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R 3 is an optionally substituted 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 3 is an optionally substituted 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen or sulfur.
[0236] In some embodiments, R 3 is methyl. In some embodiments, R 3 teeth [ka] In some embodiments, R3 teeth [ka] It is.
[0237] In some embodiments, R 3 teeth [ka] In some embodiments, R 3 teeth [ka] In some embodiments, R 3 has (S) stereochemistry at the binding site [ka] In some embodiments, R 3 has (R) stereochemistry at the binding site [ka] In some embodiments, R 3 has (S) stereochemistry at the binding site [ka] In some embodiments, R 3 has (R) stereochemistry at the binding site [ka] It is.
[0238] In some embodiments, R 3 has (S) stereochemistry at the binding site [ka] In some embodiments, R 3 has (R) stereochemistry at the binding site [ka] It is.
[0239] In some embodiments, R 3 and R 3’ may optionally be joined together with the carbon atoms between them to form a 3-8 membered saturated or partially unsaturated spirocyclic carbocyclic ring. 3 and R 3’ may optionally be joined together with the carbon atoms therebetween to form a 4-8 membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0240] In some embodiments, R 3 is selected from those shown in Table 1 below.
[0241] In some embodiments, R is R 2 In some embodiments, R a2 is R as described herein. 2 In some embodiments, R a3 is R as described herein. 2 It is.
[0242] In some embodiments, R 5 is hydrogen. In some embodiments, R 5 is C 1-6An optionally substituted group selected from aliphatic, 3- to 8-membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, 8- to 10-membered bicyclic aromatic carbocyclic ring, 4- to 8-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 5- to 6-membered monocyclic heteroaromatic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 8- to 10-membered bicyclic heteroaromatic ring having 1 to 5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 5 is an optionally substituted C 1-6 In some embodiments, R 5 is an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, R 5 is an optionally substituted phenyl. In some embodiments, R 5 is an optionally substituted 8-10 membered bicyclic aromatic carbocyclic ring. In some embodiments, R 5 is an optionally substituted 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R 5 is an optionally substituted 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 5 is an optionally substituted 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen or sulfur.
[0243] In some embodiments, R 5 is methyl. In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 has (S) stereochemistry at the binding site [ka] In some embodiments, R 5 has (R) stereochemistry at the binding site [ka] In some embodiments, R 5 has (S) stereochemistry at the binding site [ka] In some embodiments, R 5 has (R) stereochemistry at the binding site [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] It is.
[0244] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] It is.
[0245] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] It is.
[0246] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] It is.
[0247] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 5 teeth [ka] In some embodiments, R 4 has (S) stereochemistry at the binding site [ka] In some embodiments, R 4 has (R) stereochemistry at the binding site [ka] It is.
[0248] In some embodiments, R 5 and R 5’ The groups may optionally be joined together with the carbon atoms between them to form a 3-8 membered saturated or partially unsaturated spirocyclic carbocyclic ring. 5 and R 5’ The groups may optionally be joined together with the carbon atoms between them to form a 4-8 membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen or sulfur.
[0249] In some embodiments, two R 5 The groups, together with the atoms between them, form a divalent C 1-10 forming a linear or branched saturated or unsaturated hydrocarbon chain, wherein one to three methylene units of the chain are independently selected from the group consisting of -S-, -SS-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -S(O)-, -S(O) 2 -or- Cy 1 -, where each -Cy 1 - is independently a 5-6 membered heteroarylenyl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0250] In some embodiments, two R 5 The groups, together with the atoms between them, [ka] In some embodiments, two R 5 The groups, together with the atoms between them, [ka] In some embodiments, two R 5 The groups, together with the atoms between them, [ka] In some embodiments, two R 5 The groups, together with the atoms between them, [ka] Form.
[0251] In some embodiments, R 5 is selected from those shown in Table 1 below.
[0252] In some embodiments, R is R 5 In some embodiments, R a2 is R as described herein. 5 In some embodiments, R a3 is R as described herein. 5 It is.
[0253] R, as defined above and described herein, 1’ , R 3’ and R 5’ each independently represents hydrogen or C 1-3 It is aliphatic.
[0254] In some embodiments, R 1’ is hydrogen. In some embodiments, R 1’ is C 1-3 It is aliphatic.
[0255] In some embodiments, R 1’is methyl. In some embodiments, R 1’ is ethyl. In some embodiments, R 1’ is n-propyl. In some embodiments, R 1’ is isopropyl. In some embodiments, R 1’ is cyclopropyl.
[0256] In some embodiments, R 1’ is selected from those shown in Table 1 below.
[0257] In some embodiments, R 3’ is hydrogen. In some embodiments, R 3’ is C 1-3 It is aliphatic.
[0258] In some embodiments, R 3’ is methyl. In some embodiments, R 3’ is ethyl. In some embodiments, R 3’ is n-propyl. In some embodiments, R 3’ is isopropyl. In some embodiments, R 3’ is cyclopropyl.
[0259] In some embodiments, R 3’ is selected from those shown in Table 1 below.
[0260] In some embodiments, R 5’ is hydrogen. In some embodiments, R 5’ is C 1-3 It is aliphatic.
[0261] In some embodiments, R 5’ is methyl. In some embodiments, R 5’ is ethyl. In some embodiments, R 5’ is n-propyl. In some embodiments, R 5’is isopropyl. In some embodiments, R 5’ is cyclopropyl.
[0262] In some embodiments, R 5’ is selected from those shown in Table 1 below.
[0263] R, as defined above and described herein, 2 , R 4 and R 6 each independently represents hydrogen or C 1-4 Aliphatic or: R 2 and R 1 may optionally combine with their atoms to form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur; R 4 and R 3 may optionally be joined together with the atoms therebetween to form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or R 6 group and adjacent R 5 The groups may optionally be joined together with the atoms between them to form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen or sulfur.
[0264] In some embodiments, R 2 is hydrogen. In some embodiments, R 2 is C 1-4 In some embodiments, R 2 is methyl. In some embodiments, R 2 is ethyl. In some embodiments, R 2 is n-propyl. In some embodiments, R 2 is isopropyl. In some embodiments, R 2 is n-butyl. In some embodiments, R2 is isobutyl. In some embodiments, R 2 is tert-butyl.
[0265] In some embodiments, R 2 and R 1 together with the atoms therebetween form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen or sulfur.
[0266] In some embodiments, R 2 and R 1 are united with the atoms between them, [ka] In some embodiments, R 2 and R 1 are united with the atoms between them, [ka] Form.
[0267] In some embodiments, R 2 is selected from those shown in Table 1 below.
[0268] In some embodiments, R 4 is hydrogen. In some embodiments, R 4 is C 1-4 In some embodiments, R 4 is methyl. In some embodiments, R 4 is ethyl. In some embodiments, R 4 is n-propyl. In some embodiments, R 4 is isopropyl. In some embodiments, R 4 is n-butyl. In some embodiments, R 4 is isobutyl. In some embodiments, R4 is tert-butyl.
[0269] In some embodiments, R 4 and R 3 is a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen or sulfur, together with the atoms therebetween.
[0270] In some embodiments, R 4 and R 3 are united with the atoms between them, [ka] In some embodiments, R 4 and R 3 are united with the atoms between them, [ka] Form.
[0271] In some embodiments, R 4 is selected from those shown in Table 1 below.
[0272] In some embodiments, R 6 is hydrogen. In some embodiments, R 6 is C 1-4 In some embodiments, R 6 is methyl. In some embodiments, R 6 is ethyl. In some embodiments, R 6 is n-propyl. In some embodiments, R 6 is isopropyl. In some embodiments, R 6 is n-butyl. In some embodiments, R 6 is isobutyl. In some embodiments, R 6 is tert-butyl.
[0273] In some embodiments, R 6 group and adjacent R 5 The groups, together with the atoms between them, form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen or sulfur.
[0274] In some embodiments, R 6 group and adjacent R 5 The groups, together with the atoms between them, [ka] In some embodiments, R 6 group and adjacent R 5 The groups, together with the atoms between them, [ka] Form.
[0275] In some embodiments, R 6 is selected from those shown in Table 1 below.
[0276] In some embodiments, R is R 1’ In some embodiments, R a2 is R as described herein. 1’ In some embodiments, R a3 is R as described herein. 1’ In some embodiments, R is R 3’ In some embodiments, R a2 is R as described herein. 3’ In some embodiments, R a3 is R as described herein. 3’ In some embodiments, R is R 2 In some embodiments, R a2is R as described herein. 2 In some embodiments, R a3 is R as described herein. 2 In some embodiments, R is R 4 In some embodiments, R a2 is R as described herein. 4 In some embodiments, R a3 is R as described herein. 4 In some embodiments, R is R 6 In some embodiments, R a2 is R as described herein. 6 In some embodiments, R a3 is R as described herein. 6 It is.
[0277] As defined above and described herein, L 1 teeth [ka] is a trivalent linker moiety that links
[0278] In some embodiments, L 1 teeth [ka] In some embodiments, L 1 teeth [ka] In some embodiments, L 1 teeth [ka] In some embodiments, L 1 teeth [ka] In some embodiments, L 1 teeth [ka] In some embodiments, L 1 teeth [ka] In some embodiments, L 1 teeth [ka] In some embodiments, L 1 teeth [ka] In some embodiments, L 1 teeth [ka] In some embodiments, L 1 teeth [ka] In some embodiments, L 1 teeth [ka] In some embodiments, L 1 teeth [ka] In some embodiments, L 1 teeth [ka] In some embodiments, L 1 teeth [ka] In some embodiments, L 1 teeth [ka] It is.
[0279] In some embodiments, L 1 teeth [ka] In some embodiments, L 1 teeth [ka] In some embodiments, L 1 teeth [ka] In some embodiments, L 1 teeth [ka] In some embodiments, L 1 teeth [ka] In some embodiments, L 1 teeth [ka] In some embodiments, L 1 teeth [ka] It is.
[0280] In some embodiments, L 1 is selected from those shown in Table 1 below.
[0281] As defined above and described herein, L 2 is a covalent bond or a divalent C 1-10 A straight or branched chain saturated or unsaturated hydrocarbon chain, wherein one to three methylene units of the chain are independently selected from the group consisting of -S-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -S(O)-, -S(O) 2 -, [ka] Or -Cy 1 -, where each -Cy 1 - is independently a 5-6 membered heteroarylenyl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0282] In some embodiments, L 2 is a covalent bond. In some embodiments, L 2 is a divalent linear or branched saturated or unsaturated hydrocarbon chain, wherein one to three methylene units of the chain are independently selected from the group consisting of -S-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -S(O)-, -S(O) 2 -, [ka] Or -Cy 1 -, where each -Cy 1 - is independently a 5-6 membered heteroarylenyl having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0283] In some embodiments, L 2 teeth [ka] In some embodiments, L 2 teeth [ka] In some embodiments, L 2 teeth [ka] In some embodiments, L 2 teeth [ka] In some embodiments, L 2 teeth [ka] In some embodiments, L 2 teeth [ka] It is.
[0284] In some embodiments, L 2 is selected from those shown in Table 1 below.
[0285] In some embodiments, L is L as described herein. 2 It is.
[0286] As defined above and described herein, TBT is a target binding moiety.
[0287] In some embodiments, TBT is the target binding moiety.
[0288] In some embodiments, TBT is [ka] In some embodiments, TBT is [ka] It is.
[0289] In some embodiments, the TBT is selected from those shown in Table 1 below.
[0290] As defined above and described herein, each of m and n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10.
[0291] In some embodiments, m is 1. In some embodiments, m is 2. In some embodiments, m is 3. In some embodiments, m is 4. In some embodiments, m is 5. In some embodiments, m is 6. In some embodiments, m is 7. In some embodiments, m is 8. In some embodiments, m is 9. In some embodiments, m is 10.
[0292] In some embodiments, m is selected from those shown in Table 1 below.
[0293] In some embodiments, n is 1. In some embodiments, n is 2. In some embodiments, n is 3. In some embodiments, n is 4. In some embodiments, n is 5. In some embodiments, n is 6. In some embodiments, n is 7. In some embodiments, n is 8. In some embodiments, n is 9. In some embodiments, n is 10.
[0294] In some embodiments, n is selected from those shown in Table 1 below.
[0295] As defined above and described herein, each R 7 are independently hydrogen or C 1-6an optionally substituted group selected from aliphatic, 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, 8-10 membered bicyclic aromatic carbocyclic ring, 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen or sulfur, 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen or sulfur, or 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen or sulfur; or R 7 Groups and R 7’ The groups may optionally be joined together with the carbon atoms between them to form a 3- to 8-membered saturated or partially unsaturated spirocyclic carbocyclic ring or a 4- to 8-membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen or sulfur.
[0296] In some embodiments, R 7 is hydrogen. In some embodiments, R 7 is C 1-6 An optionally substituted group selected from aliphatic, 3- to 8-membered saturated or partially unsaturated monocyclic carbocyclic ring, phenyl, 8- to 10-membered bicyclic aromatic carbocyclic ring, 4- to 8-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, 5- to 6-membered monocyclic heteroaromatic ring having 1 to 4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or 8- to 10-membered bicyclic heteroaromatic ring having 1 to 5 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 7 is an optionally substituted C 1-6 In some embodiments, R 7 is an optionally substituted 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring. In some embodiments, R 7 is an optionally substituted phenyl. In some embodiments, R 7is an optionally substituted 8-10 membered bicyclic aromatic carbocyclic ring. In some embodiments, R 7 is an optionally substituted 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R 7 is an optionally substituted 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. 7 is an optionally substituted 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen or sulfur.
[0297] In some embodiments, R 7 is methyl. In some embodiments, R 7 teeth [ka] In some embodiments, R 7 teeth [ka] In some embodiments, R 7 teeth [ka] In some embodiments, R 7 teeth [ka] It is.
[0298] In some embodiments, R 7 teeth [ka] In some embodiments, R 7 teeth [ka] In some embodiments, R 7 teeth [ka] In some embodiments, R 7 teeth [ka] It is.
[0299] In some embodiments, R 7 teeth [ka] In some embodiments, R 7 teeth [ka] In some embodiments, R 7 teeth [ka] In some embodiments, R 7 teeth [ka] It is.
[0300] In some embodiments, R 7 teeth [ka] In some embodiments, R 7 teeth [ka] In some embodiments, R 7 teeth [ka] In some embodiments, R 7 teeth [ka] In some embodiments, R 7 teeth [ka] In some embodiments, R 7 teeth [ka] In some embodiments, R 7 teeth [ka] In some embodiments, R 7 teeth [ka] It is.
[0301] In some embodiments, R 7 Groups and R 7’ The R groups, together with the carbon atoms between them, form a 3-8 membered saturated or partially unsaturated spirocyclic carbocyclic ring. 7 Groups and R 7’ The groups, together with the carbon atoms between them, form a 4-8 membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen or sulfur.
[0302] In some embodiments, R 7 is selected from those shown in Table 1 below.
[0303] As defined above and described herein, each R7’ are independently hydrogen or C 1-3 It is aliphatic.
[0304] In some embodiments, R 7’ is hydrogen. In some embodiments, R 7’ is methyl. In some embodiments, R 7’ is ethyl. In some embodiments, R 7’ is n-propyl. In some embodiments, R 7’ is isopropyl.
[0305] In some embodiments, R 7’ is selected from those shown in Table 1 below.
[0306] As defined above and described herein, each R 8 are independently hydrogen or C 1-4 Aliphatic or;R 8 group and adjacent R 7 The groups may optionally form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur.
[0307] In some embodiments, R 8 is hydrogen. In some embodiments, R 8 is C 1-4 In some embodiments, R 8 is methyl. In some embodiments, R 8 is ethyl. In some embodiments, R 8 is n-propyl. In some embodiments, R 8 is isopropyl. In some embodiments, R 8 is n-butyl. In some embodiments, R 8 is isobutyl. In some embodiments, R 8 is tert-butyl.
[0308] In some embodiments, R 8 group and adjacent R 7 The groups, together with the atoms between them, form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen or sulfur.
[0309] In some embodiments, R 8 group and adjacent R 7 The groups, together with the atoms between them, [ka] In some embodiments, R 8 group and adjacent R 7 The groups, together with the atoms between them, [ka] Form.
[0310] In some embodiments, R 8 is selected from those shown in Table 1 below.
[0311] R, as defined above and described herein, 9 is hydrogen, C 1-3 Aliphatic or -C(O)C 1-3 It is aliphatic.
[0312] In some embodiments, R 9 is hydrogen. In some embodiments, R 9 is C 1-3 In some embodiments, R 9 -C(O)C 1-3 It is aliphatic.
[0313] In some embodiments, R 9 is methyl. In some embodiments, R 9is ethyl. In some embodiments, R 9 is n-propyl. In some embodiments, R 9 is isopropyl. In some embodiments, R 9 is cyclopropyl.
[0314] In some embodiments, R 9 is -C(O)Me. In some embodiments, R 9 is -C(O)Et. In some embodiments, R 9 -C(O)CH 2 CH 2 CH 3 In some embodiments, R 9 -C(O)CH(CH 3 ) 2 In some embodiments, R 9 is -C(O)cyclopropyl.
[0315] In some embodiments, R 9 is selected from those shown in Table 1 below.
[0316] In some embodiments, R is R 7 In some embodiments, R a2 is R as described herein. 7 In some embodiments, R a3 is R as described herein. 7 In some embodiments, R is R 7’ In some embodiments, R a2 is R as described herein. 7’ In some embodiments, R a3 is R as described herein. 7’ In some embodiments, R is R 8 In some embodiments, R a2 is R as described herein. 8 In some embodiments, Ra3 is R as described herein. 8 In some embodiments, R is R 8’ In some embodiments, R a2 is R as described herein. 8’ In some embodiments, R a3 is R as described herein. 8’ In some embodiments, R is R 9 In some embodiments, R a2 is R as described herein. 9 In some embodiments, R a3 is R as described herein. 9 It is.
[0317] As defined above and described herein, L 3 teeth [ka] and TBT.
[0318] In some embodiments, L 3 teeth [ka] and TBT.
[0319] In some embodiments, L 3 teeth [ka] In some embodiments, L 3 teeth [ka] In some embodiments, L 3 teeth [ka] In some embodiments, L 3 teeth [ka] In some embodiments, L 3 teeth [ka] In some embodiments, L 3 teeth [ka] It is.
[0320] In some embodiments, L 3 is selected from those shown in Table 1 below.
[0321] In some embodiments, L is L as described herein. 3 It is.
[0322] As defined above and described herein, o is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10.
[0323] In some embodiments, o is 1. In some embodiments, o is 2. In some embodiments, o is 3. In some embodiments, o is 4. In some embodiments, o is 5. In some embodiments, o is 6. In some embodiments, o is 7. In some embodiments, o is 8. In some embodiments, o is 9. In some embodiments, o is 10.
[0324] In some embodiments, o is selected from those shown in Table 1 below.
[0325] In certain embodiments, a useful agent, such as an ARM, is 2 but [ka] and TBT is [ka] whereby the compound of formula II-a: [ka] [In the formula, L 1 , R 1 , R 1’ , R 2 , R 3 , R 3’ , R 4 , R 5 , R 5’ , R 6 and m, both alone or in combination, are as defined above and described in the embodiments herein. or a salt thereof, forming a compound of formula II:
[0326] In certain embodiments, a useful agent, such as an ARM, is 2 but [ka] and TBT is [ka] and thereby formula II-b: [ka] [In the formula, L 1 , R 1 , R 1’ , R 2 , R 3 , R 3’ , R 4 , R 5 , R 5’ , R 6 and m, both alone or in combination, are as defined above and described in the embodiments herein. or a salt thereof, forming a compound of formula II:
[0327] In certain embodiments, a useful agent, such as an ARM, is 2 but [ka] and TBT is [ka] and thereby formula II-c: [ka] [In the formula, L 1 , R 1 , R 1’ , R 2 , R 3 , R 3’ , R 4 , R 5 , R 5’ , R 6 and m, both alone or in combination, are as defined above and described in the embodiments herein. or a salt thereof, forming a compound of formula II:
[0328] In certain embodiments, a useful agent, such as an ARM, is 2 but [ka] and TBT is [ka] and thereby formula II-d: [ka] [In the formula, L 1 , R 1 , R 1’ , R 2 , R 3 , R 3’ , R 4 , R5 , R 5’ , R 6 and m, both alone or in combination, are as defined above and described in the embodiments herein. or a salt thereof, forming a compound of formula II:
[0329] In certain embodiments, a useful agent, such as an ARM, is 2 but [ka] and TBT is [ka] and thereby formula II-e: [ka] [In the formula, L 1 , R 1 , R 1’ , R 2 , R 3 , R 3’ , R 4 , R 5 , R 5’ , R 6 and m, both alone or in combination, are as defined above and described in the embodiments herein. or a salt thereof, forming a compound of formula II:
[0330] In certain embodiments, a useful agent, such as an ARM, is 2 but [ka] and TBT is [ka] and thereby formula II-f: [ka] [In the formula, L1 , R 1 , R 1’ , R 2 , R 3 , R 3’ , R 4 , R 5 , R 5’ , R 6 and m, both alone or in combination, are as defined above and described in the embodiments herein. or a salt thereof, forming a compound of formula II:
[0331] In some embodiments, R a1 is R as described herein. In some embodiments, R a1 is an optionally substituted C 1-4 It is aliphatic.
[0332] In some embodiments, L a1 is L as described herein. a In some embodiments, L a1 is a covalent bond.
[0333] In some embodiments, L a2 is L as described herein. a In some embodiments, L a2 is a covalent bond.
[0334] In some embodiments, L a is a covalent bond. In some embodiments, L a is C 1 -C 10 Aliphatic or C with 1-5 heteroatoms 1 -C 10 heteroaliphatic, wherein one or more methylene units of said group are optionally independently selected from -C(R') 2-, -Cy-, -O-, -S-, -SS-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O) 2 -, -S(O) 2 In some embodiments, L may be substituted with -N(R')-, -C(O)S-, or -C(O)O-. a is C 1 -C 5 Aliphatic or C with 1-5 heteroatoms 1 -C 5 heteroaliphatic, wherein one or more methylene units of said group are optionally independently selected from -C(R') 2 -, -Cy-, -O-, -S-, -SS-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O) 2 -, -S(O) 2 In some embodiments, L is substituted with -N(R')-, -C(O)S-, or -C(O)O-. a is an optionally substituted divalent C 1 -C 5 aliphatic, wherein one or more methylene units of said group are optionally independently -C(R') 2 -, -Cy-, -O-, -S-, -SS-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O) 2 -, -S(O) 2 In some embodiments, L may be substituted with -N(R')-, -C(O)S-, or -C(O)O-. a is an optionally substituted divalent C 1 -C 5 In some embodiments, L ais an optionally substituted divalent C having 1 to 3 heteroatoms independently selected from nitrogen, oxygen and sulfur; 1 -C 5 It is heteroaliphatic.
[0335] In some embodiments, R a2 is R as described herein. In some embodiments, R a2 is the side chain of a natural amino acid. In some embodiments, R a3 is R as described herein. In some embodiments, R a3 is the side chain of a natural amino acid. In some embodiments, R 2a and R 3a One of the groups is hydrogen.
[0336] In some embodiments, each -Cy- is independently 3-20 Cycloaliphatic ring, C 6-20 An optionally substituted divalent group selected from an aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon. In some embodiments, -Cy- is, for example, a divalent group selected from R and Cy. L embedded image is an optionally substituted ring as described herein, but is divalent.
[0337] In some embodiments, -Cy- is monocyclic. In some embodiments, -Cy- is bicyclic. In some embodiments, -Cy- is polycyclic. In some embodiments, -Cy- is saturated. In some embodiments, -Cy- is partially unsaturated. In some embodiments, -Cy- is aromatic. In some embodiments, -Cy- comprises a saturated cyclic moiety. In some embodiments, -Cy- comprises a partially unsaturated cyclic moiety. In some embodiments, -Cy- comprises an aromatic cyclic moiety. In some embodiments, -Cy- comprises a combination of saturated, partially unsaturated and / or aromatic cyclic moieties. In some embodiments, -Cy- is 3-membered. In some embodiments, -Cy- is 4-membered. In some embodiments, -Cy- is 5-membered. In some embodiments, -Cy- is 6-membered. In some embodiments, -Cy- is 7-membered. In some embodiments, -Cy- is 8-membered. In some embodiments, -Cy- is 9-membered. In some embodiments, -Cy- is 10-membered. In some embodiments, -Cy- is 11-membered. In some embodiments, -Cy- is 12-membered. In some embodiments, -Cy- is 13-membered. In some embodiments, -Cy- is 14-membered. In some embodiments, -Cy- is 15-membered. In some embodiments, -Cy- is 16-membered. In some embodiments, -Cy- is 17-membered. In some embodiments, -Cy- is 18-membered. In some embodiments, -Cy- is 19-membered. In some embodiments, -Cy- is 20-membered.
[0338] In some embodiments, -Cy- is an optionally substituted divalent C 3-20 In some embodiments, -Cy- is an optionally substituted, divalent, saturated C 3-20 In some embodiments, -Cy- is an optionally substituted divalent, partially unsaturated C 3-20In some embodiments, -Cy-H is an optionally substituted cycloaliphatic embodiment of R, such as an optionally substituted cycloaliphatic embodiment of R, as described herein.
[0339] In some embodiments, -Cy- is an optionally substituted C 6-20 In some embodiments, -Cy- is an aryl ring. In some embodiments, -Cy- is an optionally substituted phenylene. In some embodiments, -Cy- is an optionally substituted 1,2-phenylene. In some embodiments, -Cy- is an optionally substituted 1,3-phenylene. In some embodiments, -Cy- is an optionally substituted 1,4-phenylene. In some embodiments, -Cy- is an optionally substituted divalent naphthalene ring. In some embodiments, -Cy-H is an optionally substituted aryl as described in the present invention, for example, in the aryl embodiment for R.
[0340] In some embodiments, -Cy- is an optionally substituted divalent 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, -Cy- is an optionally substituted divalent 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen and sulfur. In some embodiments, -Cy- is an optionally substituted divalent 5-6 membered heteroaryl ring having 1-4 heteroatoms independently selected from oxygen, nitrogen and sulfur. In some embodiments, -Cy- is an optionally substituted divalent 5-6 membered heteroaryl ring having 1-3 heteroatoms independently selected from oxygen, nitrogen and sulfur. In some embodiments, -Cy- is an optionally substituted divalent 5-6 membered heteroaryl ring having 1-2 heteroatoms independently selected from oxygen, nitrogen and sulfur. In some embodiments, -Cy- is an optionally substituted divalent 5-6 membered heteroaryl ring having one heteroatom independently selected from oxygen, nitrogen, and sulfur. In some embodiments, -Cy-H is an optionally substituted heteroaryl as described herein, e.g., heteroaryl embodiments for R. In some embodiments, -Cy- is [ka] It is.
[0341] In some embodiments, -Cy- is an optionally substituted divalent 3- to 20-membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon. In some embodiments, -Cy- is an optionally substituted divalent 3- to 20-membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, and sulfur. In some embodiments, -Cy- is an optionally substituted divalent 3- to 6-membered heterocyclyl ring having 1-4 heteroatoms independently selected from oxygen, nitrogen, and sulfur. In some embodiments, -Cy- is an optionally substituted divalent 5- to 6-membered heterocyclyl ring having 1-4 heteroatoms independently selected from oxygen, nitrogen, and sulfur. In some embodiments, -Cy- is an optionally substituted divalent 5- to 6-membered heterocyclyl ring having 1-3 heteroatoms independently selected from oxygen, nitrogen, and sulfur. In some embodiments, -Cy- is an optionally substituted divalent 5-6 membered heterocyclyl ring having 1-2 heteroatoms independently selected from oxygen, nitrogen, and sulfur. In some embodiments, -Cy- is an optionally substituted divalent 5-6 membered heterocyclyl ring having 1 heteroatom independently selected from oxygen, nitrogen, and sulfur. In some embodiments, -Cy- is an optionally substituted divalent saturated heterocyclyl group. In some embodiments, -Cy- is an optionally substituted divalent partially unsaturated heterocyclyl group. In some embodiments, -Cy-H is an optionally substituted heterocyclyl as described herein, e.g., in the heterocyclyl embodiments for R.
[0342] In some embodiments, each Xaa is independently an amino acid residue. In some embodiments, each Xaa is independently an amino acid residue of an amino acid of AI.
[0343] In some embodiments, t is 0. In some embodiments, t is 1 to 50. In some embodiments, t is z, as described herein.
[0344] In some embodiments, z is 1. In some embodiments, z is 2. In some embodiments, z is 3. In some embodiments, z is 4. In some embodiments, z is 5. In some embodiments, z is 6. In some embodiments, z is 7. In some embodiments, z is 8. In some embodiments, z is 9. In some embodiments, z is 10. In some embodiments, z is 11. In some embodiments, z is 12. In some embodiments, z is 13. In some embodiments, z is 14. In some embodiments, z is 15. In some embodiments, z is 16. In some embodiments, z is 17. In some embodiments, z is 18. In some embodiments, z is 19. In some embodiments, z is 20. In some embodiments, z is greater than 20.
[0345] In some embodiments, R c is R' as described herein. In some embodiments, R c is R as described herein. In some embodiments, R c is -N(R') 2 wherein each R' is independently as described herein. In some embodiments, R c Ha-NH 2 In some embodiments, R c is RC(O)-, where R is as described herein.
[0346] In some embodiments, a is 1. In some embodiments, a is 2-100. In some embodiments, a is 5. In some embodiments, a is 10. In some embodiments, a is 20. In some embodiments, a is 50.
[0347] In some embodiments, b is 1. In some embodiments, b is 2-100. In some embodiments, b is 5. In some embodiments, b is 10. In some embodiments, b is 20. In some embodiments, b is 50.
[0348] In some embodiments, a1 is 0. In some embodiments, a1 is 1.
[0349] In some embodiments, a2 is 0. In some embodiments, a2 is 1.
[0350] In some embodiments, L b is the L a In some embodiments, L b In some embodiments, L comprises -Cy-. b In some embodiments, L b In some embodiments, L includes -S-. b In some embodiments, L includes -SS-. b includes -C(O)-N(R')-.
[0351] In some embodiments, R' is -R, -C(O)R, -C(O)OR or -S(O) 2In some embodiments, R' is R, where R is as described herein. In some embodiments, R' is -C(O)R, where R is as described herein. In some embodiments, R' is -C(O)OR, where R is as described herein. In some embodiments, R' is -S(O) 2 R, where R is as described herein. In some embodiments, R' is hydrogen. In some embodiments, R' is not hydrogen. In some embodiments, R' is R, where R is an optionally substituted C, as described herein. 1-20 In some embodiments, R' is R, where R is an optionally substituted C 1-20 In some embodiments, R' is R, where R is an optionally substituted C 6-20 In some embodiments, R' is R, where R is an optionally substituted C 6-20 In some embodiments, R' is R, where R is an optionally substituted C 6-20 Arylheteroaliphatic. In some embodiments, R' is R, where R is an optionally substituted 5-20 membered heteroaryl as described herein. In some embodiments, R' is R, where R is an optionally substituted 3-20 membered heterocyclyl as described herein. In some embodiments, two or more R' are R, optionally independently and together forming an optionally substituted ring as described herein.
[0352] In some embodiments, each R is independently -H or C 1-30C having 1 to 10 heteroatoms independently selected from aliphatic, oxygen, nitrogen, sulfur, phosphorus and silicon 1-30 Heteroaliphatic, C 6-30 Aryl, C 6-30 C having 1 to 10 heteroatoms independently selected from arylaliphatic, oxygen, nitrogen, sulfur, phosphorus, and silicon 6-30 an optionally substituted group selected from arylheteroaliphatic, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; or The two R groups may optionally independently be joined together to form a covalent bond, or: two or more R groups on the same atom may optionally independently, together with the atom, form an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; or Two or more R groups on two or more atoms may optionally form independently an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atoms between, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon.
[0353] In some embodiments, each R is independently -H or C 1-30 C having 1 to 10 heteroatoms independently selected from aliphatic, oxygen, nitrogen, sulfur, phosphorus and silicon 1-30 Heteroaliphatic, C 6-30 Aryl, C 6-30 C having 1 to 10 heteroatoms independently selected from arylaliphatic, oxygen, nitrogen, sulfur, phosphorus, and silicon 6-30an optionally substituted group selected from arylheteroaliphatic, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; or The two R groups may optionally independently be joined together to form a covalent bond, or: Two or more R groups on the same atom may optionally independently, together with that atom, form an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having, in addition to that atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; Two or more R groups on two or more atoms may optionally form independently an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atoms between them, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon.
[0354] In some embodiments, each R is independently -H or C 1-20 C having 1 to 10 heteroatoms independently selected from aliphatic, oxygen, nitrogen, sulfur, phosphorus and silicon 1-20 Heteroaliphatic, C 6-20 Aryl, C 6-20 C having 1 to 10 heteroatoms independently selected from arylaliphatic, oxygen, nitrogen, sulfur, phosphorus, and silicon 6-20 an optionally substituted group selected from arylheteroaliphatic, 5-20 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and 3-20 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; or The two R groups may optionally independently be joined together to form a covalent bond, or: Two or more R groups on the same atom may optionally independently, together with that atom, form an optionally substituted 3-20 membered monocyclic, bicyclic or polycyclic ring having in addition to that atom 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; Two or more R groups on two or more atoms can optionally independently combine with the atoms between them to form an optionally substituted 3-20 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atoms between them, 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon.
[0355] In some embodiments, each R is independently -H or C 1-30 C having 1 to 10 heteroatoms independently selected from aliphatic, oxygen, nitrogen, sulfur, phosphorus and silicon 1-30 Heteroaliphatic, C 6-30 Aryl, C 6-30 C having 1 to 10 heteroatoms independently selected from arylaliphatic, oxygen, nitrogen, sulfur, phosphorus, and silicon 6-30 Aryl is an optionally substituted group selected from heteroaliphatic, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon.
[0356] In some embodiments, each R is independently -H or C 1-20 C having 1 to 10 heteroatoms independently selected from aliphatic, oxygen, nitrogen, sulfur, phosphorus and silicon 1-20 Heteroaliphatic, C 6-20 Aryl, C 6-20 C having 1 to 10 heteroatoms independently selected from arylaliphatic, oxygen, nitrogen, sulfur, phosphorus, and silicon 6-20Aryl is an optionally substituted group selected from heteroaliphatic, 5-20 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and 3-20 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon.
[0357] In some embodiments, R is hydrogen. In some embodiments, R is not hydrogen. In some embodiments, R is C 1-30 C having 1 to 10 heteroatoms independently selected from aliphatic, oxygen, nitrogen, sulfur, phosphorus and silicon 1-30 Heteroaliphatic, C 6-30 An optionally substituted group selected from a 5- to 30-membered heteroaryl ring having 1 to 10 heteroatoms independently selected from aryl, oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3- to 30-membered heterocyclic ring having 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon.
[0358] In some embodiments, R is hydrogen or C 1-20 an optionally substituted group selected from aliphatic, phenyl, a 3- to 7-membered saturated or partially unsaturated carbocyclic ring, an 8- to 10-membered bicyclic saturated, partially unsaturated or aryl ring, a 5- to 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur, a 4- to 7-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen and sulfur, a 7- to 10-membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen and sulfur, or an 8- to 10-membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen and sulfur.
[0359] In some embodiments, R is an optionally substituted C 1-30 In some embodiments, R is an optionally substituted C1-20 In some embodiments, R is an optionally substituted C 1-15 In some embodiments, R is an optionally substituted C 1-10 In some embodiments, R is an optionally substituted C 1-6 In some embodiments, R is an optionally substituted C 1-6 In some embodiments, R is an optionally substituted hexyl, pentyl, butyl, propyl, ethyl or methyl. In some embodiments, R is an optionally substituted hexyl. In some embodiments, R is an optionally substituted pentyl. In some embodiments, R is an optionally substituted butyl. In some embodiments, R is an optionally substituted propyl. In some embodiments, R is an optionally substituted ethyl. In some embodiments, R is an optionally substituted methyl. In some embodiments, R is hexyl. In some embodiments, R is pentyl. In some embodiments, R is butyl. In some embodiments, R is propyl. In some embodiments, R is ethyl. In some embodiments, R is methyl. In some embodiments, R is isopropyl. In some embodiments, R is n-propyl. In some embodiments, R is tert-butyl. In some embodiments, R is sec-butyl. In some embodiments, R is n-butyl. In some embodiments, R is -(CH 2 ) 2 It is CN.
[0360] In some embodiments, R is an optionally substituted C 3-30 In some embodiments, R is an optionally substituted C 3-20In some embodiments, R is an optionally substituted C 3-10 It is cycloaliphatic. In some embodiments, R is an optionally substituted cyclohexyl. In some embodiments, R is cyclohexyl. In some embodiments, R is an optionally substituted cyclopentyl. In some embodiments, R is cyclopentyl. In some embodiments, R is an optionally substituted cyclobutyl. In some embodiments, R is cyclobutyl. In some embodiments, R is an optionally substituted cyclopropyl. In some embodiments, R is cyclopropyl.
[0361] In some embodiments, R is an optionally substituted 3-30 membered saturated or partially unsaturated carbocyclic ring. In some embodiments, R is an optionally substituted 3-7 membered saturated or partially unsaturated carbocyclic ring. In some embodiments, R is an optionally substituted 3 membered saturated or partially unsaturated carbocyclic ring. In some embodiments, R is an optionally substituted 4 membered saturated or partially unsaturated carbocyclic ring. In some embodiments, R is an optionally substituted 5 membered saturated or partially unsaturated carbocyclic ring. In some embodiments, R is an optionally substituted 6 membered saturated or partially unsaturated carbocyclic ring. In some embodiments, R is an optionally substituted 7 membered saturated or partially unsaturated carbocyclic ring. In some embodiments, R is an optionally substituted cycloheptyl. In some embodiments, R is cycloheptyl. In some embodiments, R is optionally substituted cyclohexyl. In some embodiments, R is cyclohexyl. In some embodiments, R is optionally substituted cyclopentyl. In some embodiments, R is cyclopentyl. In some embodiments, R is optionally substituted cyclobutyl. In some embodiments, R is cyclobutyl. In some embodiments, R is optionally substituted cyclopropyl. In some embodiments, R is cyclopropyl.
[0362] In some embodiments, when R is or includes a ring structure, such as cycloaliphatic, cycloheteroaliphatic, aryl, heteroaryl, etc., the ring structure can be monocyclic, bicyclic or polycyclic.In some embodiments, R is or includes a monocyclic structure.In some embodiments, R is or includes a bicyclic structure.In some embodiments, R is or includes a polycyclic structure.
[0363] In some embodiments, R is an optionally substituted C having 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon. 1-30 In some embodiments, R is an optionally substituted C alkyl group having 1 to 10 heteroatoms. 1-20 In some embodiments, R is an optionally substituted C alkyl group having 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, or silicon (optionally including one or more oxidized forms of nitrogen, sulfur, phosphorus, or selenium). 1-20 In some embodiments, R is [ka] -N=, ≡N, -S-, -S(O)-, -S(O) 2 -, -O-, =O, [ka] Optionally substituted C containing 1 to 10 groups independently selected from 1-30 It is heteroaliphatic.
[0364] In some embodiments, R is an optionally substituted C 6-30 In some embodiments, R is aryl. In some embodiments, R is optionally substituted phenyl. In some embodiments, R is phenyl. In some embodiments, R is substituted phenyl.
[0365] In some embodiments, R is an optionally substituted 8-10 membered bicyclic saturated, partially unsaturated or aryl ring. In some embodiments, R is an optionally substituted 8-10 membered bicyclic saturated ring. In some embodiments, R is an optionally substituted 8-10 membered bicyclic partially unsaturated ring. In some embodiments, R is an optionally substituted 8-10 membered bicyclic aryl ring. In some embodiments, R is an optionally substituted naphthyl.
[0366] In some embodiments, R is an optionally substituted 5-30 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon. In some embodiments, R is an optionally substituted 5-30 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, and sulfur. In some embodiments, R is an optionally substituted 5-30 membered heteroaryl ring having 1-5 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon. In some embodiments, R is an optionally substituted 5-30 membered heteroaryl ring having 1-5 heteroatoms independently selected from oxygen, nitrogen, and sulfur.
[0367] In some embodiments, R is an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is a substituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an unsubstituted 5-6 membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, sulfur, and oxygen. In some embodiments, R is a substituted 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an unsubstituted 5-6 membered monocyclic heteroaryl ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0368] In some embodiments, R is an optionally substituted 5-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R is an optionally substituted 6-membered monocyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0369] In some embodiments, R is an optionally substituted 5-membered monocyclic heteroaryl ring having one heteroatom selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted pyrrolyl, furanyl, or thienyl.
[0370] In some embodiments, R is an optionally substituted 5-membered heteroaryl ring with 2 heteroatoms independently selected from nitrogen, oxygen and sulfur.In certain embodiments, R is an optionally substituted 5-membered heteroaryl ring with 1 nitrogen atom and additional heteroatoms independently selected from sulfur or oxygen.In some embodiments, R is an optionally substituted 5-membered heteroaryl ring with 3 heteroatoms independently selected from nitrogen, oxygen and sulfur.In some embodiments, R is an optionally substituted 5-membered heteroaryl ring with 4 heteroatoms independently selected from nitrogen, oxygen and sulfur.
[0371] In some embodiments, R is an optionally substituted 6-membered heteroaryl ring having 1-4 nitrogen atoms. In some embodiments, R is an optionally substituted 6-membered heteroaryl ring having 1-3 nitrogen atoms. In other embodiments, R is an optionally substituted 6-membered heteroaryl ring having 1-2 nitrogen atoms. In some embodiments, R is an optionally substituted 6-membered heteroaryl ring having 4 nitrogen atoms. In some embodiments, R is an optionally substituted 6-membered heteroaryl ring having 3 nitrogen atoms. In some embodiments, R is an optionally substituted 6-membered heteroaryl ring having 2 nitrogen atoms. In certain embodiments, R is an optionally substituted 6-membered heteroaryl ring having 1 nitrogen atom.
[0372] In certain embodiments, R is an optionally substituted 8-10 membered bicyclic heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur. In some embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur. In certain embodiments, R is an optionally substituted 6,6-fused heteroaryl ring having 1-4 heteroatoms independently selected from nitrogen, oxygen and sulfur.
[0373] In some embodiments, R is a 3-30 membered heterocyclic ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon. In some embodiments, R is a 3-30 membered heterocyclic ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, and sulfur. In some embodiments, R is a 3-30 membered heterocyclic ring having 1-5 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon. In some embodiments, R is a 3-30 membered heterocyclic ring having 1-5 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon.
[0374] In some embodiments, R is an optionally substituted 3- to 7-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is a substituted 3- to 7-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is a 3- to 7-membered saturated or partially unsaturated heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R is an optionally substituted 5- to 7-membered partially unsaturated monocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R is an optionally substituted 5- to 6-membered partially unsaturated monocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R is an optionally substituted 5-membered partially unsaturated monocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R is an optionally substituted 6-membered partially unsaturated monocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In certain embodiments, R is an optionally substituted 7-membered partially unsaturated monocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 3-membered heterocyclic ring having 1 heteroatom independently selected from nitrogen, oxygen, or sulfur. In some embodiments, R is an optionally substituted 4-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 5-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 6-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.In some embodiments, R is an optionally substituted 7-membered heterocyclic ring having 1-3 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0375] In some embodiments, R is an optionally substituted 3-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 4-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 5-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 6-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 7-membered saturated or partially unsaturated heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0376] In certain embodiments, R is an optionally substituted 5-6 membered partially unsaturated monocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen and sulfur. In certain embodiments, R is an optionally substituted tetrahydropyridinyl, dihydrothiazolyl, dihydrooxazolyl or oxazolinyl group.
[0377] In some embodiments, R is an optionally substituted 7-10 membered bicyclic saturated or partially unsaturated heterocyclic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen and sulfur. In some embodiments, R is an optionally substituted indolinyl. In some embodiments, R is an optionally substituted isoindolinyl. In some embodiments, R is an optionally substituted 1,2,3,4-tetrahydroquinolinyl. In some embodiments, R is an optionally substituted 1,2,3,4-tetrahydroisoquinolinyl. In some embodiments, R is an optionally substituted azabicyclo[3.2.1]octanyl.
[0378] In some embodiments, R is an optionally substituted 8-10 membered bicyclic heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur. In some embodiments, R is an optionally substituted 5,6-fused heteroaryl ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, and sulfur.
[0379] In some embodiments, R is an optionally substituted C 6-30 In some embodiments, R is an optionally substituted C 6-20 In some embodiments, R is an optionally substituted C 6-10 It is arylaliphatic. In some embodiments, the aryl moiety of the arylaliphatic has 6, 10 or 14 aryl carbon atoms. In some embodiments, the aryl moiety of the arylaliphatic has 6 aryl carbon atoms. In some embodiments, the aryl moiety of the arylaliphatic has 10 aryl carbon atoms. In some embodiments, the aryl moiety of the arylaliphatic has 14 aryl carbon atoms. In some embodiments, the aryl moiety is an optionally substituted phenyl.
[0380] In some embodiments, R is an optionally substituted C alkyl group having 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon. 6-30 In some embodiments, R is an optionally substituted C alkyl group having 1 to 10 heteroatoms independently selected from oxygen, nitrogen, and sulfur. 6-30 In some embodiments, R is an optionally substituted C alkyl group having 1 to 10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon. 6-20 In some embodiments, R is an optionally substituted C alkyl group having 1 to 10 heteroatoms independently selected from oxygen, nitrogen, and sulfur. 6-20 In some embodiments, R is an optionally substituted C alkyl group having 1 to 5 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon. 6-10 In some embodiments, R is an optionally substituted C alkyl group having 1 to 5 heteroatoms independently selected from oxygen, nitrogen, and sulfur. 6-10 It is arylheteroaliphatic.
[0381] In some embodiments, two R groups optionally independently join together to form a covalent bond. In some embodiments, -C=O is formed. In some embodiments, -C=C- is formed. In some embodiments, -C≡C- is formed.
[0382] In some embodiments, two or more R groups on the same atom may optionally independently combine with the atom to form an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, two or more R groups on the same atom may optionally independently combine with the atom to form an optionally substituted 3-20 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, two or more R groups on the same atom may optionally independently combine with the atom to form an optionally substituted 3-10 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atom, 0-5 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, two or more R groups on the same atom may optionally independently form, together with that atom, an optionally substituted 3-6 membered monocyclic, bicyclic or polycyclic ring having, in addition to that atom, 0-3 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, two or more R groups on the same atom may optionally independently form an optionally substituted 3-5 membered monocyclic, bicyclic or polycyclic ring having, in addition to that atom, 0-3 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon.
[0383] In some embodiments, two or more R groups on two or more atoms may optionally independently combine with the atoms between them to form an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atoms between them, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, two or more R groups on two or more atoms may optionally independently combine with the atoms between them to form an optionally substituted 3-20 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atoms between them, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, two or more R groups on two or more atoms may optionally independently combine with the atoms between them to form an optionally substituted 3-10 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atoms between them, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, two or more R groups on two or more atoms may optionally independently combine with the atoms between them to form an optionally substituted 3-10 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atoms between them, 0-5 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, two or more R groups on two or more atoms may optionally independently combine with the atoms between them to form an optionally substituted 3-6 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atoms between them, 0-3 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. In some embodiments, two or more R groups on two or more atoms may optionally independently combine with the atoms between them to form an optionally substituted 3-5 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atoms between them, 0-3 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon.
[0384] In some embodiments, the heteroatom in the R group or the structure formed by two or more R groups taken together is selected from oxygen, nitrogen and sulfur. In some embodiments, the ring formed is 3-membered, 4-membered, 5-membered, 6-membered, 7-membered, 8-membered, 9-membered, 10-membered, 11-membered, 12-membered, 13-membered, 14-membered, 15-membered, 16-membered, 17-membered, 18-membered, 19-membered or 20-membered. In some embodiments, the ring formed is saturated. In some embodiments, the ring formed is partially saturated. In some embodiments, the ring formed is aromatic. In some embodiments, the ring formed comprises saturated, partially saturated or aromatic ring moieties. In some embodiments, the ring formed comprises 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19 or 20 aromatic ring atoms. In some embodiments, the ring formed contains 5 or less, 6 or less, 7 or less, 8 or less, 9 or less, 10 or less, 11 or less, 12 or less, 13 or less, 14 or less, 15 or less, 16 or less, 17 or less, 18 or less, 19 or less, or 20 or less aromatic ring atoms. In some embodiments, the aromatic ring atoms are selected from carbon, nitrogen, oxygen, and sulfur.
[0385] In some embodiments, the ring formed by two or more R groups taken together (or two or more groups selected from the variables that can be R and R) is C 3-30 Cycloaliphatic, C 6-30 aryl, a 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, or a 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, a ring as described for R, but which is a divalent or polyvalent ring.
[0386] Representative compounds of the invention are shown in Table 1 below. Table 1. Representative compounds [Table 2-1]
Table 2-2
Table 2-3
Table 2-4
Table 2-5
Table 2-6
Table 2-7
Table 2-8
Table 2-9
Table 2-10
Table 2-11
Table 2-12
Table 2-13
Table 2-14
Table 2-15
Table 2-16
Table 2-17
Table 2-18
[0387] In some embodiments, a useful ARM is a compound shown in Table 1 above, or a pharma- ceutically acceptable salt thereof.
[0388] Typical production methods for immune cells and ARM drugs To produce immune cells, such as NK cells, and the medicaments of the present invention, various techniques in the art can be utilized.Specific methods, including isolation, purification, preactivation, characterization, evaluation, etc., are described in Romee et al., Blood 120, 4751-4760, (2012);Leong et al., Biol. Blood Marrow Transplant. 20, 463-473 (2014);Romee et al., Sci Transl Med. 2016 Sep 21;8 (357):357ra123. doi: 10.1126 / scitranslmed.aaf2341, etc.
[0389] Agents such as ARMs can be prepared, for example, by the methods shown in the Examples.
[0390] For example, in some embodiments, useful compounds, such as ARMs, are constructed by cycloaddition reactions, such as click chemistry or modifications thereof.
[0391] In some embodiments, a compound, e.g., a compound useful for preparing an agent of the invention, e.g., an ARM, has Formula IV: [ka] [During the ceremony, ABT is the antibody binding moiety; L is a linker moiety; R d -L a -R', where R d is -C≡C- or -N 3 Includes; Each L a are independently a covalent bond or C 1-C 20 Aliphatic or C with 1-5 heteroatoms 1 -C 20 heteroaliphatic, wherein one or more methylene units of said group are optionally independently selected from -C(R') 2 -, -Cy-, -O-, -S-, -SS-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O) 2 -, -S(O) 2 substituted with -N(R')-, -C(O)S- or -C(O)O-; Each -Cy- is independently 3-20 Cycloaliphatic ring, C 6-20 an optionally substituted divalent group selected from an aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; Each R' is independently -R, -C(O)R, -CO 2 R or -SO 2 R; Each R is independently -H or C 1-30 C having 1 to 10 heteroatoms independently selected from aliphatic, oxygen, nitrogen, sulfur, phosphorus and silicon 1-30 Heteroaliphatic, C 6-30 Aryl, C 6-30 C having 1 to 10 heteroatoms independently selected from arylaliphatic, oxygen, nitrogen, sulfur, phosphorus, and silicon 6-30 an optionally substituted group selected from arylheteroaliphatic, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; or The two R groups may optionally independently be joined together to form a covalent bond, or: two or more R groups on the same atom may optionally independently, together with that atom, form an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having, in addition to that atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; or Two or more R groups on two or more atoms may optionally, independently, be joined together with the atoms between them to form an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atoms between them, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. or a salt thereof.
[0392] In some embodiments, a compound, e.g., a compound useful for preparing an agent of the invention, e.g., an ARM, has formula IV-a: [ka] wherein each variable is independently as described herein. or a salt thereof.
[0393] In some embodiments, a compound, e.g., a compound useful for preparing an agent of the invention, e.g., an ARM, has formula IV-b: [ka] wherein each variable is independently as described herein. or a salt thereof.
[0394] In some embodiments, a compound, e.g., a compound useful for preparing an agent of the invention, e.g., an ARM, has formula IV-c: [ka] wherein each variable is independently as described herein. or a salt thereof.
[0395] In some embodiments, a compound, e.g., a compound useful for preparing an agent of the invention, e.g., an ARM, has formula IV-d: [ka] wherein each variable is independently as described herein. or a salt thereof.
[0396] In some embodiments, a compound, e.g., a compound useful for producing an agent, e.g., an ARM, of the invention has Formula V: [ka] wherein each variable is independently as described herein. or a salt thereof.
[0397] In some embodiments, a method for producing a compound, such as an ARM, comprises the steps of: providing a first compound of formula IV, formula IV-a, formula IV-b, formula IV-c or formula IV-d, or a salt thereof, comprising a first reactive moiety; providing a second compound of formula V or a salt thereof comprising a second reactive moiety; and Reacting a first compound with a second compound, where the first reactive moiety reacts with the second reactive moiety via a cycloaddition reaction.
[0398] Many cycloaddition reactions can be utilized according to the present invention. In some embodiments, the cycloaddition reaction is a [4+2] reaction. In some embodiments, the cycloaddition reaction is a [3+2] reaction. In some embodiments, the [3+2] reaction is a click chemistry reaction. In some embodiments, the first reactive moiety is -C≡C- and the second reactive moiety is -N 3In some embodiments, the first reactive moiety is -N 3 and the second reactive moiety is -C≡C-.
[0399] 6. Use, Formulation and Administration Pharmaceutically acceptable compositions In some embodiments, the present invention provides a composition comprising immune cells, such as preactivated memory-like NK cells, and a pharma- ceutically acceptable carrier, adjuvant, or vehicle. In some embodiments, the present invention provides a composition comprising a drug and its pharma- ceutically acceptable derivatives, and a pharma- ceutically acceptable carrier, adjuvant, or vehicle. In some embodiments, the present invention provides a composition comprising immune cells and a drug and its pharma- ceutically acceptable derivatives, and a pharma- ceutically acceptable carrier, adjuvant, or vehicle. In some embodiments, the immune cells and the useful agent, such as an ARM, are provided in separate compositions. In some embodiments, the immune cells and the useful agent, such as an ARM, are provided in separate compositions.
[0400] In many embodiments, the immune cells are typically administered in an amount sufficient to provide therapeutic benefit without serious side effects. For example, in some embodiments, immune cells are administered at 10,000 to 100 million, 100,000 to 50 million, 10,000 to 20 million, 100,000 to 10 million, 50,000, 100,000, 200,000, 300,000, 300,000, 500,000, 1 million, 2 million, 3 million, 4 million, 5 million, 6 million, 7 million, 8 million, 9 million, 10 million, 15 million, 20 million, 25 million, 30 million, 35 million, 40 million, 45 million, 50 million, 60 million, 70 million, 80 million, or 90 million per kg of subject body weight.
[0401] The agent, e.g., an ARM, is typically administered in an amount effective to selectively redirect endogenous antibodies (e.g., endogenous antibodies) and / or fragments thereof to target cells, e.g., cancer cells, thereby inducing antibody-directed cell-mediated immunity, e.g., cytotoxicity. In certain embodiments, the amount of the compound in the composition of the present invention is sufficient to selectively redirect endogenous antibodies to target cells, e.g., cancer cells, in a biological sample or subject, thereby inducing antibody-directed cell-mediated cytotoxicity. In some embodiments, the amount is 0.01 to 100 mg / kg body weight. In some embodiments, the amount is 0.01 to 50 mg / kg body weight. In some embodiments, the amount is about 1 mg / kg to about 25 mg / kg.
[0402] In some embodiments, pharmaceutically acceptable carrier, adjuvant or vehicle is a non-toxic carrier, adjuvant or vehicle that does not impair the pharmacological activity of the compound that is formulated together.The pharmaceutically acceptable carrier, adjuvant or vehicle that can be used in the composition of the present invention includes, but is not limited to, ion exchanger, alumina, aluminum stearate, lecithin, serum protein, such as human serum albumin, phosphate, buffer substances such as glycine, sorbic acid, potassium sorbate, partial glyceride mixture of saturated vegetable fatty acid, water, salt or electrolyte, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salt, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylate, wax, polyethylene-polyoxypropylene-block polymer, polyethylene glycol and wool fat.In some embodiments, immune cells can be provided in a suitable medium.
[0403] In some embodiments, the agent may be provided as a pharma- ceutically acceptable derivative, which may be a non-toxic salt, ester, salt of an ester, or other derivative of a compound of the present disclosure that is capable of providing an agent, directly or indirectly, upon administration to a receptor.
[0404] The compositions of the present invention can be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, bucally, vaginally or via an implanted reservoir. In some embodiments, parenteral administration includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously. Preferably, the compositions containing immune cells are administered intravenously. Sterile injectable forms of the compositions of the present invention can be aqueous or oily suspensions. Suspensions can be formulated by techniques known in the art using suitable dispersing or wetting agents and suspending agents. Sterile injectable preparations can also be sterile injectable solutions or suspensions as non-toxic parenterally acceptable diluents or solvents, for example, 1,3-butanediol solutions. Among the acceptable vehicles and solvents that can be used are water, Ringer's solution and physiological saline. In addition, sterile, non-volatile oils are conventionally used as solvents or suspending media.
[0405] In some embodiments, the agent, such as an ARM, is formulated as a composition for delayed and / or sustained release. Technologies for sustained release and / or slow absorption technologies are widely available in the art and can be utilized in accordance with the present invention.
[0406] In some embodiments, bland fixed oils can be used, including synthetic monoglycerides or diglycerides. Fatty acids, such as oleic acid and its glyceride derivatives, can be useful for the preparation of injectables, as can natural pharmaceutically acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated forms. Such oil solutions or suspensions can also contain long-chain alcohol diluents or dispersants, such as carboxymethylcellulose or similar dispersants commonly used in the formulation of pharmaceutically acceptable dosage forms, including emulsions and suspensions. Other commonly used surfactants, such as Tween, Span and other emulsifiers, or bioavailability enhancers commonly used in pharmaceutically acceptable solid, liquid or other dosage forms, can also be used for formulation purposes.
[0407] The pharmaceutically acceptable composition of the agent of the present invention, such as ARM, is orally administered in any orally acceptable dosage form, such as capsule, tablet, aqueous suspension or solution.For tablets for oral use, commonly used carriers include lactose and corn starch.Lubricants such as magnesium stearate can also be added.For oral administration in capsule form, useful diluents include lactose and dried corn starch.When aqueous suspension is required for oral use, active ingredient is combined with emulsifier and suspending agent.If desired, certain sweeteners, flavors or colorings can also be added.
[0408] Solid dosage forms, such as solid dosage forms for oral administration, include capsules, tablets, pills, powders, and granules. In some embodiments, the agent to be delivered, e.g., an ARM, is mixed with at least one inert, pharma- ceutically acceptable excipient or carrier, e.g., sodium citrate citrate or dicalcium phosphate, and / or a) fillers or extenders, e.g., starch, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders, e.g., carboxymethylcellulose, alginic acid, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants, e.g., glycerol, d) disintegrants, e.g., agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarders, e.g., paraffin, f) absorption accelerators, e.g., quaternary ammonium compounds, g) humectants, e.g., cetyl alcohol and glycerol monostearate, h) absorbents, e.g., kaolin and bentonite clay, and i) lubricants, e.g., talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents.
[0409] Solid compositions can also be used as fillers in soft gelatin and hard gelatin capsules, using excipients such as lactose or milk sugar and high molecular weight polyethylene glycols.In some embodiments, solid dosage forms such as tablets, sugar-coated tablets, capsules, pills and granules can be prepared with coatings and shells, such as enteric coatings and other coatings known in the pharmaceutical formulation field.In some embodiments, solid compositions can optionally contain opacifiers, and can release the drug delivered only or preferentially in certain parts of the subject (e.g., certain parts of the digestive tract), optionally in a delayed manner.Examples of the embedding composition used include polymeric substances and waxes.
[0410] In some embodiments, the drug, such as the ARM, can be in microencapsulated form with one or more of the excipients described above.In some embodiments, the solid dosage forms of tablets, sugar-coated tablets, capsules, pills and granules can be prepared with coatings and shells, enteric coatings, release-controlling coatings and other coatings known in the pharmaceutical formulation field.In such solid dosage forms, the drug to be delivered can be mixed with at least one inert diluent, such as sucrose, lactose or starch.Such dosage forms can also contain additional substances, such as tableting lubricants and other tableting aids, such as magnesium stearate and microcrystalline cellulose, in the usual practice.In some embodiments, in the case of capsules, tablets and pills, the dosage form can contain buffering agents.
[0411] Alternatively, the pharma- ceutically acceptable composition can be administered in the form of suppositories for rectal administration. These can be prepared by mixing the drug with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature, and therefore melts in the rectum to release the drug. Such materials include cocoa butter, beeswax, and polyethylene glycol.
[0412] The pharma- ceutically acceptable compositions of the present invention may be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower gastrointestinal tract. Suitable topical formulations may be readily prepared for each of these areas or organs.
[0413] For topical application, the pharma- ceutically acceptable composition may be formulated in a suitable ointment containing the active ingredient suspended or dissolved in one or more carriers.Carriers for topical administration of the compounds of the present invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compounds, emulsifying wax and water.Alternatively, the pharma-ceutically acceptable composition may be formulated in a suitable lotion or cream containing the active ingredient suspended or dissolved in one or more pharma-ceutically acceptable carriers.Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.
[0414] For ophthalmic use, the pharma- ceutically acceptable compositions may be formulated as a micronized suspension in pH-adjusted sterile saline, with or without a preservative such as benzylalkonium chloride, or, preferably, as a solution in pH-adjusted sterile saline. Alternatively, for ophthalmic use, the pharma-ceutically acceptable compositions may be formulated in an ointment such as petrolatum.
[0415] Pharmaceutically acceptable compositions may be administered by nasal aerosol or inhalation. Such compositions may be prepared by techniques known in the art of pharmaceutical formulation and may be prepared as saline solutions using benzyl alcohol or other suitable preservatives, absorption enhancers to enhance bioavailability, fluorocarbons and / or other conventional solubilizing or dispersing agents.
[0416] Pharmaceutically acceptable compositions of agents, such as ARMs, can be formulated for oral administration.Such formulations can be administered with or without food.In some embodiments, pharmaceutically acceptable compositions are administered without food.In other embodiments, pharmaceutically acceptable compositions are administered with food.
[0417] It should also be understood that the specific dosage and treatment regimen for a particular subject will depend on a variety of factors, such as the activity of the particular immune cells and / or agents used, age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician, as well as the severity of the particular disease being treated.
[0418] use In particular, the present invention encompasses the recognition that certain immune cells, such as preactivated memory-like NK cells, have improved properties and / or activity against their targets, such as cancer cells, and may be particularly effective for treating conditions, disorders or diseases, such as cancer.However, such immune cells induce more severe side effects, such as off-target consequences, for example, due to increased cytotoxicity.Thus, in some embodiments, the present invention provides techniques for exposing such immune cells to both agents, such as ARMs, which can facilitate targeting immune cells to desired targets (e.g., cancer cells) and reducing the side effects of such immune cell therapy.
[0419] In some embodiments, the useful agent selectively targets antibodies, e.g., endogenous antibodies, to diseased cells, e.g., cancer cells, thereby inducing and / or promoting cell-mediated immune responses directed to the antibodies, e.g., cytotoxicity by immune cells, e.g., preactivated memory-like NK cells (e.g., cytokine-induced memory-like NK cells). In some embodiments, the mobilized antibodies include one or more endogenous antibodies. In some embodiments, the mobilized antibodies have specificity for one or more antigens. In some embodiments, the mobilized antibodies have specificity for one or more peptide antigens or proteins. In some embodiments, the mobilized antibodies are heterologous in that they are not antibodies against the same antigen or protein.
[0420] In some embodiments, the useful agent, for example, ARM, induces, develops, promotes, and / or strengthens one or more immune system against a target. In some embodiments, the immune system activity is or includes ADCC by NK cells. In some embodiments, the immune system activity is or includes ADCC by preactivated memory-like NK cells (e.g., cytokine-induced memory-like NK cells). In some embodiments, the target is a cancer cell. In some embodiments, the target is a cancer cell in a subject.
[0421] The immune cells described herein, for example, preactivated memory-like NK cells (e.g., cytokine-induced memory-like NK cells) and an agent such as an ARM are administered so that the subject is exposed to the therapy. In some embodiments, the immune cells (or a dose thereof) are administered before the ARM agent (or a dose thereof). In some embodiments, the immune cells (or a dose thereof) are administered subsequent to the ARM agent (or a dose thereof). In some embodiments, the immune cells (or a dose thereof) are administered simultaneously with the ARM agent (or a dose thereof). When administered simultaneously, the immune cells and the ARM can be administered in one composition or as separate compositions. In some embodiments, the immune cells and the ARM are detected within 0 hours, 1 hour, 2 hours, 3 hours, 4 hours, 5 hours, 6 hours, 7 hours, 8 hours, 9 hours, 10 hours, 11 hours, 12 hours, 13 hours, 14 hours, 15 hours, 16 hours, 17 hours, 18 hours, 19 hours, 20 hours, 21 hours, 22 hours, 23 hours, or 24 hours of each other. The immune cells and the agent (e.g., ARM) can be administered independently as a single dose or multiple doses. In some embodiments, the administered immune cells, such as preactivated memory-like NK cells, form a complex with the administered ARM combined with a target (e.g., cancer cells) and an antibody (or a fragment thereof) in the subject, where the antibody (or a fragment thereof) interacts with the immune cells and the ARM, and the ARM interacts with the antibody (or a fragment thereof) and the target (e.g., cancer cells).
[0422] In some embodiments, "treat" or "treatment" as used herein includes reversing, alleviating, delaying the onset or inhibiting the progression of a condition, disorder or disease or one or more of its symptoms. In some embodiments, treatment may be performed after one or more symptoms have occurred. In other embodiments, treatment may be performed in the absence of symptoms. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., taking into account a history of the condition and / or taking into account genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay recurrence.
[0423] In some embodiments, the present invention provides a method for treating one or more disorders, diseases, and / or conditions, wherein the disorder, disease, or condition is cancer. In particular, the provided techniques (e.g., compounds, compositions, methods, etc.) are particularly useful for preventing and / or treating cancer.
[0424] In some embodiments, cancer is a cancerous or malignant neoplasm, i.e., a pathological process that leads to the formation and growth of abnormal tissues that grow by cell proliferation, and often grows faster than normal, and continues to grow after the stimulus that initiates new growth has stopped.Malignant neoplasms show partial or complete lack of structural tissue and functional coordination with normal tissue, many of which can invade surrounding tissues, metastasize to several locations, recur after removal attempts, and may cause the death of the patient unless properly treated.In some embodiments, the term neoplasm as used herein includes all cancerous disease states, and includes or encompasses the pathological processes associated with malignant hematogenous, ascites, and solid tumors. Representative cancers include, for example, prostate cancer, metastatic prostate cancer, gastric cancer, colon cancer, rectal cancer, liver cancer, pancreatic cancer, lung cancer, breast cancer, cervical cancer, uterine cancer, ovarian cancer, testicular cancer, bladder cancer, kidney cancer, brain / CNS cancer, head and neck cancer, pharyngeal cancer, Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, leukemia, melanoma, non-melanoma skin cancer, acute lymphocytic leukemia, acute myeloid leukemia, Ewing's sarcoma, small cell lung cancer, choriocarcinoma, rhabdomyosarcoma, Wilms' tumor, neuroblastoma, hairy cell leukemia, oral / pharyngeal cancer, esophageal, laryngeal, renal cancer and lymphoma, among others, which may be treated with one or more compounds according to the present invention.
[0425] In some embodiments, the cancer is leukemia. In some embodiments, the provided techniques are particularly useful for treating leukemia. In some embodiments, the provided techniques are particularly useful for treating acute myeloid leukemia (AML). In some embodiments, the cancer is lymphoma. In some embodiments, the cancer is melanoma.
[0426] In some embodiments, prior to administration of the treatment of the present invention (e.g., exposure to both administered pre-activated memory-like NK cells and ARM), the subject may have been treated with another treatment, such as chemotherapy, immunotherapy, surgery, etc. In some embodiments, the subject is susceptible to or has relapsed or refractory cancer. In some embodiments, the subject is susceptible to or has relapsed or refractory leukemia. In some embodiments, the subject is susceptible to or has relapsed or refractory AML.
[0427] In some embodiments, treatment is carried out on the subject undergoing lymphocyte depletion regimen.In some embodiments, for example, depletion of immune regulatory elements by cytotoxic drugs or total body irradiation can enhance the activity of administered immune cells.In some embodiments, subject is administered cytotoxic drugs such as fludarabine, cyclophosphamide and / or alemtuzumab.
[0428] Combination therapy In certain embodiments, the techniques provided, for example, techniques comprising immune cells (e.g., memory-like NK cells) and ARM, are administered in combination with one or more other therapies.In some embodiments, in addition to immune cells (e.g., memory-like NK cells) and ARM agents, subject receives another therapy.In some embodiments, subject has cancer, and such another therapy is cancer therapy, for example, chemotherapy, immunotherapy, surgery, etc.
[0429] In particular, the technology of the present invention involving immune cells (e.g., memory-like NK cells) and ARMs can be used in combination with other therapies. That is, such technology can be administered simultaneously with, prior to, or subsequent to one or more therapeutic agents or medical treatments, particularly various cancer treatments. In some embodiments, such technology can be utilized in combination with other anti-proliferative compounds. In some embodiments, the therapeutic agent useful in the combination is a chemotherapeutic agent or an anti-proliferative compound. Exemplary chemotherapeutic agents include, but are not limited to, alkylating agents, nitrosoureas, antimetabolites, antitumor antibiotics, plant-derived alkaloids, topoisomerase inhibitors, hormone therapy agents, hormone antagonists, aromatase inhibitors, P-glycoprotein inhibitors, platinum complex derivatives, other immunotherapy agents, and other anti-cancer agents. In addition, the provided technology can be used with or produced as a mixture of leukocytosis (neutrophilization) agents, thrombocytopenia agents, antiemetics, and cancer analgesics for the restoration of patient quality of life, which are cancer treatment adjuvants. In some embodiments, the therapeutic agent is an antibody. In some embodiments, the therapeutic agent is an immunomodulatory agent. In some embodiments, the immunomodulator targets a cell surface signaling molecule on an immune cell. In some embodiments, the immunomodulator targets a cell surface signaling molecule on an immune cell, wherein the agent is an antagonist that inhibits a co-inhibitory pathway. In some embodiments, the immunomodulator is a checkpoint inhibitor. In some embodiments, the immunomodulator is an antibody ...
Claims
1. A plurality of natural killer cells; and Antibody recruiting molecules (ARMs) comprising an antibody binding moiety capable of binding to one or more antibodies or fragments thereof, a target binding moiety capable of binding to a cell, and optionally a linker moiety connecting the antibody binding moiety and the target binding moiety. and exposing the system to both, thereby reducing the number of cells in the system compared to when both the natural killer cell and antibody recruiting molecule are absent.
2. For subjects with disabilities or diseases Multiple natural killer cells and Antibody recruiting molecules (ARMs) comprising an antibody binding moiety capable of binding to one or more antibodies or fragments thereof, a target binding moiety capable of binding to a cell, and optionally a linker moiety connecting the antibody binding moiety and the target binding moiety.
23. A method of treating a condition, disorder or disease comprising administering
3. 3. The method of claim 2, wherein the condition, disorder or disease is cancer.
4. Target A plurality of natural killer cells; and an antibody mobilizing molecule (ARM) comprising an antibody binding moiety capable of binding to one or more antibodies or fragments thereof, a target binding moiety capable of binding to a target, and optionally a linker moiety connecting the antibody binding moiety and the target binding moiety; 23. A method for reducing side effects of treatment with natural killer cells, comprising administering
5. Target A plurality of natural killer cells; and an antibody mobilizing molecule (ARM) comprising an antibody binding moiety capable of binding to one or more antibodies or fragments thereof, a target binding moiety capable of binding to a target, and optionally a linker moiety connecting the antibody binding moiety and the target binding moiety; 23. A method for reducing toxicity of treatment with natural killer cells comprising administering
6. The method according to any one of claims 1 to 5, wherein the natural killer cells are memory-like natural killer cells.
7. The method according to any one of claims 1 to 5, wherein the natural killer cells are cytokine-induced memory-like natural killer cells induced by IL-12, IL-15 and IL-18.
8. 7. The method of claim 6, wherein the natural killer cells and the ARM are administered simultaneously, optionally in a single composition.
9. The method of claim 6, wherein the natural killer cells are administered before or after the ARM.
10. The method of claim 6 , wherein the antibody binding portion of the ARM is a universal antibody binding portion.
11. ARM is of formula I: 【Chemistry 1】 [During the ceremony, ABT is an antibody binding moiety; L is a divalent linker moiety connecting ABT and TBT; TBT is the target binding moiety. or a pharma- ceutically acceptable salt thereof.
12. ARM is of formula II: 【Chemistry 2】 [During the ceremony, R 1 , R 3 and R 5 Each of is independently hydrogen or C 1-6 an optionally substituted group selected from an aliphatic, a 3-8 membered saturated or partially unsaturated monocyclic carbocyclic ring, a phenyl, an 8-10 membered bicyclic aromatic carbocyclic ring, a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5-6 membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8-10 membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or R 1 and R 1’ may optionally be joined together with the carbon atoms therebetween to form a 3- to 8-membered saturated or partially unsaturated spirocyclic carbocyclic ring or a 4- to 8-membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R 3 and R 3’ may optionally be joined together with the carbon atoms therebetween to form a 3- to 8-membered saturated or partially unsaturated spirocyclic carbocyclic ring or a 4- to 8-membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R bonded to the same carbon atom 5 Groups and R 5’ the groups may optionally be joined together with the carbon atoms between them to form a 3- to 8-membered saturated or partially unsaturated spirocyclic carbocyclic ring or a 4- to 8-membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or; Two R's 5 The groups, together with the atoms between them, may optionally be divalent C 1-10 forming a straight or branched saturated or unsaturated hydrocarbon chain, wherein 1 to 3 methylene units of the chain are independently selected from the group consisting of -S-, -SS-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -S(O)-, -S(O) 2 -or-Cy 1 -, where each -Cy 1 - is independently a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R 1’ , R 3’ and R 5’ Each of is independently hydrogen or C 1-3 is aliphatic; R 2 , R 4 and R 6 Each of is independently hydrogen or C 1-4 aliphatic or: R 2 and R 1 may optionally be joined together with the atoms therebetween to form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R 2 and R 1 may optionally be joined together with the atoms therebetween to form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R 4 and R 3 may optionally be joined together with the atoms between them to form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or R 6 group and the adjacent R 5 The groups may optionally be joined together with the atoms between them to form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; L 1 teeth 【Chemistry 3】 is a trivalent linker moiety linking L 2 is a covalent bond or a divalent C 1-10 A straight or branched chain saturated or unsaturated hydrocarbon chain, wherein one to three methylene units of the chain are independently selected from the group consisting of -S-, -N(R)-, -O-, -C(O)-, -OC(O)-, -C(O)O-, -C(O)N(R)-, -N(R)C(O)-, -S(O)-, -S(O) 2 --, 【Chemistry 4】 Or -Cy 1 -, where each -Cy 1 - is independently a 5-6 membered heteroarylenyl having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur; TBT is the target binding moiety; Each of m and n is independently 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10. or a pharma- ceutically acceptable salt thereof; or ARM is of formula III: 【Chemistry 5】 [During the ceremony, Each R 7 are independently hydrogen or C 1-6 an optionally substituted group selected from an aliphatic, a 3- to 8-membered saturated or partially unsaturated monocyclic carbocyclic ring, a phenyl, an 8- to 10-membered bicyclic aromatic carbocyclic ring, a 4- to 8-membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur, a 5- to 6-membered monocyclic heteroaromatic ring having 1-4 heteroatoms independently selected from nitrogen, oxygen, or sulfur, or an 8- to 10-membered bicyclic heteroaromatic ring having 1-5 heteroatoms independently selected from nitrogen, oxygen, or sulfur; or R bonded to the same carbon atom 7 Groups and R 7’ the groups may optionally be joined together with the carbon atoms between them to form a 3- to 8-membered saturated or partially unsaturated spirocyclic carbocyclic ring or a 4- to 8-membered saturated or partially unsaturated spirocyclic heterocyclic ring having 1 to 2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; Each R 7’ are independently hydrogen or C 1-3 is aliphatic; Each R 8 are independently hydrogen or C 1-4 Is aliphatic, or R 8 group and the adjacent R 7 The groups may optionally be joined together with the atoms between them to form a 4-8 membered saturated or partially unsaturated monocyclic heterocyclic ring having 1-2 heteroatoms independently selected from nitrogen, oxygen, or sulfur; R 9 is hydrogen, C 1-3 Aliphatic or -C(O)C 1-3 is aliphatic; L 3 teeth 【Chemistry 6】 and TBT; TBT is the target binding moiety; o is 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10. or a pharma- ceutically acceptable salt thereof.
13. ARM is of formula Ia: 【Chemistry 7】 [During the ceremony, each Xaa is independently an amino acid residue; t is 0 to 50; z is 1 to 50; L is a linker moiety; TBT is the target binding moiety; Each R c are independently -L a -R'; Each of a and b is independently 1 to 200; Each L a are independently a covalent bond or C 1 -C 20 Aliphatic or C having 1 to 5 heteroatoms 1 -C 20 heteroaliphatic, wherein one or more methylene units of said group are optionally independently selected from -C(R') 2 -, -Cy-, -O-, -S-, -S-S-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O) 2 -, -S(O) 2 optionally substituted with -N(R')-, -C(O)S- or -C(O)O-; Each -Cy- is independently 3-20 Cycloaliphatic ring, C 6-20 an optionally substituted divalent group selected from an aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; Each R' is independently -R, -C(O)R, -CO 2 R or -SO 2 R; Each R is independently -H or C 1-30 C having 1 to 10 heteroatoms independently selected from aliphatic, oxygen, nitrogen, sulfur, phosphorus and silicon 1-30 Heteroaliphatic, C 6-30 Aryl, C 6-30 C having 1 to 10 heteroatoms independently selected from arylaliphatic, oxygen, nitrogen, sulfur, phosphorus and silicon 6-30 an optionally substituted group selected from arylheteroaliphatic, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; or The two R groups may optionally independently form a covalent bond with that atom or: two or more R groups on the same atom may optionally independently combine with that atom to form an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having, in addition to that atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; or Two or more R groups on two or more atoms may optionally, independently, be joined with the atoms between them to form an optionally substituted 3-30 membered, monocyclic, bicyclic or polycyclic ring having, in addition to the atoms between them, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. or a salt thereof, or ARM is of formula Ib: 【Chemistry 8】 [During the ceremony, each Xaa is independently an amino acid residue; each z is independently 1 to 50; each L is independently a linker moiety; TBT is a target binding moiety, Each R c are independently -L a -R'; each of a1 and a2 is independently 0 to 200, where at least one of a1 and a2 is not 0; b is 1 to 200; Each L a are independently a covalent bond or C 1 -C 20 Aliphatic or C having 1 to 5 heteroatoms 1 -C 20 heteroaliphatic, wherein one or more methylene units of said group are optionally independently selected from -C(R') 2 -, -Cy-, -O-, -S-, -S-S-, -N(R')-, -C(O)-, -C(S)-, -C(NR')-, -C(O)N(R')-, -N(R')C(O)N(R')-, -N(R')C(O)O-, -S(O)-, -S(O) 2 -, -S(O) 2 optionally substituted with -N(R')-, -C(O)S- or -C(O)O-; Each -Cy- is independently 3-20 Cycloaliphatic ring, C 6-20 an optionally substituted divalent group selected from an aryl ring, a 5-20 membered heteroaryl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and a 3-20 membered heterocyclyl ring having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; Each R' is independently -R, -C(O)R, -CO 2 R or -SO 2 R; Each R is independently -H or C 1-30 C having 1 to 10 heteroatoms independently selected from aliphatic, oxygen, nitrogen, sulfur, phosphorus and silicon 1-30 Heteroaliphatic, C 6-30 Aryl, C 6-30 C having 1 to 10 heteroatoms independently selected from arylaliphatic, oxygen, nitrogen, sulfur, phosphorus and silicon 6-30 an optionally substituted group selected from arylheteroaliphatic, 5-30 membered heteroaryl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon, and 3-30 membered heterocyclyl having 1-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus, and silicon; or The two R groups may optionally independently join together to form a covalent bond, or: two or more R groups on the same atom may optionally independently combine with that atom to form an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having, in addition to that atom, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon; or Two or more R groups on two or more atoms may optionally independently combine with the atoms between them to form an optionally substituted 3-30 membered monocyclic, bicyclic or polycyclic ring having, in addition to the atoms between them, 0-10 heteroatoms independently selected from oxygen, nitrogen, sulfur, phosphorus and silicon. The method according to claim 6, wherein the compound has the structure:
14. The method of claim 6 , wherein the ARM is administered in conjunction with an antibody or fragment thereof.
15. 7. The method of claim 6, wherein the antibody binding moiety is or comprises a peptide unit which is or comprises DCAWHLGELVWCT, wherein the two cysteine residues may optionally form a disulfide bond.
16. The method of claim 6, wherein the antibody binding portion is or comprises a peptide unit which is or comprises CDCAWHLGELVWCTC, in which the first and last cysteines and the two central cysteines of the sequence may each independently and optionally form a disulfide bond.
17. A plurality of natural killer cells; and an antibody mobilizing molecule (ARM) comprising an antibody binding moiety capable of binding to one or more antibodies or fragments thereof, a target binding moiety capable of binding to a target, and optionally a linker moiety connecting the antibody binding moiety and the target binding moiety; A combination comprising:
18. The combination of claim 17, wherein the natural killer cells are natural killer cells according to any one of claims 1 to 16 and / or the ARM is an ARM according to any one of claims 1 to 16.
19. A plurality of natural killer cells; and Antibody recruiting molecules (ARMs) comprising an antibody binding moiety capable of binding to one or more antibodies or fragments thereof, a target binding moiety capable of binding to a target, and optionally a linker moiety connecting the antibody binding moiety and the target binding moiety. A composition comprising:
20. The composition of claim 19, wherein the natural killer cells are natural killer cells according to any one of claims 1 to 16, and / or the ARM is an ARM according to any one of claims 1 to 16.
21. 21. The composition of claim 19 or 20, comprising an antibody or a fragment thereof.
22. 104. The method, improvement, combination or composition according to any one of the preceding embodiments.
Citation Information
Patent Citations
Combined therapy of ARM and natural killer cells
JP7704678B2
